|
SI1523496T1
(sl)
|
2002-07-18 |
2011-11-30 |
Merus B V |
Rekombinantno proizvajanje zmesi protiteles
|
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
EP2395017A3
(en)
|
2003-05-30 |
2012-12-19 |
Merus B.V. |
Design and use of paired variable regions of specific binding molecules
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
DK3050963T3
(da)
|
2005-03-31 |
2019-12-09 |
Chugai Pharmaceutical Co Ltd |
Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement
|
|
DK2009101T3
(en)
|
2006-03-31 |
2018-01-15 |
Chugai Pharmaceutical Co Ltd |
Antibody modification method for purification of a bispecific antibody
|
|
EP2006381B1
(en)
|
2006-03-31 |
2016-02-03 |
Chugai Seiyaku Kabushiki Kaisha |
Method for controlling blood pharmacokinetics of antibodies
|
|
HUE028379T2
(en)
|
2006-09-29 |
2016-12-28 |
Oncomed Pharm Inc |
Preparations and procedures for the diagnosis and treatment of cancer
|
|
CN105061577A
(zh)
|
2006-12-14 |
2015-11-18 |
爱勒让治疗公司 |
双巯基大环化系统
|
|
CN109627287A
(zh)
|
2007-02-23 |
2019-04-16 |
爱勒让治疗公司 |
三唑大环系统
|
|
JP5631201B2
(ja)
|
2007-03-28 |
2014-11-26 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ステッチングされたポリペプチド
|
|
CA2681974C
(en)
|
2007-03-29 |
2019-12-31 |
Genmab A/S |
Bispecific antibodies and methods for production thereof
|
|
CA2700701C
(en)
|
2007-09-26 |
2020-12-29 |
Chugai Seiyaku Kabushiki Kaisha |
Method of modifying isoelectric point of antibody via amino acid substitution in cdr
|
|
CL2008002886A1
(es)
|
2007-09-26 |
2009-12-04 |
Chugai Pharmaceutical Co Ltd |
Region constante de un anticuerpo humano; anticuerpo anti-receptor de interleucina-6 (il-6) y composicion farmaceutica que la comprende.
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
WO2009089004A1
(en)
*
|
2008-01-07 |
2009-07-16 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
|
CA2722466A1
(en)
|
2008-04-29 |
2009-11-05 |
Tariq Ghayur |
Dual variable domain immunoglobulins and uses thereof
|
|
SG191639A1
(en)
|
2008-06-03 |
2013-07-31 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
KR20220002710A
(ko)
|
2008-06-26 |
2022-01-06 |
악셀레론 파마 인코포레이티드 |
액티빈-ａｃｔｒｉｉａ 길항물질을 투약하는 방법 및 치료된 환자의 모니터링
|
|
KR20110031369A
(ko)
|
2008-07-08 |
2011-03-25 |
아보트 러보러터리즈 |
프로스타글란딘 ｅ2 이원 가변 도메인 면역글로불린 및 이의 용도
|
|
US8652843B2
(en)
|
2008-08-12 |
2014-02-18 |
Oncomed Pharmaceuticals, Inc. |
DDR1-binding agents and methods of use thereof
|
|
EP2376100B1
(en)
|
2009-01-14 |
2017-10-25 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles
|
|
WO2010085495A1
(en)
|
2009-01-21 |
2010-07-29 |
Amgen Inc. |
Compositions and methods of treating inflammatory and autoimmune diseases
|
|
JP2012515540A
(ja)
*
|
2009-01-26 |
2012-07-12 |
ゲンマブ エー／エス |
抗体混合物を産生するための方法
|
|
EP2826789A1
(en)
|
2009-03-19 |
2015-01-21 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
|
WO2010107110A1
(ja)
|
2009-03-19 |
2010-09-23 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
CN102365297B
(zh)
|
2009-03-25 |
2014-10-29 |
霍夫曼-拉罗奇有限公司 |
新型抗-α5β1抗体及其应用
|
|
ES2537100T3
(es)
|
2009-04-07 |
2015-06-02 |
Roche Glycart Ag |
Anticuerpos biespecíficos trivalentes
|
|
AU2013203859B2
(en)
*
|
2009-04-27 |
2016-09-08 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
|
EP2424567B1
(en)
*
|
2009-04-27 |
2018-11-21 |
OncoMed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
SI2975051T1
(sl)
|
2009-06-26 |
2021-08-31 |
Regeneron Pharmaceuticals, Inc. |
Zlahka izolirana bispecifična protitelesa z nativnim imunoglobulinskim formatom
|
|
JP2012532608A
(ja)
|
2009-07-08 |
2012-12-20 |
アムジェン インコーポレイテッド |
ＣＨ３ドメイン界面操作を通じた、安定でそして凝集しない抗体Ｆｃ分子の設計
|
|
TW201109438A
(en)
*
|
2009-07-29 |
2011-03-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
US9493578B2
(en)
*
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
AU2010296018B2
(en)
|
2009-09-16 |
2016-05-05 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
|
WO2011038049A1
(en)
|
2009-09-22 |
2011-03-31 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles
|
|
EP2481752B1
(en)
|
2009-09-24 |
2016-11-09 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant regions
|
|
TW201119676A
(en)
|
2009-10-15 |
2011-06-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
ES2895226T3
(es)
|
2009-10-16 |
2022-02-18 |
Mereo Biopharma 5 Inc |
Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensivos
|
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
CA2781539C
(en)
|
2009-11-23 |
2021-07-20 |
Amgen Inc. |
Monomeric antibody fc
|
|
NZ600820A
(en)
*
|
2009-12-29 |
2014-12-24 |
Emergent Product Dev Seattle |
Heterodimer binding proteins and uses thereof
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
DK2505654T4
(da)
|
2010-02-08 |
2020-07-27 |
Regeneron Pharma |
Mus med fælles letkæde
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
ES2519348T3
(es)
|
2010-02-18 |
2014-11-06 |
Genentech, Inc. |
Antagonistas de neurregulina y uso de los mismos en el tratamiento del cáncer
|
|
WO2011108714A1
(ja)
|
2010-03-04 |
2011-09-09 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
EP2550295A1
(en)
|
2010-03-24 |
2013-01-30 |
F. Hoffmann-La Roche AG |
Anti-lrp6 antibodies
|
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
|
BR112012024565B1
(pt)
|
2010-03-26 |
2022-02-08 |
Trustees Of Dartmouth College |
Proteína de fusão vista imunossupressora multimérica isolada ou recombinante e composição
|
|
JP2013528360A
(ja)
|
2010-04-09 |
2013-07-11 |
アムジェン インコーポレイテッド |
Ｂｔｎｌ９タンパク質、核酸および抗体ならびにそれらの使用
|
|
AU2016219622A1
(en)
*
|
2010-04-20 |
2016-09-15 |
Genmab A/S |
Heterodimeric antibody FC-containing proteins and methods for production thereof
|
|
JP2019048814A
(ja)
*
|
2010-04-20 |
2019-03-28 |
ゲンマブ エー／エス |
ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
|
|
PL2560993T3
(pl)
|
2010-04-20 |
2024-11-04 |
Genmab A/S |
Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania
|
|
AU2013203221B2
(en)
*
|
2010-04-20 |
2016-06-02 |
Genmab A/S |
Heterodimeric antibody FC-containing proteins and methods for production thereof
|
|
KR101860963B1
(ko)
|
2010-04-23 |
2018-05-24 |
제넨테크, 인크. |
이종다량체 단백질의 생산
|
|
US9527926B2
(en)
|
2010-05-14 |
2016-12-27 |
Rinat Neuroscience Corp. |
Heterodimeric proteins and methods for producing and purifying them
|
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
|
NZ604003A
(en)
|
2010-05-27 |
2015-04-24 |
Genmab As |
Monoclonal antibodies against her2
|
|
TW201204388A
(en)
|
2010-06-18 |
2012-02-01 |
Genentech Inc |
Anti-Axl antibodies and methods of use
|
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
|
WO2011161189A1
(en)
|
2010-06-24 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods of use
|
|
CN103097418A
(zh)
|
2010-07-09 |
2013-05-08 |
霍夫曼-拉罗奇有限公司 |
抗神经毡蛋白抗体及使用方法
|
|
JP2013538338A
(ja)
|
2010-07-19 |
2013-10-10 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
抗癌治療への応答可能性の増大した患者を同定する方法
|
|
CN104730243A
(zh)
|
2010-07-19 |
2015-06-24 |
霍夫曼-拉罗奇有限公司 |
鉴定响应抗癌疗法的可能性升高的患者的方法
|
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
|
CN105585630B
(zh)
|
2010-07-29 |
2020-09-15 |
Xencor公司 |
具有修改的等电点的抗体
|
|
EP2601218A4
(en)
|
2010-08-03 |
2015-02-18 |
Abbvie Inc |
VARIABLE DOUBLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
|
|
KR20130045914A
(ko)
|
2010-08-03 |
2013-05-06 |
에프. 호프만-라 로슈 아게 |
만성 림프구성 백혈병(cll) 생체지표
|
|
BR112013002532A2
(pt)
|
2010-08-05 |
2016-05-31 |
Hoffmann La Roche |
proteína de fusão de citocina anti-viral do anticorpo anti-mhc
|
|
MX355543B
(es)
|
2010-08-13 |
2018-04-20 |
Aileron Therapeutics Inc Star |
Macrociclos peptidomiméticos.
|
|
HUE036077T2
(hu)
|
2010-08-13 |
2018-06-28 |
Roche Glycart Ag |
Anti-FAP ellenanyagok és alkalmazásukra szolgáló eljárások
|
|
RU2584597C2
(ru)
|
2010-08-13 |
2016-05-20 |
Рош Гликарт Аг |
Антитела против а2 тенасцина с и способы их применения
|
|
WO2012025536A1
(en)
|
2010-08-25 |
2012-03-01 |
F. Hoffmann-La Roche Ag |
Antibodies against il-18r1 and uses thereof
|
|
BR112013004581A2
(pt)
|
2010-08-26 |
2017-06-27 |
Abbvie Inc |
imunoglobulinas de domínio variável dual e seus usos
|
|
BR112013004673A8
(pt)
|
2010-08-31 |
2018-01-02 |
Genentech Inc |
biomarcadores e métodos de tratamento.
|
|
US8551479B2
(en)
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
|
RS59589B1
(sr)
*
|
2010-11-05 |
2019-12-31 |
Zymeworks Inc |
Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu
|
|
TW201300417A
(zh)
|
2010-11-10 |
2013-01-01 |
Genentech Inc |
用於神經疾病免疫療法之方法及組合物
|
|
MX355060B
(es)
|
2010-11-17 |
2018-04-03 |
Chugai Pharmaceutical Co Ltd |
Molecula multiespecifica de union a antigeno que tiene funcion alternativa a la funcion del factor viii de coagulacion sanguinea.
|
|
WO2012069466A1
(en)
|
2010-11-24 |
2012-05-31 |
Novartis Ag |
Multispecific molecules
|
|
DK2646470T3
(en)
|
2010-11-30 |
2017-05-08 |
Hoffmann La Roche |
ANTI-TRANSFERRIN RECEPTOR ANTIBODIES WITH LOW AFFINITY AND ITS USE FOR TRANSPORTING THERAPEUTIC SCFV OVER THE BLOOD-BRAIN BARRIER
|
|
MX349057B
(es)
|
2010-11-30 |
2017-07-07 |
Chugai Pharmaceutical Co Ltd |
Agente terapeutico que induce citotoxicidad.
|
|
RU2737245C2
(ru)
|
2010-12-16 |
2020-11-26 |
Дженентек, Инк. |
Способы диагностики и лечения, связанные с ингибированием тн2
|
|
EP3296321B1
(en)
|
2010-12-20 |
2020-07-15 |
F. Hoffmann-La Roche AG |
Anti-mesothelin antibodies and immunoconjugates
|
|
EA201390929A1
(ru)
|
2010-12-22 |
2013-12-30 |
Дженентек, Инк. |
Антитела к pcsk9 и способы их применения
|
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
|
MX355255B
(es)
|
2011-02-04 |
2018-04-11 |
Genentech Inc |
Variantes de fc y métodos para su producción.
|
|
EP2673294B1
(en)
|
2011-02-10 |
2016-04-27 |
Roche Glycart AG |
Mutant interleukin-2 polypeptides
|
|
CA2824824A1
(en)
|
2011-02-28 |
2012-09-07 |
F. Hoffmann-La Roche Ag |
Monovalent antigen binding proteins
|
|
BR112013019975A2
(pt)
|
2011-02-28 |
2017-08-01 |
Hoffmann La Roche |
proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
|
|
ES2676878T3
(es)
|
2011-03-03 |
2018-07-25 |
Zymeworks Inc. |
Diseño de armazón de heteromultímero multivalente y constructos
|
|
AU2012229048B2
(en)
|
2011-03-16 |
2016-01-21 |
Amgen Inc |
Fc variants
|
|
SG10201602371VA
(en)
*
|
2011-03-25 |
2016-04-28 |
Glenmark Pharmaceuticals Sa |
Hetero-dimeric immunoglobulins
|
|
KR20160044598A
(ko)
|
2011-03-29 |
2016-04-25 |
로슈 글리카트 아게 |
항체 Fc 변이체
|
|
WO2012138975A1
(en)
|
2011-04-07 |
2012-10-11 |
Genentech, Inc. |
Anti-fgfr4 antibodies and methods of use
|
|
EP2694092B1
(en)
|
2011-04-08 |
2017-01-04 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
|
|
SI2697257T1
(sl)
|
2011-04-13 |
2017-02-28 |
Bristol-Myers Squibb Company |
FC fuzijski proteini, ki vsebujejo nove linkerje ali razmestitve
|
|
AU2012245116A1
(en)
|
2011-04-20 |
2013-11-07 |
Genmab A/S |
Bispecific antibodies against HER2 and CD3
|
|
WO2012143523A1
(en)
*
|
2011-04-20 |
2012-10-26 |
Genmab A/S |
Bispecifc antibodies against her2
|
|
MX2013012071A
(es)
|
2011-04-20 |
2014-01-20 |
Roche Glycart Ag |
Metodo y constructos para el pasaje dependiente del ph de la barrera hematoencefalica.
|
|
EP2699260B1
(en)
|
2011-04-20 |
2024-11-20 |
Genmab A/S |
Bispecifc antibodies against her2
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
EP2707723B1
(en)
|
2011-05-12 |
2016-02-10 |
Genentech, Inc. |
Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
|
|
LT2710035T
(lt)
|
2011-05-16 |
2017-06-26 |
F. Hoffmann-La Roche Ag |
Fgfr1 agonistai ir jų naudojimo būdai
|
|
KR101629073B1
(ko)
|
2011-06-15 |
2016-06-09 |
에프. 호프만-라 로슈 아게 |
항-인간 에리스로포이에틴 수용체 항체 및 이의 사용 방법
|
|
RU2013155695A
(ru)
|
2011-06-30 |
2015-08-10 |
Дженентек, Инк. |
Препараты антител против с-мет
|
|
TWI687441B
(zh)
*
|
2011-06-30 |
2020-03-11 |
中外製藥股份有限公司 |
異源二聚化多胜肽
|
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
|
EP2543680A1
(en)
*
|
2011-07-07 |
2013-01-09 |
Centre National de la Recherche Scientifique |
Multispecific mutated antibody Fab fragments
|
|
RU2014103185A
(ru)
|
2011-07-18 |
2015-08-27 |
Артс Байолоджикс А/С |
Биологически активное соединение на основе лютеинизирующего гормона (lh) с пролонгированным действием
|
|
MX2014001019A
(es)
*
|
2011-07-27 |
2014-05-13 |
Glaxo Group Ltd |
Dominios variables singulares anti-vgf fusionados con dominios de fc.
|
|
MY172718A
(en)
|
2011-08-05 |
2019-12-11 |
Regeneron Pharma |
Humanized universal light chain mice
|
|
WO2013025853A1
(en)
|
2011-08-17 |
2013-02-21 |
Genentech, Inc. |
Neuregulin antibodies and uses thereof
|
|
US20130058936A1
(en)
|
2011-08-23 |
2013-03-07 |
Peter Bruenker |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
|
US20130078250A1
(en)
|
2011-08-23 |
2013-03-28 |
Oliver Ast |
Bispecific t cell activating antigen binding molecules
|
|
KR20140048292A
(ko)
|
2011-08-23 |
2014-04-23 |
로슈 글리카트 아게 |
항-mcsp 항체
|
|
ES2686327T3
(es)
|
2011-08-23 |
2018-10-17 |
Roche Glycart Ag |
Moléculas de unión a antígeno biespecíficas
|
|
PE20141521A1
(es)
|
2011-08-23 |
2014-10-25 |
Roche Glycart Ag |
Moleculas biespecificas de union a antigeno activadoras de celulas t
|
|
JP2015527869A
(ja)
|
2011-08-26 |
2015-09-24 |
メリマック ファーマシューティカルズ インコーポレーティッド |
タンデムＦｃ二重特異性抗体
|
|
EP2756300A1
(en)
|
2011-09-15 |
2014-07-23 |
F.Hoffmann-La Roche Ag |
Methods of promoting differentiation
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
RU2014114617A
(ru)
|
2011-09-19 |
2015-10-27 |
Дженентек, Инк. |
Комбинированные виды лечения, содержащие антагонисты с-мет и антагонисты b-raf
|
|
ES2806146T3
(es)
|
2011-09-22 |
2021-02-16 |
Amgen Inc |
Proteínas de unión al antígeno CD27L
|
|
PT2758073T
(pt)
|
2011-09-23 |
2019-02-01 |
Oncomed Pharm Inc |
Agentes de ligação a vegf/dll4 e utilizações dos mesmos
|
|
CA2791109C
(en)
|
2011-09-26 |
2021-02-16 |
Merus B.V. |
Generation of binding molecules
|
|
US9663573B2
(en)
|
2011-10-05 |
2017-05-30 |
Genentech, Inc. |
Methods of treating liver conditions using Notch2 antagonists
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
KR102492792B1
(ko)
|
2011-10-11 |
2023-01-30 |
제넨테크, 인크. |
이중특이적 항체의 개선된 어셈블리
|
|
KR102102862B1
(ko)
|
2011-10-14 |
2020-04-22 |
제넨테크, 인크. |
항-HtrA1 항체 및 사용 방법
|
|
JP6254087B2
(ja)
|
2011-10-15 |
2017-12-27 |
ジェネンテック， インコーポレイテッド |
癌を治療するためのｓｃｄ１アンタゴニスト
|
|
TWI643868B
(zh)
|
2011-10-18 |
2018-12-11 |
艾利倫治療公司 |
擬肽巨環化合物
|
|
WO2013059531A1
(en)
|
2011-10-20 |
2013-04-25 |
Genentech, Inc. |
Anti-gcgr antibodies and uses thereof
|
|
SG10201805291TA
(en)
|
2011-10-27 |
2018-08-30 |
Genmab As |
Production of heterodimeric proteins
|
|
BR112014009953A2
(pt)
|
2011-10-28 |
2017-12-05 |
Genentech Inc |
método de inibição do crescimento de tumores, de tratamento de melanoma, artigo industrializado e uso
|
|
MX359775B
(es)
*
|
2011-10-31 |
2018-10-10 |
Chugai Pharmaceutical Co Ltd |
Molecula enlazada al antigeno que tiene conjugacion regulada entre cadena ligera y cadena pesada.
|
|
WO2013063702A1
(en)
|
2011-11-04 |
2013-05-10 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the fc domain
|
|
US20130129718A1
(en)
|
2011-11-21 |
2013-05-23 |
Genentech, Inc. |
Purification of anti-c-met antibodies
|
|
HK1203519A1
(en)
|
2011-11-23 |
2015-10-30 |
Amgen Inc. |
Methods of treatment using an antibody against interferon gamma
|
|
WO2013083497A1
(en)
|
2011-12-06 |
2013-06-13 |
F. Hoffmann-La Roche Ag |
Antibody formulation
|
|
AU2012355435A1
(en)
|
2011-12-21 |
2014-07-17 |
Amgen Inc. |
Variant Fc-polypeptides with enhanced binding to the neonatal Fc receptor
|
|
SG10201805622QA
(en)
|
2011-12-22 |
2018-08-30 |
Hoffmann La Roche |
Expression Vector Organization, Novel Production Cell Generation Methods And Their Use For The Recombinant Production Of Polypeptides
|
|
KR102285184B1
(ko)
|
2011-12-22 |
2021-08-03 |
에프. 호프만-라 로슈 아게 |
발현 벡터 구성원 조합, 신규한 제조 세포 생성 방법 및 폴리펩티드의 재조합적 제조를 위한 그의 용도
|
|
CA2854246A1
(en)
|
2011-12-22 |
2013-06-27 |
F. Hoffmann-La Roche Ag |
Full length antibody display system for eukaryotic cells and its use
|
|
AR089434A1
(es)
|
2011-12-23 |
2014-08-20 |
Genentech Inc |
Procedimiento para preparar formulaciones con alta concentracion de proteinas
|
|
JP2015508994A
(ja)
|
2011-12-30 |
2015-03-26 |
アッヴィ・インコーポレイテッド |
Ｉｌ−１３および／またはｉｌ−１７に対する二重可変ドメイン免疫グロブリン
|
|
CN102558355B
(zh)
*
|
2011-12-31 |
2015-02-25 |
苏州康宁杰瑞生物科技有限公司 |
基于电荷网络的异二聚体fc改造方法及异二聚体蛋白的制备方法
|
|
CA2862424A1
(en)
|
2012-01-18 |
2013-07-25 |
Genentech, Inc. |
Methods of using fgf19 modulators
|
|
SG10201601747XA
(en)
|
2012-01-18 |
2016-04-28 |
Genentech Inc |
Anti-LRP5 Antibodies And Methods Of Use
|
|
BR112014018575A2
(pt)
*
|
2012-01-26 |
2017-07-04 |
Amgen Inc |
polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
|
|
US10633451B2
(en)
|
2012-02-03 |
2020-04-28 |
Hoffmann-La Roche Inc. |
Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine
|
|
SG11201404751UA
(en)
|
2012-02-09 |
2014-09-26 |
Chugai Pharmaceutical Co Ltd |
Modified fc region of antibody
|
|
BR112014019741A2
(pt)
|
2012-02-11 |
2020-12-22 |
Genentech, Inc |
Usos de um antagonista da via wnt, uso de uma terapia anticâncer, método de identificação de um indivíduo com câncer, métodos para prever, método de inibição da proliferação de uma célula de câncer, uso de um antagonista da translocação de r-spondina e antagonista da translocação de r-spondina isolado
|
|
CN104125852B9
(zh)
|
2012-02-15 |
2017-05-17 |
弗·哈夫曼-拉罗切有限公司 |
基于Fc‑受体的亲和色谱
|
|
EP2819688A4
(en)
|
2012-02-15 |
2015-10-28 |
Aileron Therapeutics Inc |
PEPTIDOMIMETIC MACROCYCLES CROSS-LINKED WITH TRIAZOLE AND THIOETHER
|
|
SG11201404648PA
(en)
|
2012-02-15 |
2014-09-26 |
Aileron Therapeutics Inc |
Peptidomimetic macrocycles
|
|
EP2831115A1
(en)
|
2012-03-27 |
2015-02-04 |
F. Hoffmann-La Roche AG |
Diagnosis and treatments relating to her3 inhibitors
|
|
WO2013148117A1
(en)
|
2012-03-27 |
2013-10-03 |
Ngm Biopharmaceuticals, Inc. |
Compositions and methods of use for treating metabolic disorders
|
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
|
EP2834273B1
(en)
|
2012-04-05 |
2018-08-22 |
F.Hoffmann-La Roche Ag |
Bispecific antibodies against human tweak and human il17 and uses thereof
|
|
CA2870821C
(en)
|
2012-04-20 |
2022-06-14 |
Merus B.V. |
Methods and means for the production of ig-like molecules
|
|
US9090694B2
(en)
|
2012-04-30 |
2015-07-28 |
Janssen Biotech, Inc. |
ST2L antibody antagonists
|
|
SG11201407106XA
(en)
|
2012-05-01 |
2014-11-27 |
Genentech Inc |
Anti-pmel17 antibodies and immunoconjugates
|
|
EP2847230B1
(en)
*
|
2012-05-10 |
2020-08-12 |
Zymeworks Inc. |
Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
|
|
WO2013166604A1
(en)
*
|
2012-05-10 |
2013-11-14 |
Zymeworks Inc. |
Single-arm monovalent antibody constructs and uses thereof
|
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
|
AR091069A1
(es)
|
2012-05-18 |
2014-12-30 |
Amgen Inc |
Proteinas de union a antigeno dirigidas contra el receptor st2
|
|
US20150353639A1
(en)
|
2012-05-21 |
2015-12-10 |
Genentech, Inc. |
Methods for improving safety of blood-brain barrier transport
|
|
JP6294311B2
(ja)
|
2012-05-23 |
2018-03-14 |
ジェネンテック， インコーポレイテッド |
治療薬の選択方法
|
|
EP4310191A3
(en)
|
2012-06-14 |
2024-05-15 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing modified fc region
|
|
CA2875096A1
(en)
|
2012-06-15 |
2013-12-19 |
Genentech, Inc. |
Anti-pcsk9 antibodies, formulations, dosing, and methods of use
|
|
FI3421486T3
(fi)
|
2012-06-22 |
2023-12-15 |
Dartmouth College |
Uusia vista-ig-rakenteita ja vista-ig:n käyttö autoimmuuni-, allergia- ja tulehdushäiriöiden hoitamiseksi
|
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
|
US9499634B2
(en)
|
2012-06-25 |
2016-11-22 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
|
CN107973856B
(zh)
|
2012-07-04 |
2021-11-23 |
弗·哈夫曼-拉罗切有限公司 |
共价连接的抗原-抗体缀合物
|
|
MX354303B
(es)
|
2012-07-04 |
2018-02-23 |
Hoffmann La Roche |
Anticuerpos de anti-biotina y metodos de uso.
|
|
MX353951B
(es)
|
2012-07-04 |
2018-02-07 |
Hoffmann La Roche |
Anticuerpos de anti-teofilina y metodos de uso.
|
|
CN110042114B
(zh)
|
2012-07-05 |
2024-09-10 |
弗·哈夫曼-拉罗切有限公司 |
表达和分泌系统
|
|
EP3632462A1
(en)
|
2012-07-06 |
2020-04-08 |
Genmab B.V. |
Dimeric protein with triple mutations
|
|
WO2014006217A1
(en)
|
2012-07-06 |
2014-01-09 |
Genmab B.V. |
Dimeric protein with triple mutations
|
|
TW201406785A
(zh)
|
2012-07-09 |
2014-02-16 |
Genentech Inc |
抗ｃｄ２２抗體及免疫結合物
|
|
JP2015523380A
(ja)
|
2012-07-09 |
2015-08-13 |
ジェネンテック， インコーポレイテッド |
抗ｃｄ７９ｂ抗体を含む免疫複合体
|
|
HK1207972A1
(en)
|
2012-07-09 |
2016-02-19 |
基因泰克公司 |
Immunoconjugates comprising anti - cd79b antibodies
|
|
TW201408696A
(zh)
|
2012-07-09 |
2014-03-01 |
Genentech Inc |
抗ｃｄ２２抗體及免疫結合物
|
|
AU2013289883B2
(en)
*
|
2012-07-13 |
2018-11-01 |
Zymeworks Bc Inc. |
Bispecific asymmetric heterodimers comprising anti-CD3 constructs
|
|
UA120029C2
(uk)
|
2012-07-13 |
2019-09-25 |
Рош Глікарт Аг |
Спосіб зниження в'язкості біспецифічного антитіла до vegf/ang-2 та застосування такого антитіла для лікування судинних очних захворювань
|
|
CA2876730A1
(en)
|
2012-07-13 |
2014-01-16 |
The Trustees Of The University Of Pennsylvania |
Enhancing activity of car t cells by co-introducing a bispecific antibody
|
|
IN2015DN01115A
(OSRAM)
|
2012-07-13 |
2015-06-26 |
Zymeworks Inc |
|
|
WO2014015148A1
(en)
|
2012-07-19 |
2014-01-23 |
Amgen Inc. |
Human btnl3 proteins, nucleic acids, and antibodies and uses thereof
|
|
CN102851338A
(zh)
*
|
2012-07-25 |
2013-01-02 |
苏州康宁杰瑞生物科技有限公司 |
利用电荷排斥作用制备同二聚体蛋白混合物的方法
|
|
AR092044A1
(es)
|
2012-08-07 |
2015-03-18 |
Roche Glycart Ag |
Inmunoterapia mejorada
|
|
US9771427B2
(en)
|
2012-08-09 |
2017-09-26 |
Roche Glycart Ag |
ASGPR antibodies and uses thereof
|
|
JP6774164B2
(ja)
|
2012-08-24 |
2020-10-21 |
中外製薬株式会社 |
マウスＦｃγＲＩＩ特異的Ｆｃ抗体
|
|
EP3721900A1
(en)
|
2012-08-24 |
2020-10-14 |
Chugai Seiyaku Kabushiki Kaisha |
Fcgammariib-specific fc region variant
|
|
JP6368308B2
(ja)
|
2012-09-07 |
2018-08-01 |
トラスティーズ・オブ・ダートマス・カレッジ |
癌の診断および治療のためのｖｉｓｔａ調節剤
|
|
HK1215950A1
(zh)
|
2012-09-25 |
2016-09-30 |
艾科诺斯科技股份有限公司 |
异源二聚免疫球蛋白的纯化
|
|
LT2900694T
(lt)
|
2012-09-27 |
2018-11-12 |
Merus N.V. |
Bispecifiniai igg antikūnai kaip t ląstelių aktyvatoriai
|
|
US9771573B2
(en)
|
2012-10-03 |
2017-09-26 |
Zymeworks Inc. |
Methods of quantitating heavy and light chain polypeptide pairs
|
|
JP6273205B2
(ja)
|
2012-10-05 |
2018-01-31 |
協和発酵キリン株式会社 |
ヘテロダイマータンパク質組成物
|
|
MX2015003616A
(es)
|
2012-10-08 |
2015-06-05 |
Roche Glycart Ag |
Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de uso.
|
|
EP2914961A4
(en)
|
2012-10-31 |
2016-04-20 |
Oncomed Pharm Inc |
METHODS AND MONITORING A TREATMENT BY AN ANTAGONIST OF DLL4
|
|
KR20150082307A
(ko)
|
2012-11-01 |
2015-07-15 |
에일러론 테라퓨틱스 인코포레이티드 |
이치환 아미노산 및 이의 제조 및 사용 방법
|
|
RU2636043C2
(ru)
|
2012-11-01 |
2017-11-17 |
Эббви Инк. |
Анти-vegf/dll4-иммуноглобулины с двойными вариабельными доменами и их применения
|
|
US10344099B2
(en)
|
2012-11-05 |
2019-07-09 |
Zenyaku Kogyo Kabushikikaisha |
Antibody and antibody composition production method
|
|
US11230589B2
(en)
|
2012-11-05 |
2022-01-25 |
Foundation Medicine, Inc. |
Fusion molecules and uses thereof
|
|
HK1214830A1
(zh)
|
2012-11-05 |
2016-08-05 |
Foundation Medicine, Inc. |
新型ntrk1融合分子及其应用
|
|
KR20150064205A
(ko)
|
2012-11-08 |
2015-06-10 |
에프. 호프만-라 로슈 아게 |
Her3의 베타-헤어핀에 결합하는 her3 항원 결합 단백질
|
|
PH12019501031A1
(en)
|
2012-11-13 |
2022-11-14 |
Genentech Inc |
Anti-hemagglutinin antibodies and methods of use
|
|
UY35148A
(es)
*
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
CN104271602B
(zh)
|
2012-11-21 |
2020-08-21 |
武汉友芝友生物制药有限公司 |
双特异性抗体
|
|
KR101522954B1
(ko)
*
|
2012-11-27 |
2015-05-27 |
아주대학교산학협력단 |
항체 중쇄불변부위의 이종이중체 고효율 형성을 유도하는 ch3 도메인 변이체 쌍, 이의 제조방법, 및 용도
|
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
|
US10077298B2
(en)
|
2012-11-28 |
2018-09-18 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
|
KR102249779B1
(ko)
|
2012-12-27 |
2021-05-07 |
추가이 세이야쿠 가부시키가이샤 |
헤테로이량화 폴리펩티드
|
|
ES2984345T3
(es)
|
2013-01-10 |
2024-10-29 |
Genmab Bv |
Variantes de la región FC de IGG1 humana y usos de las mismas
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
DK2943511T3
(da)
|
2013-01-14 |
2019-10-21 |
Xencor Inc |
Nye heterodimeriske proteiner
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
WO2014113510A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
AU2014207342C1
(en)
|
2013-01-18 |
2019-04-04 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
|
WO2014114801A1
(en)
|
2013-01-25 |
2014-07-31 |
Amgen Inc. |
Antibodies targeting cdh19 for melanoma
|
|
US9161966B2
(en)
|
2013-01-30 |
2015-10-20 |
Ngm Biopharmaceuticals, Inc. |
GDF15 mutein polypeptides
|
|
WO2014120619A2
(en)
|
2013-01-30 |
2014-08-07 |
Ngm Biopharmaceuticals, Inc. |
Compositions and methods of use in treating metabolic disorders
|
|
WO2014124326A1
(en)
*
|
2013-02-08 |
2014-08-14 |
Stem Centrx, Inc. |
Novel multispecific constructs
|
|
EP3744728A1
(en)
|
2013-02-12 |
2020-12-02 |
Bristol-Myers Squibb Company |
Tangential flow filtration based protein refolding methods
|
|
ES2751735T3
(es)
|
2013-02-12 |
2020-04-01 |
Bristol Myers Squibb Co |
Métodos de replegado de proteínas a elevado pH
|
|
PL2956471T3
(pl)
*
|
2013-02-15 |
2024-06-24 |
R-Pharm International, Llc |
Kompozycja inhibitora il-1beta i jej zastosowanie
|
|
MX2015010791A
(es)
|
2013-02-22 |
2015-11-26 |
Hoffmann La Roche |
Metodos para tratar el cancer y prevenir la resistencia a farmacos.
|
|
MX2015010843A
(es)
|
2013-02-26 |
2016-04-04 |
Roche Glycart Ag |
Moleculas biespecificas de union al antigeno que activan celulas t.
|
|
PT2961771T
(pt)
|
2013-02-26 |
2020-02-28 |
Roche Glycart Ag |
Moléculas de ligação ao antigénio biespecíficas para ativação das células t, específicas para cd3 e cea
|
|
CA2896259A1
(en)
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Anti-mcsp antibodies
|
|
CN105143270B
(zh)
|
2013-02-26 |
2019-11-12 |
罗切格利卡特公司 |
双特异性t细胞活化抗原结合分子
|
|
WO2014138449A1
(en)
|
2013-03-06 |
2014-09-12 |
Merrimack Pharmaceuticals, Inc. |
Anti-c-met tandem fc bispecific antibodies
|
|
CN105246511A
(zh)
|
2013-03-06 |
2016-01-13 |
豪夫迈·罗氏有限公司 |
治疗和预防癌症药物抗性的方法
|
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
|
EP3486255A3
(en)
*
|
2013-03-13 |
2019-11-13 |
Ibentrus Inc. |
Protein in which electrical interaction is introduced within hydrophobic interaction site and preparation method therefor
|
|
PH12022550138A1
(en)
|
2013-03-13 |
2023-03-06 |
Amgen Inc |
Proteins specific for baff and b7rp1 and uses thereof
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
US9546203B2
(en)
|
2013-03-14 |
2017-01-17 |
Amgen Inc. |
Aglycosylated Fc-containing polypeptides with cysteine substitutions
|
|
KR20150127199A
(ko)
|
2013-03-14 |
2015-11-16 |
제넨테크, 인크. |
항-b7-h4 항체 및 면역접합체
|
|
HK1220916A1
(zh)
|
2013-03-14 |
2017-05-19 |
基因泰克公司 |
治疗癌症和预防癌症药物抗性的方法
|
|
SG11201507477XA
(en)
|
2013-03-14 |
2015-10-29 |
Genentech Inc |
Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
CN105143265A
(zh)
|
2013-03-15 |
2015-12-09 |
豪夫迈·罗氏有限公司 |
抗CRTh2抗体及其用途
|
|
JP6568514B2
(ja)
|
2013-03-15 |
2019-08-28 |
エーシー イミューン エス．エー． |
抗タウ抗体及び使用方法
|
|
SG10201701380TA
(en)
|
2013-03-15 |
2017-04-27 |
Genentech Inc |
Biomarkers and methods of treating pd-1 and pd-l1 related conditions
|
|
KR20150130451A
(ko)
|
2013-03-15 |
2015-11-23 |
제넨테크, 인크. |
암 치료 방법 및 항암제 내성 예방을 위한 방법
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
CN105324396A
(zh)
|
2013-03-15 |
2016-02-10 |
艾伯维公司 |
针对IL-1β和/或IL-17的双重特异性结合蛋白
|
|
JP6527132B2
(ja)
|
2013-03-15 |
2019-06-05 |
ジェネンテック， インコーポレイテッド |
肝臓がんの診断及び治療のための組成物及び方法
|
|
JP6404313B2
(ja)
*
|
2013-03-15 |
2018-10-10 |
アムジエン・インコーポレーテツド |
ヘテロ二量体性二重特異性抗体
|
|
EP3587448B1
(en)
*
|
2013-03-15 |
2021-05-19 |
Xencor, Inc. |
Heterodimeric proteins
|
|
DK2970486T3
(en)
|
2013-03-15 |
2018-08-06 |
Xencor Inc |
MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
|
|
EP2970461A4
(en)
|
2013-03-15 |
2016-11-23 |
Janssen Biotech Inc |
INTERFERON ALPHA AND OMEGA ANTIBODY ANTAGONISTS
|
|
US20140302037A1
(en)
*
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
|
UA119319C2
(uk)
|
2013-03-18 |
2019-06-10 |
Біосерокс Продактс Б.В. |
Гуманізоване антитіло до cd134 (ox40) і його застосування
|
|
KR102318483B1
(ko)
|
2013-04-02 |
2021-10-27 |
추가이 세이야쿠 가부시키가이샤 |
Ｆｃ영역 개변체
|
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
|
ES2746136T3
(es)
|
2013-04-29 |
2020-03-04 |
Hoffmann La Roche |
Anticuerpos modificados de unión a FcRn humano y procedimientos de uso
|
|
SG11201508910WA
(en)
|
2013-04-29 |
2015-11-27 |
Hoffmann La Roche |
Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
|
|
KR102266819B1
(ko)
*
|
2013-04-29 |
2021-06-18 |
에프. 호프만-라 로슈 아게 |
Fc-수용체 결합 개질된 비대칭 항체 및 이의 사용 방법
|
|
US10239951B2
(en)
|
2013-05-08 |
2019-03-26 |
Zymeworks Inc. |
Bispecific HER2 and HER3 antigen binding constructs
|
|
HRP20240107T1
(hr)
|
2013-05-20 |
2024-04-12 |
F. Hoffmann - La Roche Ag |
Protutijela na transferinski receptor i postupci uporabe
|
|
EP4349864A3
(en)
|
2013-05-30 |
2024-06-26 |
Kiniksa Pharmaceuticals, Ltd. |
Oncostatin m receptor antigen binding proteins
|
|
MX373245B
(es)
|
2013-07-05 |
2020-05-11 |
Genmab As |
Anticuerpos cd3 humanizados o quiméricos.
|
|
WO2015017710A1
(en)
|
2013-07-31 |
2015-02-05 |
Amgen Inc. |
Growth differentiation factor 15 (gdf-15) constructs
|
|
AU2014332458B2
(en)
*
|
2013-09-05 |
2020-03-12 |
Igm Biosciences, Inc. |
Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies
|
|
HK1218124A1
(zh)
|
2013-09-17 |
2017-02-03 |
豪夫迈．罗氏有限公司 |
使用抗lgr5抗体的方法
|
|
US20160257748A1
(en)
|
2013-09-25 |
2016-09-08 |
Amgen Inc. |
V-c-fc-v-c antibody
|
|
MX382731B
(es)
|
2013-09-27 |
2025-03-13 |
Chugai Pharmaceutical Co Ltd |
Metodo para producir heteromultimeros de polipeptidos.
|
|
RU2016115866A
(ru)
|
2013-10-11 |
2017-11-16 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи
|
|
KR20160068855A
(ko)
|
2013-10-11 |
2016-06-15 |
제넨테크, 인크. |
Nsp4 억제제 및 사용 방법
|
|
EP3057615B1
(en)
|
2013-10-18 |
2021-02-24 |
F.Hoffmann-La Roche Ag |
Anti-rspo antibodies and methods of use
|
|
WO2015061441A1
(en)
|
2013-10-23 |
2015-04-30 |
Genentech, Inc. |
Methods of diagnosing and treating eosinophilic disorders
|
|
PL3065774T3
(pl)
|
2013-11-06 |
2021-12-13 |
Janssen Biotech, Inc |
Przeciwciała anty-ccl17
|
|
CA2930307A1
(en)
|
2013-11-13 |
2015-05-21 |
Zymeworks Inc. |
Monovalent antigen binding constructs targeting egfr and/or her2 and uses thereof
|
|
PL3071597T3
(pl)
|
2013-11-21 |
2020-11-30 |
F.Hoffmann-La Roche Ag |
Przeciwciała przeciwko alfa-synukleinie i sposoby stosowania
|
|
EP3074424B1
(en)
|
2013-11-27 |
2025-02-12 |
Zymeworks BC Inc. |
Bispecific antigen-binding constructs targeting her2
|
|
TW201533060A
(zh)
|
2013-12-13 |
2015-09-01 |
Genentech Inc |
抗ｃｄ３３抗體及免疫結合物
|
|
LT3083680T
(lt)
|
2013-12-20 |
2020-04-10 |
F. Hoffmann-La Roche Ag |
Humanizuoti anti-tau(ps422) antikūnai ir jų naudojimo būdai
|
|
TWI728373B
(zh)
|
2013-12-23 |
2021-05-21 |
美商建南德克公司 |
抗體及使用方法
|
|
US10273301B2
(en)
|
2013-12-24 |
2019-04-30 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments
|
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
|
RU2694981C2
(ru)
|
2014-01-03 |
2019-07-18 |
Ф. Хоффманн-Ля Рош Аг |
Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения
|
|
MX373017B
(es)
|
2014-01-03 |
2020-04-28 |
Hoffmann La Roche |
Conjugados de toxina polipeptidica-anticuerpo unidos covalentemente.
|
|
PL3089996T3
(pl)
|
2014-01-03 |
2021-12-13 |
F. Hoffmann-La Roche Ag |
Dwuswoiste przeciwciała przeciw haptenowi/przeciw receptorowi występującemu w barierze krew-mózg, ich kompleksy i ich zastosowanie jako przenośniki wahadłowe występujące w barierze krew-mózg
|
|
JP6557664B2
(ja)
|
2014-01-06 |
2019-08-07 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
一価の血液脳関門シャトルモジュール
|
|
KR20160103058A
(ko)
|
2014-01-08 |
2016-08-31 |
샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 |
Il-15 이종 이량체 단백질 및 그의 용도
|
|
CN105899534B
(zh)
|
2014-01-15 |
2020-01-07 |
豪夫迈·罗氏有限公司 |
具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体
|
|
RU2698969C2
(ru)
|
2014-01-15 |
2019-09-02 |
Ф.Хоффманн-Ля Рош Аг |
Варианты fc-области с улучшенной способностью связываться с белком а
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
SG11201605903SA
(en)
|
2014-01-24 |
2016-08-30 |
Genentech Inc |
Methods of using anti-steap1 antibodies and immunoconjugates
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
TWI705824B
(zh)
|
2014-02-08 |
2020-10-01 |
美商建南德克公司 |
治療阿茲海默症之方法
|
|
EP3102230B1
(en)
|
2014-02-08 |
2021-04-28 |
F. Hoffmann-La Roche AG |
Methods of treating alzheimer's disease
|
|
JP6571115B2
(ja)
|
2014-02-12 |
2019-09-04 |
ジェネンテック， インコーポレイテッド |
抗ｊａｇｇｅｄ１抗体及び使用方法
|
|
WO2015127405A2
(en)
|
2014-02-21 |
2015-08-27 |
Genentech, Inc. |
Anti-il-13/il-17 bispecific antibodies and uses thereof
|
|
WO2015130172A1
(en)
|
2014-02-28 |
2015-09-03 |
Merus B.V. |
Antibodies that bind egfr and erbb3
|
|
JP6967853B2
(ja)
|
2014-02-28 |
2021-11-17 |
メルス ナムローゼ フェンノートシャップ |
ＥｒｂＢ−２およびＥｒｂＢ−３に結合する抗体
|
|
US9732154B2
(en)
|
2014-02-28 |
2017-08-15 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
|
|
LT3116909T
(lt)
|
2014-03-14 |
2020-02-10 |
Novartis Ag |
Antikūno molekulės prieš lag-3 ir jų panaudojimas
|
|
CN106103730B
(zh)
|
2014-03-14 |
2021-06-08 |
豪夫迈·罗氏有限公司 |
用于分泌异源多肽的方法和组合物
|
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
|
WO2015140591A1
(en)
|
2014-03-21 |
2015-09-24 |
Nordlandssykehuset Hf |
Anti-cd14 antibodies and uses thereof
|
|
BR112016021572A2
(pt)
|
2014-03-21 |
2017-10-03 |
Regeneron Pharma |
Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação
|
|
EP3122900A1
(en)
|
2014-03-24 |
2017-02-01 |
F. Hoffmann-La Roche AG |
Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
|
|
US12180264B2
(en)
|
2014-03-24 |
2024-12-31 |
R-Pharm Overseas, Inc. |
IL1-R1 derived inhibitor of IL-1β and use thereof
|
|
BR112016022385A2
(pt)
|
2014-03-28 |
2018-06-19 |
Xencor, Inc |
anticorpos específicos que se ligam a cd38 e cd3
|
|
CA2943834A1
(en)
|
2014-03-31 |
2015-10-08 |
Genentech, Inc. |
Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
|
|
HRP20192285T1
(hr)
|
2014-03-31 |
2020-03-06 |
F. Hoffmann - La Roche Ag |
Anti-ox40 protutijela i postupci uporabe
|
|
EP3126384B1
(en)
|
2014-04-01 |
2020-12-02 |
Adimab, LLC |
Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
|
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
|
SG10202107077QA
(en)
|
2014-04-02 |
2021-07-29 |
Hoffmann La Roche |
Method for detecting multispecific antibody light chain mispairing
|
|
CA2943943C
(en)
|
2014-04-07 |
2023-01-10 |
Chugai Seiyaku Kabushiki Kaisha |
Immunoactivating antigen-binding molecule
|
|
WO2015160940A1
(en)
*
|
2014-04-15 |
2015-10-22 |
President And Fellows Of Harvard College |
Bi-specific agents
|
|
WO2015164615A1
(en)
|
2014-04-24 |
2015-10-29 |
University Of Oslo |
Anti-gluten antibodies and uses thereof
|
|
IL286367B2
(en)
*
|
2014-05-02 |
2023-03-01 |
Momenta Pharmaceuticals Inc |
Compositions and methods relating to engineered fc constructs
|
|
MX2016014409A
(es)
|
2014-05-06 |
2017-01-20 |
Genentech Inc |
Produccion de proteinas heteromultimericas usando celulas de mamifero.
|
|
JP7179400B2
(ja)
|
2014-05-13 |
2022-11-29 |
バイオアトラ インコーポレイテッド |
条件的活性型生物学的タンパク質
|
|
JP6894702B2
(ja)
|
2014-05-13 |
2021-06-30 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子
|
|
US10392438B2
(en)
|
2014-05-16 |
2019-08-27 |
Pfizer Inc. |
Bispecific antibodies
|
|
WO2015179658A2
(en)
|
2014-05-22 |
2015-11-26 |
Genentech, Inc. |
Anti-gpc3 antibodies and immunoconjugates
|
|
EP3146071B1
(en)
|
2014-05-23 |
2020-09-02 |
F. Hoffmann-La Roche AG |
Mit biomarkers and methods using the same
|
|
RU2729467C2
(ru)
|
2014-05-28 |
2020-08-06 |
Займворкс Инк. |
Модифицированные антигенсвязывающие полипептидные конструкции и их применение
|
|
KR102305109B1
(ko)
|
2014-06-04 |
2021-09-27 |
악셀레론 파마 인코포레이티드 |
폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물
|
|
US10010498B2
(en)
|
2014-06-04 |
2018-07-03 |
Acceleron Pharma Inc. |
Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
|
|
MX2016016233A
(es)
|
2014-06-11 |
2017-03-31 |
Genentech Inc |
Anticuerpos anti-lgr5 y sus usos.
|
|
WO2015191881A2
(en)
|
2014-06-11 |
2015-12-17 |
Green Kathy A |
Use of vista agonists and antagonists to suppress or enhance humoral immunity
|
|
WO2015191986A1
(en)
|
2014-06-13 |
2015-12-17 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
|
TWI713453B
(zh)
|
2014-06-23 |
2020-12-21 |
美商健生生物科技公司 |
干擾素α及ω抗體拮抗劑
|
|
AR100978A1
(es)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
|
|
RU2705299C2
(ru)
|
2014-06-26 |
2019-11-06 |
Ф. Хоффманн-Ля Рош Аг |
Антитела против 5-бром-2'-дезоксиуридина и способы применения
|
|
WO2015197598A2
(en)
|
2014-06-27 |
2015-12-30 |
Innate Pharma |
Multispecific antigen binding proteins
|
|
EP3161002A1
(en)
|
2014-06-27 |
2017-05-03 |
Innate Pharma |
MULTISPECIFIC NKp46 BINDING PROTEINS
|
|
TW201623329A
(zh)
|
2014-06-30 |
2016-07-01 |
亞佛瑞司股份有限公司 |
針對骨調素截斷變異體的疫苗及單株抗體暨其用途
|
|
US10308944B2
(en)
|
2014-07-03 |
2019-06-04 |
Genentech, Inc. |
Polypeptide expression systems
|
|
EP3166966A1
(en)
|
2014-07-10 |
2017-05-17 |
Affiris AG |
Substances and methods for the use in prevention and/or treatment in huntington's disease
|
|
MX2017000363A
(es)
|
2014-07-11 |
2017-04-27 |
Genentech Inc |
Inhibicion de la via de notch.
|
|
KR102360693B1
(ko)
|
2014-07-11 |
2022-02-08 |
벤타나 메디컬 시스템즈, 인코포레이티드 |
항-pd-l1 항체 및 이의 진단 용도
|
|
HRP20200283T1
(hr)
|
2014-07-11 |
2020-05-29 |
Genmab A/S |
Protutijela koja se vežu na axl
|
|
JP6831777B2
(ja)
|
2014-07-21 |
2021-02-17 |
ノバルティス アーゲー |
Ｃｄ３３キメラ抗原受容体を使用する癌の処置
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
JP7054622B2
(ja)
|
2014-07-21 |
2022-04-14 |
ノバルティス アーゲー |
ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置
|
|
EP3193915A1
(en)
|
2014-07-21 |
2017-07-26 |
Novartis AG |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
US9777073B2
(en)
*
|
2014-07-21 |
2017-10-03 |
Wuhan Yzy Biopharma Co., Ltd. |
Construction and application of bispecific antibody EpCAM×CD3
|
|
EP3174897B1
(en)
*
|
2014-07-29 |
2020-02-12 |
F.Hoffmann-La Roche Ag |
Multispecific antibodies
|
|
ES2883158T3
(es)
|
2014-07-30 |
2021-12-07 |
Ngm Biopharmaceuticals Inc |
Composiciones y procedimientos de uso para el tratamiento de trastornos metabólicos
|
|
WO2016019300A1
(en)
|
2014-07-31 |
2016-02-04 |
Novartis Ag |
Subset-optimized chimeric antigen receptor-containing t-cells
|
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
CR20170032A
(es)
|
2014-08-04 |
2017-04-04 |
Hoffmann La Roche |
Moleculas biespecíficas de unión a antígeno activadoras de células t
|
|
AU2015301460B2
(en)
|
2014-08-14 |
2021-04-08 |
Novartis Ag |
Treatment of cancer using GFR alpha-4 chimeric antigen receptor
|
|
WO2016028896A1
(en)
|
2014-08-19 |
2016-02-25 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
|
ES3034398T3
(en)
|
2014-08-28 |
2025-08-18 |
Bioatla Inc |
Conditionally active chimeric antigen receptors for modified t-cells
|
|
US11111288B2
(en)
|
2014-08-28 |
2021-09-07 |
Bioatla, Inc. |
Conditionally active chimeric antigen receptors for modified t-cells
|
|
MX386703B
(es)
|
2014-09-03 |
2025-03-19 |
Bioatla Llc |
Descubrimiento y producción de proteínas biológicas condicionalmente activas en las mismas células hospederas eucariotas de producción.
|
|
BR112017004614A2
(pt)
|
2014-09-09 |
2018-02-27 |
Janssen Biotech, Inc. |
terapias de combinação com anticorpos anti-cd38
|
|
SG11201701623UA
(en)
|
2014-09-12 |
2017-03-30 |
Genentech Inc |
Anti-her2 antibodies and immunoconjugates
|
|
JP6943760B2
(ja)
|
2014-09-12 |
2021-10-06 |
ジェネンテック， インコーポレイテッド |
抗ｂ７−ｈ４抗体及び免疫複合体
|
|
BR112017003236A2
(pt)
|
2014-09-12 |
2017-11-28 |
Genentech Inc |
anticorpos elaborados com cisteína, conjugados de droga e anticorpos, método de preparação de conjugado de droga e anticorpo e composição farmacêutica
|
|
EA201790569A1
(ru)
|
2014-09-12 |
2017-08-31 |
Дженентек, Инк. |
Антитела и иммуноконъюгаты против cll-1
|
|
JP6956631B2
(ja)
|
2014-09-15 |
2021-11-02 |
アムジェン インコーポレイテッド |
二重特異性抗ｃｇｒｐ受容体／ｐａｃ１受容体抗原結合タンパク質及びその使用
|
|
US10577417B2
(en)
|
2014-09-17 |
2020-03-03 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
KR20170055521A
(ko)
|
2014-09-17 |
2017-05-19 |
제넨테크, 인크. |
항-her2 항체를 포함하는 면역콘주게이트
|
|
SI3262071T1
(sl)
|
2014-09-23 |
2020-07-31 |
F. Hoffmann-La Roche Ag |
Način uporabe imunokonjugatov proti CD79b
|
|
SG11201702223UA
(en)
|
2014-09-24 |
2017-04-27 |
Aileron Therapeutics Inc |
Peptidomimetic macrocycles and uses thereof
|
|
EP3197477A4
(en)
|
2014-09-24 |
2018-07-04 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles and formulations thereof
|
|
JP2017529853A
(ja)
|
2014-09-25 |
2017-10-12 |
アムジエン・インコーポレーテツド |
プロテアーゼにより活性化可能な二重特異性タンパク質
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
ES2850325T3
(es)
|
2014-10-09 |
2021-08-27 |
Engmab Sarl |
Anticuerpos biespecíficos contra CD3epsilon y ROR1
|
|
EP3206711B1
(en)
|
2014-10-14 |
2023-05-31 |
Novartis AG |
Antibody molecules to pd-l1 and uses thereof
|
|
JP2017536102A
(ja)
|
2014-10-16 |
2017-12-07 |
ジェネンテック， インコーポレイテッド |
抗アルファ−シヌクレイン抗体及び使用方法
|
|
HK1243333A1
(zh)
|
2014-10-31 |
2018-07-13 |
The Trustees Of The University Of Pennsylvania |
用於修饰的t细胞的方法和组合物
|
|
AP2017009828A0
(en)
|
2014-10-31 |
2017-03-31 |
Ngm Biopharmaceuticals Inc |
Compositions and methods of use for treating metabolic disorders
|
|
AU2015338974B2
(en)
|
2014-10-31 |
2021-08-26 |
Oncomed Pharmaceuticals, Inc. |
Combination therapy for treatment of disease
|
|
BR112017009151A2
(pt)
|
2014-11-03 |
2018-03-06 |
Genentech, Inc. |
ensaios para detectar subgrupos imunológicos de célula t e métodos de uso dos mesmos
|
|
WO2016073380A1
(en)
|
2014-11-03 |
2016-05-12 |
Genentech, Inc. |
Method and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
|
US11773166B2
(en)
|
2014-11-04 |
2023-10-03 |
Ichnos Sciences SA |
CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
|
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
|
BR112017006591A2
(pt)
|
2014-11-06 |
2018-01-16 |
Hoffmann La Roche |
polipeptídeo heterodimérico, formulação farmacêutica e uso de um polipeptídeo heterodimérico
|
|
BR112017006178A2
(pt)
|
2014-11-06 |
2018-05-02 |
F. Hoffmann-La Roche Ag |
região fc, anticorpos, formulação farmacêutica e usos dos anticorpos
|
|
WO2016077369A1
(en)
|
2014-11-10 |
2016-05-19 |
Genentech, Inc. |
Animal model for nephropathy and agents for treating the same
|
|
EA201791029A1
(ru)
|
2014-11-10 |
2017-12-29 |
Дженентек, Инк. |
Антитела против интерлейкина-33 и их применение
|
|
CN114634570B
(zh)
|
2014-11-14 |
2025-05-06 |
豪夫迈·罗氏有限公司 |
包含tnf家族配体三聚体的抗原结合分子
|
|
JP6779876B2
(ja)
|
2014-11-19 |
2020-11-04 |
ジェネンテック， インコーポレイテッド |
抗トランスフェリン受容体抗体及びその使用方法
|
|
WO2016081639A1
(en)
|
2014-11-19 |
2016-05-26 |
Genentech, Inc. |
Antibodies against bace1 and use thereof for neural disease immunotherapy
|
|
JP6993228B2
(ja)
|
2014-11-19 |
2022-03-03 |
ジェネンテック， インコーポレイテッド |
抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
|
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
MX2017006571A
(es)
|
2014-11-20 |
2017-09-29 |
Hoffmann La Roche |
Moleculas de union a antigeno biespecificas activadoras de celulas t.
|
|
PL3221357T3
(pl)
|
2014-11-20 |
2020-11-02 |
F. Hoffmann-La Roche Ag |
Wspólne łańcuchy lekkie i sposoby zastosowania
|
|
HRP20240959T1
(hr)
|
2014-11-20 |
2024-10-25 |
F. Hoffmann - La Roche Ag |
Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t stanice i antagonistom vezivanja osi pd-1
|
|
CN107406512A
(zh)
|
2014-11-26 |
2017-11-28 |
Xencor公司 |
结合cd3和cd38的异二聚体抗体
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
KR102689285B1
(ko)
|
2014-11-26 |
2024-07-31 |
젠코어 인코포레이티드 |
Ｃｄ3 및 종양 항원과 결합하는 이종이량체 항체
|
|
WO2016082044A1
(en)
|
2014-11-27 |
2016-06-02 |
Zymeworks Inc. |
Methods of using bispecific antigen-binding constructs targeting her2
|
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
JP6721590B2
(ja)
|
2014-12-03 |
2020-07-15 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
多重特異性抗体
|
|
EA202092609A1
(ru)
|
2014-12-04 |
2021-10-29 |
Янссен Байотек, Инк. |
Антитела к cd38 для лечения острого миелолейкоза
|
|
WO2016090347A1
(en)
|
2014-12-05 |
2016-06-09 |
Immunext, Inc. |
Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
|
|
JP6802158B2
(ja)
|
2014-12-05 |
2020-12-16 |
ジェネンテック， インコーポレイテッド |
抗ＣＤ７９ｂ抗体及び使用方法
|
|
SG11201703750XA
(en)
|
2014-12-10 |
2017-06-29 |
Genentech Inc |
Blood brain barrier receptor antibodies and methods of use
|
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
|
RU2698205C2
(ru)
|
2014-12-18 |
2019-08-23 |
Ф. Хоффманн-Ля Рош Аг |
Способ определения антител, вызывающих комплемент-зависимую цитотоксичность
|
|
US10865253B2
(en)
|
2014-12-19 |
2020-12-15 |
Genmab A/S |
Rodent bispecific heterodimeric proteins
|
|
KR102650420B1
(ko)
|
2014-12-19 |
2024-03-21 |
추가이 세이야쿠 가부시키가이샤 |
항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
|
|
TWI617580B
(zh)
|
2014-12-19 |
2018-03-11 |
中外製藥股份有限公司 |
抗ｃ５抗體及使用方法
|
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
|
CN105820251B
(zh)
*
|
2015-01-08 |
2019-10-15 |
江苏康宁杰瑞生物制药有限公司 |
具有共同轻链的双特异性抗体或抗体混合物
|
|
WO2016117346A1
(en)
|
2015-01-22 |
2016-07-28 |
Chugai Seiyaku Kabushiki Kaisha |
A combination of two or more anti-c5 antibodies and methods of use
|
|
MA41375A
(fr)
|
2015-01-22 |
2017-11-28 |
Lilly Co Eli |
Anticorps igg bispécifiques et leurs procédés de préparation
|
|
US10828353B2
(en)
|
2015-01-31 |
2020-11-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for T cell delivery of therapeutic molecules
|
|
KR102605798B1
(ko)
|
2015-02-05 |
2023-11-23 |
추가이 세이야쿠 가부시키가이샤 |
이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
|
|
WO2016141110A1
(en)
|
2015-03-03 |
2016-09-09 |
Schlumberger Technology Corporation |
Multi-mode acoustic tool and method
|
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
ES2761726T3
(es)
|
2015-03-06 |
2020-05-20 |
Hoffmann La Roche |
DsbA y DsbC ultrapurificadas y procedimientos de preparación y uso de las mismas
|
|
AR103935A1
(es)
|
2015-03-16 |
2017-06-14 |
Genentech Inc |
Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th-2
|
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
|
CA2979702A1
(en)
|
2015-03-19 |
2016-09-22 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
|
KR20170129879A
(ko)
|
2015-03-20 |
2017-11-27 |
에일러론 테라퓨틱스 인코포레이티드 |
펩티드모방 거대고리 및 이의 용도
|
|
CN107636154A
(zh)
*
|
2015-03-26 |
2018-01-26 |
阿塞勒隆制药公司 |
促滤泡素抑制素相关的融合蛋白及其用途
|
|
WO2016159213A1
(ja)
|
2015-04-01 |
2016-10-06 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
|
CN114456272A
(zh)
|
2015-04-03 |
2022-05-10 |
优瑞科生物技术公司 |
靶向afp肽/mhc复合体的构建体及其用途
|
|
MA41916A
(fr)
|
2015-04-06 |
2021-04-14 |
Acceleron Pharma Inc |
Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations
|
|
AU2016246602B2
(en)
|
2015-04-06 |
2020-11-19 |
Acceleron Pharma Inc. |
Single-arm type I and type II receptor fusion proteins and uses thereof
|
|
MA41919A
(fr)
|
2015-04-06 |
2018-02-13 |
Acceleron Pharma Inc |
Hétéromultimères alk4:actriib et leurs utilisations
|
|
WO2016164480A1
(en)
|
2015-04-07 |
2016-10-13 |
Genentech, Inc. |
Antigen binding complex having agonistic activity and methods of use
|
|
MX393951B
(es)
|
2015-04-07 |
2025-03-24 |
Alector Llc |
Anticuerpos antisortilina y métodos para su uso.
|
|
PT3280729T
(pt)
|
2015-04-08 |
2022-08-01 |
Novartis Ag |
Terapias para cd20, terapias para cd22 e terapias de combinação com uma célula que expressa o recetor de antigénio quimérico (car) para cd19
|
|
EA201792250A1
(ru)
|
2015-04-10 |
2018-05-31 |
Эмджен Инк. |
Мутеины интерлейкина-2 для роста регуляторных т-клеток
|
|
WO2016164708A1
(en)
|
2015-04-10 |
2016-10-13 |
Adimab, Llc |
Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species
|
|
CA2982657A1
(en)
|
2015-04-17 |
2016-10-20 |
Elsalys Biotech |
Anti-tyro3 antibodies and uses thereof
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
CN107787332B
(zh)
|
2015-04-24 |
2022-09-09 |
豪夫迈·罗氏有限公司 |
多特异性抗原结合蛋白
|
|
CN107810197B
(zh)
|
2015-04-24 |
2022-10-25 |
豪夫迈·罗氏有限公司 |
鉴定包含结合多肽的细菌的方法
|
|
CN107592812A
(zh)
|
2015-05-11 |
2018-01-16 |
豪夫迈·罗氏有限公司 |
治疗狼疮性肾炎的组合物和方法
|
|
PT3294770T
(pt)
|
2015-05-12 |
2020-12-04 |
Hoffmann La Roche |
Métodos terapêuticos e diagnósticos para o cancro
|
|
CN108136218B
(zh)
|
2015-05-20 |
2022-12-13 |
詹森生物科技公司 |
用于治疗轻链淀粉样变性及其它cd38阳性血液恶性肿瘤的抗cd38抗体
|
|
EP3795679A1
(en)
|
2015-05-28 |
2021-03-24 |
Genentech, Inc. |
Cell-based assay for detecting anti-cd3 homodimers
|
|
HK1250723A1
(zh)
|
2015-05-29 |
2019-01-11 |
F. Hoffmann-La Roche Ag |
人源化抗埃博拉病毒糖蛋白抗体和使用方法
|
|
PL3303632T5
(pl)
|
2015-05-29 |
2023-07-03 |
F. Hoffmann-La Roche Ag |
Terapeutyczne i diagnostyczne sposoby stosowane w nowotworze
|
|
JP2018516933A
(ja)
|
2015-06-02 |
2018-06-28 |
ジェネンテック， インコーポレイテッド |
抗ｉｌ−３４抗体を使用して神経学的疾患を治療するための組成物及び方法
|
|
JP6793134B2
(ja)
|
2015-06-05 |
2020-12-02 |
ジェネンテック， インコーポレイテッド |
抗ｔａｕ抗体及び使用方法
|
|
MX2017015937A
(es)
|
2015-06-08 |
2018-12-11 |
Genentech Inc |
Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1.
|
|
AU2016274585A1
(en)
|
2015-06-08 |
2017-12-14 |
Genentech, Inc. |
Methods of treating cancer using anti-OX40 antibodies
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
CN108064246A
(zh)
|
2015-06-15 |
2018-05-22 |
基因泰克公司 |
抗体和免疫结合物
|
|
US10323094B2
(en)
|
2015-06-16 |
2019-06-18 |
Genentech, Inc. |
Humanized and affinity matured antibodies to FcRH5 and methods of use
|
|
EP3310811B1
(en)
|
2015-06-16 |
2021-06-16 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
CN107847568B
(zh)
|
2015-06-16 |
2022-12-20 |
豪夫迈·罗氏有限公司 |
抗cll-1抗体和使用方法
|
|
CA2986592A1
(en)
|
2015-06-17 |
2016-12-22 |
Genentech, Inc. |
Anti-her2 antibodies and methods of use
|
|
NZ777133A
(en)
|
2015-06-22 |
2025-05-02 |
Janssen Biotech Inc |
Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
|
|
WO2016207278A1
(en)
|
2015-06-23 |
2016-12-29 |
Innate Pharma |
Multispecific nk engager proteins
|
|
AR105089A1
(es)
|
2015-06-24 |
2017-09-06 |
Hoffmann La Roche |
ANTICUERPOS ANTI-TAU(pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
|
|
WO2016210223A1
(en)
|
2015-06-24 |
2016-12-29 |
Janssen Biotech, Inc. |
Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
|
|
JP7021955B2
(ja)
|
2015-06-24 |
2022-03-03 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｈｅｒ２及び血液脳関門受容体に特異的な三重特異性抗体及び使用方法
|
|
EP3722314A1
(en)
|
2015-06-24 |
2020-10-14 |
Janssen Pharmaceutica NV |
Anti-vista antibodies and fragments
|
|
WO2016207124A1
(en)
|
2015-06-25 |
2016-12-29 |
F. Hoffmann-La Roche Ag |
Cell based assay for determining antibody or ligand binding and function
|
|
CA2990214A1
(en)
|
2015-06-29 |
2017-01-05 |
Spring Bioscience Corporation |
Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
|
|
AU2016285596A1
(en)
|
2015-06-29 |
2018-01-18 |
Genentech, Inc. |
Type II anti-CD20 antibody for use in organ transplantation
|
|
US10059741B2
(en)
|
2015-07-01 |
2018-08-28 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles
|
|
WO2017005649A1
(en)
|
2015-07-09 |
2017-01-12 |
Genmab A/S |
Bispecific and multispecific antibodies and method for isolation of such
|
|
PL3115376T3
(pl)
|
2015-07-10 |
2019-01-31 |
Merus N.V. |
Ludzkie przeciwciało wiążące cd3
|
|
SMT202000359T1
(it)
|
2015-07-10 |
2020-09-10 |
Genmab As |
Coniugati anticorpo-farmaco specifici per axl per il trattamento del cancro
|
|
UA128057C2
(uk)
|
2015-07-15 |
2024-03-27 |
Ґенмаб А/С |
Гуманізоване або химерне антитіло, яке зв'язує cd3 людини
|
|
WO2017019897A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
|
EP3317301B1
(en)
|
2015-07-29 |
2021-04-07 |
Novartis AG |
Combination therapies comprising antibody molecules to lag-3
|
|
CN114272371A
(zh)
|
2015-07-29 |
2022-04-05 |
诺华股份有限公司 |
包含抗pd-1抗体分子的联合疗法
|
|
SMT202100527T1
(it)
|
2015-07-30 |
2021-11-12 |
Macrogenics Inc |
Molecole di legame a pd-1 e lag-3 e loro metodi d'uso
|
|
EP3331563B1
(en)
|
2015-08-05 |
2023-04-19 |
Janssen Biotech, Inc. |
Anti-cd154 antibodies and methods of using them
|
|
BR102016018074A2
(pt)
|
2015-08-07 |
2021-11-16 |
ALX Oncology Inc. |
Construção variante de sirp-alfa, seu método de preparação e seus usos, molécula de ácido nucleico, vetor, célula hospedeira, e composição farmacêutica
|
|
IL294679B2
(en)
|
2015-08-07 |
2023-10-01 |
Alx Oncology Inc |
Structures with a SIRP-alpha site or its variant
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
LT3334747T
(lt)
|
2015-08-13 |
2023-12-27 |
Amgen Inc. |
Įkrautas giluminis antigeną surišančio baltymo filtravimas
|
|
EP3307321A4
(en)
*
|
2015-08-26 |
2019-04-17 |
Bison Therapeutics Inc. |
MULTISPECIFIC ANTIBODY PLATFORM AND ASSOCIATED METHODS
|
|
US11890301B2
(en)
|
2015-08-28 |
2024-02-06 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for cells expressing a chimeric intracellular signaling molecule
|
|
US11649435B2
(en)
|
2015-08-28 |
2023-05-16 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for cells expressing a chimeric intracellular signaling molecule
|
|
WO2017044859A1
(en)
|
2015-09-10 |
2017-03-16 |
Affigen, Inc. |
Sequencing-directed selection of tumor theranostics
|
|
JP2018528217A
(ja)
|
2015-09-10 |
2018-09-27 |
エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子
|
|
MX2018003183A
(es)
|
2015-09-15 |
2018-08-23 |
Amgen Inc |
Proteinas de enlace de antigeno biespecifico y tetraespecifico tetravalentes y usos de las mismas.
|
|
MX2018003005A
(es)
|
2015-09-18 |
2018-04-11 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos que se unen a interleucina 8 (il-8) y sus usos.
|
|
JP6904947B2
(ja)
|
2015-09-22 |
2021-07-21 |
スプリング バイオサイエンス コーポレーション |
抗ｏｘ４０抗体及びその診断用途
|
|
US11339213B2
(en)
|
2015-09-23 |
2022-05-24 |
Mereo Biopharma 5, Inc. |
Methods and compositions for treatment of cancer
|
|
SG10201911226QA
(en)
|
2015-09-23 |
2020-01-30 |
Genentech Inc |
Optimized variants of anti-vegf antibodies
|
|
KR20180083313A
(ko)
|
2015-09-24 |
2018-07-20 |
에이비비트로, 엘엘씨 |
Hiv 항체 조성물 및 사용 방법
|
|
SI3353210T1
(sl)
|
2015-09-25 |
2025-03-31 |
F. Hoffmann-La Roche Ag |
Protitelesa proti TIGIT in postopki uporabe
|
|
EP3356415B1
(en)
|
2015-09-29 |
2024-05-01 |
Amgen Inc. |
Asgr inhibitors for reduzing cholesterol levels
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
WO2017055314A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
|
|
MA43025A
(fr)
|
2015-10-02 |
2021-05-26 |
Hoffmann La Roche |
Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t anti-ceaxcd3
|
|
AU2016329120B2
(en)
|
2015-10-02 |
2023-04-13 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies specific for a costimulatory TNF receptor
|
|
WO2017055395A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
|
|
EP3150637A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Multispecific antibodies
|
|
EP3356409A2
(en)
|
2015-10-02 |
2018-08-08 |
H. Hoffnabb-La Roche Ag |
Bispecific t cell activating antigen binding molecules
|
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
|
WO2017055385A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
|
|
WO2017055393A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
|
|
WO2017055399A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Cellular based fret assay for the determination of simultaneous binding
|
|
SI3356411T1
(sl)
|
2015-10-02 |
2021-09-30 |
F. Hoffmann-La Roche Ag |
Bispecifična protitelesa, specifična za PD1 in TIM3
|
|
EP3356417A1
(en)
|
2015-10-02 |
2018-08-08 |
H. Hoffnabb-La Roche Ag |
Bispecific t cell activating antigen binding molecules binding mesothelin and cd3
|
|
JP7239320B2
(ja)
*
|
2015-10-02 |
2023-03-14 |
エフ． ホフマン－ラ ロシュ アーゲー |
多重特異性抗体
|
|
IL257858B
(en)
|
2015-10-02 |
2022-09-01 |
Hoffmann La Roche |
Anti-pd1 antibodies and methods of use
|
|
WO2017055392A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
|
|
JP7074665B2
(ja)
|
2015-10-07 |
2022-05-24 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
共刺激ｔｎｆ受容体に対する四価の二重特異性抗体発明の分野
|
|
FI3359576T3
(fi)
|
2015-10-08 |
2025-01-29 |
Zymeworks Bc Inc |
Antigeeniä sitovia polypeptidirakenteita, jotka käsittävät kappa- ja lamba-kevytketjuja, ja niiden käyttötapoja
|
|
KR101851380B1
(ko)
|
2015-10-12 |
2018-04-23 |
아주대학교산학협력단 |
효모접합을 이용한 항체 ch3 도메인 이종이중체 돌연변이쌍 제조 방법 및 이에 의하여 제조된 ch3 돌연변이체 쌍
|
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
|
MA45326A
(fr)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
|
|
SG11201803359VA
(en)
|
2015-10-23 |
2018-05-30 |
Merus Nv |
Binding molecules that inhibit cancer growth
|
|
AU2016344665C1
(en)
|
2015-10-29 |
2023-07-27 |
F. Hoffmann-La Roche Ag |
Anti-variant Fc-region antibodies and methods of use
|
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
|
TW201730211A
(zh)
|
2015-10-30 |
2017-09-01 |
建南德克公司 |
抗因子d抗體及結合物
|
|
PL3368578T3
(pl)
|
2015-10-30 |
2021-07-26 |
F. Hoffmann-La Roche Ag |
Przeciwciała anty-Htra1 i sposoby ich stosowania
|
|
RS61651B1
(sr)
|
2015-11-03 |
2021-04-29 |
Janssen Biotech Inc |
Potkožne formulacije anti-cd38 antitela i njihova upotreba
|
|
EP4671281A2
(en)
|
2015-11-08 |
2025-12-31 |
F. Hoffmann-La Roche AG |
MULTISPECIFIC ANTIBODY SCREENING METHODS
|
|
US11649293B2
(en)
|
2015-11-18 |
2023-05-16 |
Chugai Seiyaku Kabushiki Kaisha |
Method for enhancing humoral immune response
|
|
JP6931329B2
(ja)
|
2015-11-18 |
2021-09-01 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
|
|
AU2016363770A1
(en)
|
2015-12-01 |
2018-06-28 |
Genmab B.V. |
Anti-DR5 antibodies and methods of use thereof
|
|
AU2016365742A1
(en)
|
2015-12-07 |
2018-06-21 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and PSMA
|
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
|
EP4026848A1
(en)
|
2015-12-09 |
2022-07-13 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing the cytokine release syndrome
|
|
SG11201804839WA
(en)
|
2015-12-14 |
2018-07-30 |
Macrogenics Inc |
Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
|
|
CR20180365A
(es)
|
2015-12-16 |
2018-09-28 |
Amgen Inc |
PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
|
|
CN106883297B
(zh)
|
2015-12-16 |
2019-12-13 |
苏州康宁杰瑞生物科技有限公司 |
基于ch3结构域的异二聚体分子、其制备方法及用途
|
|
BR112018012344A2
(pt)
|
2015-12-17 |
2018-12-04 |
Janssen Biotech Inc |
anticorpos que se ligam especificamente a hla-dr e seus usos
|
|
US20200261573A1
(en)
|
2015-12-17 |
2020-08-20 |
Novartis Ag |
Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
|
|
ES2986067T3
(es)
|
2015-12-17 |
2024-11-08 |
Novartis Ag |
Moléculas de anticuerpos frente a PD-1 y usos de las mismas
|
|
TWI605057B
(zh)
|
2015-12-18 |
2017-11-11 |
中外製藥股份有限公司 |
抗肌抑素抗體、含變異ｆｃ區之多肽及使用方法
|
|
TWI747936B
(zh)
|
2015-12-18 |
2021-12-01 |
日商中外製藥股份有限公司 |
抗ｃ５抗體及使用方法
|
|
WO2017112741A1
(en)
|
2015-12-22 |
2017-06-29 |
Novartis Ag |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
|
EP3395835B1
(en)
|
2015-12-25 |
2021-02-03 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody having enhanced activity, and method for modifying same
|
|
MX2018007781A
(es)
|
2015-12-28 |
2018-09-05 |
Chugai Pharmaceutical Co Ltd |
Metodo para promover la eficiencia de purificacion del polipeptido que contiene la region de fragmento cristalizable (fc).
|
|
WO2017117179A1
(en)
*
|
2015-12-28 |
2017-07-06 |
Massachusetts Institute Of Technology |
Bispecific antibodies having constant region mutations and uses therefor
|
|
AU2017205089B2
(en)
|
2016-01-08 |
2023-10-05 |
F. Hoffmann-La Roche Ag |
Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies
|
|
EP3405489A1
(en)
|
2016-01-20 |
2018-11-28 |
Genentech, Inc. |
High dose treatments for alzheimer's disease
|
|
MA55746A
(fr)
|
2016-01-21 |
2022-03-02 |
Novartis Ag |
Molécules multispécifiques ciblant cll-1
|
|
CN109069626A
(zh)
|
2016-02-12 |
2018-12-21 |
詹森药业有限公司 |
抗-vista(b7h5)抗体
|
|
CN114395624A
(zh)
|
2016-02-29 |
2022-04-26 |
基因泰克公司 |
用于癌症的治疗和诊断方法
|
|
US12391759B2
(en)
|
2016-03-02 |
2025-08-19 |
Momenta Pharmaceuticals, Inc. |
Methods related to engineered Fc constructs
|
|
KR20180118175A
(ko)
|
2016-03-04 |
2018-10-30 |
노파르티스 아게 |
다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도
|
|
WO2017159287A1
(ja)
|
2016-03-14 |
2017-09-21 |
中外製薬株式会社 |
癌の治療に用いるための細胞傷害誘導治療剤
|
|
US11291721B2
(en)
|
2016-03-21 |
2022-04-05 |
Marengo Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
CN108884170A
(zh)
|
2016-03-22 |
2018-11-23 |
豪夫迈·罗氏有限公司 |
蛋白酶活化的t细胞双特异性分子
|
|
MX2018011542A
(es)
|
2016-03-22 |
2019-02-07 |
Hoffmann La Roche |
Moleculas biespecificas de celulas t activadas por proteasas.
|
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
US20170315132A1
(en)
|
2016-03-25 |
2017-11-02 |
Genentech, Inc. |
Multiplexed total antibody and antibody-conjugated drug quantification assay
|
|
TWI897070B
(zh)
|
2016-03-31 |
2025-09-11 |
美商恩格姆生物製藥公司 |
結合蛋白質及其使用方法
|
|
US20170306027A1
(en)
|
2016-04-06 |
2017-10-26 |
Acceleron Pharma Inc. |
Alk7 antagonists and uses thereof
|
|
EP3865511A1
(en)
|
2016-04-14 |
2021-08-18 |
F. Hoffmann-La Roche AG |
Anti-rspo3 antibodies and methods of use
|
|
ES2850428T3
(es)
|
2016-04-15 |
2021-08-30 |
Hoffmann La Roche |
Procedimientos de monitorización y tratamiento del cáncer
|
|
PL3443096T3
(pl)
|
2016-04-15 |
2023-06-19 |
Novartis Ag |
Kompozycje i sposoby do selektywnej ekspresji chimerycznych receptorów antygenowych
|
|
WO2017180842A1
(en)
|
2016-04-15 |
2017-10-19 |
Bioatla, Llc |
Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
|
|
WO2017181079A2
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
|
US11525000B2
(en)
|
2016-04-15 |
2022-12-13 |
Immunext, Inc. |
Anti-human VISTA antibodies and use thereof
|
|
CA3015371A1
(en)
|
2016-04-20 |
2017-10-26 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for making antibodies based on use of an expression-enhancing locus
|
|
BR112018071283A2
(pt)
|
2016-04-20 |
2019-02-12 |
Regeneron Pharma |
célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, método, e, método para produção de uma proteína de ligação a antígeno.
|
|
EP3449940B1
(en)
|
2016-04-28 |
2025-11-19 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody-containing preparation
|
|
BR112018069890A2
(pt)
|
2016-05-02 |
2019-02-05 |
Hoffmann La Roche |
polipeptídio de fusão que se liga de forma específica a um alvo, polipeptídio de fusão dimérico, ácido nucleico isolado, par de ácidos nucleicos isolados, célula hospedeira, método para produzir um polipeptídio de fusão, imunoconjugado, formulação farmacêutica, polipeptídio de fusão e uso do polipeptídio de fusão
|
|
KR102687530B1
(ko)
|
2016-05-04 |
2024-07-25 |
암젠 인크 |
T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
|
|
EP3243836A1
(en)
|
2016-05-11 |
2017-11-15 |
F. Hoffmann-La Roche AG |
C-terminally fused tnf family ligand trimer-containing antigen binding molecules
|
|
JP7285076B2
(ja)
|
2016-05-11 |
2023-06-01 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｔｎｆファミリーリガンドトリマーとテネイシン結合部分とを含む抗原結合分子
|
|
CN109071640B
(zh)
|
2016-05-11 |
2022-10-18 |
豪夫迈·罗氏有限公司 |
经修饰抗生腱蛋白抗体及使用方法
|
|
CN109311987A
(zh)
|
2016-05-13 |
2019-02-05 |
生物蛋白有限公司 |
抗ror2抗体、抗体片段和它们的免疫缀合物以及其用途
|
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
|
AU2017268234A1
(en)
|
2016-05-17 |
2018-12-13 |
Genentech, Inc. |
Stromal gene signatures for diagnosis and use in immunotherapy
|
|
CN118436801A
(zh)
|
2016-05-20 |
2024-08-06 |
豪夫迈·罗氏有限公司 |
Protac抗体缀合物及其使用方法
|
|
SG11201810465RA
(en)
*
|
2016-05-23 |
2018-12-28 |
Momenta Pharmaceuticals Inc |
Compositions and methods related to engineered fc constructs
|
|
CA3025162A1
(en)
*
|
2016-05-26 |
2017-11-30 |
Qilu Puget Sound Biotherapeutics Corporation |
Mixtures of antibodies
|
|
EP3465221B1
(en)
|
2016-05-27 |
2020-07-22 |
H. Hoffnabb-La Roche Ag |
Bioanalytical method for the characterization of site-specific antibody-drug conjugates
|
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
US20210177896A1
(en)
|
2016-06-02 |
2021-06-17 |
Novartis Ag |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
|
TW201902512A
(zh)
|
2016-06-02 |
2019-01-16 |
瑞士商赫孚孟拉羅股份公司 |
治療方法
|
|
US10639378B2
(en)
|
2016-06-06 |
2020-05-05 |
Genentech, Inc. |
Silvestrol antibody-drug conjugates and methods of use
|
|
US10787518B2
(en)
|
2016-06-14 |
2020-09-29 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
|
MX2018015173A
(es)
|
2016-06-17 |
2019-07-04 |
Genentech Inc |
Purificacion de anticuerpos multiespecificos.
|
|
TWI760396B
(zh)
|
2016-06-17 |
2022-04-11 |
日商中外製藥股份有限公司 |
抗肌抑素抗體及使用方法
|
|
WO2017223405A1
(en)
|
2016-06-24 |
2017-12-28 |
Genentech, Inc. |
Anti-polyubiquitin multispecific antibodies
|
|
JP2019527678A
(ja)
|
2016-06-28 |
2019-10-03 |
ユーエムセー・ユトレヒト・ホールディング・ベー・フェー |
ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療
|
|
KR20190020341A
(ko)
|
2016-06-28 |
2019-02-28 |
젠코어 인코포레이티드 |
소마토스타틴 수용체 2에 결합하는 이종이량체 항체
|
|
CA3029627A1
(en)
|
2016-07-01 |
2018-01-04 |
Resolve Therapeutics, Llc |
Optimized binuclease fusions and methods
|
|
WO2018007314A1
(en)
|
2016-07-04 |
2018-01-11 |
F. Hoffmann-La Roche Ag |
Novel antibody format
|
|
WO2018011421A1
(en)
|
2016-07-14 |
2018-01-18 |
Genmab A/S |
Multispecific antibodies against cd40 and cd137
|
|
AU2017295886C1
(en)
|
2016-07-15 |
2024-05-16 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
|
RU2748278C2
(ru)
|
2016-07-15 |
2021-05-21 |
Акселерон Фарма Инк. |
Композиции и способы лечения легочной гипертензии
|
|
CN109476763B
(zh)
*
|
2016-07-19 |
2023-11-07 |
伊班绰斯有限责任公司 |
双特异性蛋白质及其制备方法
|
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
|
IL285146B
(en)
|
2016-07-22 |
2022-09-01 |
Amgen Inc |
Methods for purifying proteins involving fc
|
|
MX2019001043A
(es)
|
2016-07-27 |
2019-09-26 |
Acceleron Pharma Inc |
Metodos y composiciones para el tratamiento de la mielofibrosis.
|
|
SG11201900677SA
(en)
|
2016-07-28 |
2019-02-27 |
Novartis Ag |
Combination therapies of chimeric antigen receptors adn pd-1 inhibitors
|
|
US20190185578A1
(en)
|
2016-07-29 |
2019-06-20 |
Chugai Seiyaku Kabushiki Kaisha |
Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity
|
|
JP2019527696A
(ja)
|
2016-08-01 |
2019-10-03 |
ノバルティス アーゲー |
プロｍ２マクロファージ分子の阻害剤と組み合わせてキメラ抗原受容体を用いる癌の処置
|
|
WO2018026942A1
(en)
*
|
2016-08-02 |
2018-02-08 |
Merrimack Pharmaceuticals, Inc. |
Heteromeric polypeptides
|
|
TW202300168A
(zh)
|
2016-08-05 |
2023-01-01 |
日商中外製藥股份有限公司 |
Il-8相關疾病之治療用或預防用組成物
|
|
EP3494139B1
(en)
|
2016-08-05 |
2022-01-12 |
F. Hoffmann-La Roche AG |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
|
DK3511340T3
(da)
|
2016-08-10 |
2025-01-02 |
Univ Ajou Ind Academic Coop Found |
Heterodimerisk fc-fusioneret cytokin og farmaceutisk sammensætning omfattende det samme
|
|
CN109689111B
(zh)
|
2016-08-11 |
2024-04-05 |
基因泰克公司 |
吡咯并苯并二氮杂䓬前药及其抗体缀合物
|
|
WO2018038046A1
(ja)
|
2016-08-22 |
2018-03-01 |
中外製薬株式会社 |
ヒトｇｐｃ３ポリペプチドを発現する遺伝子改変非ヒト動物
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
|
JP6976315B2
(ja)
|
2016-09-19 |
2021-12-08 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
補体因子に基づくアフィニティークロマトグラフィー
|
|
AU2017330405B2
(en)
|
2016-09-23 |
2024-02-01 |
Genentech, Inc. |
Uses of IL-13 antagonists for treating atopic dermatitis
|
|
WO2018059502A1
(en)
|
2016-09-29 |
2018-04-05 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
Heterodimeric immunoglobulin constructs and preparation methods thereof
|
|
JP6785372B2
(ja)
|
2016-09-30 |
2020-11-18 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
多重特異性分子の機能分析のためのｓｐｒに基づく二重結合アッセイ
|
|
PL3519437T3
(pl)
|
2016-09-30 |
2022-01-17 |
F. Hoffmann-La Roche Ag |
Przeciwciała dwuswoiste przeciwko p95HER2
|
|
JP7280182B2
(ja)
*
|
2016-10-05 |
2023-05-23 |
アクセルロン ファーマ インコーポレイテッド |
バリアントＡｃｔＲＩＩＢタンパク質およびその使用
|
|
TW201813978A
(zh)
|
2016-10-05 |
2018-04-16 |
美商艾瑟勒朗法瑪公司 |
ＡＬＫ４：ＡｃｔＲＩＩＢ異多聚體及其用途
|
|
JP7050770B2
(ja)
|
2016-10-05 |
2022-04-08 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗体薬物コンジュゲートの調製方法
|
|
WO2018067740A1
(en)
|
2016-10-05 |
2018-04-12 |
Acceleron Pharma, Inc. |
Compositions and method for treating kidney disease
|
|
AU2017339517B2
(en)
|
2016-10-06 |
2024-03-14 |
Foundation Medicine, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
CN110225927B
(zh)
|
2016-10-07 |
2024-01-12 |
诺华股份有限公司 |
用于治疗癌症的嵌合抗原受体
|
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
|
SG11201903302UA
(en)
|
2016-10-14 |
2019-05-30 |
Xencor Inc |
Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
|
|
CA3041254A1
(en)
|
2016-10-19 |
2018-04-26 |
Invenra Inc. |
Antibody constructs
|
|
JP2019535250A
(ja)
|
2016-10-29 |
2019-12-12 |
ジェネンテック， インコーポレイテッド |
抗ｍｉｃ抗体及び使用方法
|
|
CN110461868A
(zh)
|
2016-11-01 |
2019-11-15 |
根马布私人有限公司 |
多肽变体及其用途
|
|
EP3538137A2
(en)
|
2016-11-08 |
2019-09-18 |
Qilu Puget Sound Biotherapeutics Corporation |
Anti-pd1 and anti-ctla4 antibodies
|
|
JP7051846B2
(ja)
|
2016-11-10 |
2022-04-11 |
ケロス セラピューティクス インコーポレイテッド |
アクチビンＩＩａ型受容体変異体および同変異体を含む医薬組成物
|
|
US20230137351A1
(en)
|
2016-11-14 |
2023-05-04 |
Amgen Inc. |
Bispecific or biparatopic antigen binding proteins and uses thereof
|
|
WO2018093821A1
(en)
|
2016-11-15 |
2018-05-24 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
CA3043652A1
(en)
|
2016-11-18 |
2018-05-24 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
|
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
|
JOP20190100A1
(ar)
|
2016-11-19 |
2019-05-01 |
Potenza Therapeutics Inc |
بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
|
|
BR112019010349A2
(pt)
|
2016-11-23 |
2019-10-08 |
Bioverativ Therapeutics Inc |
Anticorpos anti-fixa, anti-fxz e antifxa, molécula biespecífica, ácido nulceico, composiçãofarmacêutica e uso dos anteriores
|
|
MY198942A
(en)
|
2016-12-07 |
2023-10-03 |
Genentech Inc |
Anti-tau antibodies and methods of use
|
|
CN110248959B
(zh)
|
2016-12-07 |
2023-06-30 |
基因泰克公司 |
抗tau抗体和使用方法
|
|
EP3555620A1
(en)
|
2016-12-13 |
2019-10-23 |
H. Hoffnabb-La Roche Ag |
Method to determine the presence of a target antigen in a tumor sample
|
|
AU2017380981B2
(en)
|
2016-12-19 |
2025-01-30 |
F. Hoffmann-La Roche Ag |
Combination therapy with targeted 4-1BB (CD137) agonists
|
|
IL267406B2
(en)
|
2016-12-20 |
2025-05-01 |
Hoffmann La Roche |
Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
|
|
WO2018114878A1
(en)
|
2016-12-21 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Re-use of enzymes in in vitro glycoengineering of antibodies
|
|
AU2017384276B9
(en)
|
2016-12-21 |
2020-11-26 |
F. Hoffmann-La Roche Ag |
In vitro glycoengineering of antibodies
|
|
CN110088625B
(zh)
|
2016-12-21 |
2023-11-03 |
豪夫迈·罗氏有限公司 |
用于确定抗体或配体结合和功能的测定法
|
|
IL267352B2
(en)
|
2016-12-21 |
2023-10-01 |
Hoffmann La Roche |
Method for in vitro glycoengineering of antibodies
|
|
EP3360898A1
(en)
|
2017-02-14 |
2018-08-15 |
Boehringer Ingelheim International GmbH |
Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
|
|
EP3559032A1
(en)
|
2016-12-23 |
2019-10-30 |
Innate Pharma |
Heterodimeric antigen binding proteins
|
|
BR112019013189A2
(pt)
|
2017-01-03 |
2019-12-10 |
Hoffmann La Roche |
moléculas de ligação ao antígeno biespecífica, polinucleotídeo, célula hospedeira, método de produção da molécula de ligação ao antígeno biespecífica, composição farmacêutica, uso, métodos para inibir o crescimento de células tumorais em um indivíduo e para tratar o câncer ou uma doença infecciosa
|
|
CN117886928A
(zh)
|
2017-01-06 |
2024-04-16 |
动量制药公司 |
与经工程改造的Fc构建体相关的组合物和方法
|
|
WO2018132597A1
(en)
|
2017-01-12 |
2018-07-19 |
Eureka Therapeutics, Inc. |
Constructs targeting histone h3 peptide/mhc complexes and uses thereof
|
|
US11535662B2
(en)
|
2017-01-26 |
2022-12-27 |
Novartis Ag |
CD28 compositions and methods for chimeric antigen receptor therapy
|
|
US20190367611A1
(en)
|
2017-02-01 |
2019-12-05 |
CentryMed Pharmaceutical Inc. |
Monomeric human igg1 fc and bispecific antibodies
|
|
BR112019016204A2
(pt)
|
2017-02-07 |
2020-07-07 |
Daiichi Sankyo Company, Limited |
anticorpo ou fragmento de ligação a antígeno do anticorpo, polinucleotídeo, vetor, célula, imunócito artificial, métodos para produzir um anticorpo ou um fragmento de ligação a antígeno do anticorpo, para produzir uma molécula que se liga ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, composição medicinal para tratamento e/ou prevenção, moléculas tendo atividade de ligação a antígeno e que se ligam ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, e, usos para preparar um medicamento para tratar e/ou prevenir um câncer, para induzir citotoxicidade para as células expressando gprc5d e para redirecionamento de células t para as células expressando gprc5d
|
|
JP2020506971A
(ja)
|
2017-02-08 |
2020-03-05 |
ドラゴンフライ セラピューティクス， インコーポレイテッド |
ナチュラルキラー細胞の活性化のための多重特異性結合タンパク質およびがんを処置するためのその治療的使用
|
|
AR110873A1
(es)
|
2017-02-10 |
2019-05-08 |
Genentech Inc |
Anticuerpos contra triptasa, composiciones de estos y usos de estos
|
|
MY205850A
(en)
*
|
2017-02-10 |
2024-11-15 |
Dragonfly Therapeutics Inc |
Proteins binding bcma, nkg2d and cd16
|
|
EP3580233A1
(en)
|
2017-02-10 |
2019-12-18 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
|
US20200291089A1
(en)
|
2017-02-16 |
2020-09-17 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
|
SG11201907646YA
(en)
|
2017-02-20 |
2019-09-27 |
Dragonfly Therapeutics Inc |
Proteins binding her2, nkg2d and cd16
|
|
US12054544B2
(en)
*
|
2017-02-24 |
2024-08-06 |
Chugai Seiyaku Kabushiki Kaisha |
Compositions comprising antigen-binding molecules
|
|
WO2018160841A1
(en)
|
2017-03-01 |
2018-09-07 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
CN110382529B
(zh)
|
2017-03-02 |
2024-03-08 |
诺华股份有限公司 |
工程化的异源二聚体蛋白质
|
|
PT3592769T
(pt)
|
2017-03-09 |
2024-07-31 |
Genmab As |
Anticorpos contra pd-l1
|
|
MA48723A
(fr)
|
2017-03-10 |
2020-04-08 |
Hoffmann La Roche |
Procédé de production d'anticorps multispécifiques
|
|
JP7227151B2
(ja)
|
2017-03-22 |
2023-02-21 |
ジェネンテック， インコーポレイテッド |
眼障害の治療のために最適化された抗体組成物
|
|
CN110891611B
(zh)
|
2017-03-22 |
2024-03-29 |
阿森迪斯制药公司 |
水凝胶交联透明质酸前药组合物和方法
|
|
EP3601337A1
(en)
|
2017-03-28 |
2020-02-05 |
Genentech, Inc. |
Methods of treating neurodegenerative diseases
|
|
WO2018178055A1
(en)
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecule for a costimulatory tnf receptor
|
|
CN110382542B
(zh)
|
2017-03-29 |
2023-06-09 |
豪夫迈·罗氏有限公司 |
针对共刺激性tnf受体的双特异性抗原结合分子
|
|
US11780925B2
(en)
|
2017-03-31 |
2023-10-10 |
Merus N.V. |
ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene
|
|
UA127586C2
(uk)
|
2017-03-31 |
2023-10-25 |
Ґенмаб Холдінґ Б.В. |
Біспецифічні анти-cd37-антитіла, моноклональні анти-cd37-антитіла та способи їх застосування
|
|
KR102629905B1
(ko)
|
2017-04-01 |
2024-01-30 |
베이징 한미 파마슈티컬 컴퍼니 리미티드 |
항-pd-l1/항-pd-1 천연 항체 구조-유사 헤테로다이머 이중특이성 항체 및 그의 제조
|
|
EP3606963B1
(en)
|
2017-04-03 |
2023-08-30 |
F. Hoffmann-La Roche AG |
Antibodies binding to steap-1
|
|
MX2019011770A
(es)
|
2017-04-03 |
2020-01-09 |
Hoffmann La Roche |
Inmunoconjugados de un anticuerpo anti-pd-1 con un mutante il-2 o con il-15.
|
|
WO2018187227A1
(en)
|
2017-04-03 |
2018-10-11 |
Concologie, Inc. |
Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
|
|
EP3606947B1
(en)
|
2017-04-03 |
2022-12-21 |
F. Hoffmann-La Roche AG |
Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
|
|
KR102364599B1
(ko)
|
2017-04-04 |
2022-02-21 |
에프. 호프만-라 로슈 아게 |
Cd40 및 fap에 특이적으로 결합할 수 있는 새로운 이중특이적 항원 결합 분자
|
|
DK3606955T3
(da)
|
2017-04-05 |
2025-01-13 |
Hoffmann La Roche |
Bispecifikke antistoffer, der specifikt binder sig til PD1 og LAG3
|
|
MX2019011916A
(es)
|
2017-04-05 |
2020-01-09 |
Hoffmann La Roche |
Anticuerpos anti-lag3.
|
|
IL269826B1
(en)
|
2017-04-11 |
2025-09-01 |
Inhibrx Inc |
Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
|
|
EP3609537A1
(en)
|
2017-04-13 |
2020-02-19 |
H. Hoffnabb-La Roche Ag |
An interleukin-2 immunoconjugate, a cd40 agonist, and optionally a pd-1 axis binding antagonist for use in methods of treating cancer
|
|
KR20190141686A
(ko)
|
2017-04-21 |
2019-12-24 |
제넨테크, 인크. |
질환 치료를 위한 klk5 길항제의 용도
|
|
JOP20190248A1
(ar)
|
2017-04-21 |
2019-10-20 |
Amgen Inc |
بروتينات ربط مولد ضد trem2 واستخداماته
|
|
MX420947B
(es)
|
2017-04-26 |
2025-02-10 |
Eureka Therapeutics Inc |
Constructos que reconocen específicamente glipicano 3 y usos de estos.
|
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
BR112019024230A2
(pt)
|
2017-05-17 |
2020-06-09 |
Merus N.V. |
combinação de um anticorpo bispecífico erbb-2 / erbb-3 com terapia endócrina para câncer de mama
|
|
WO2018222901A1
(en)
|
2017-05-31 |
2018-12-06 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
|
CN111328335A
(zh)
|
2017-06-07 |
2020-06-23 |
根马布私人有限公司 |
基于突变igg六聚体的治疗性抗体
|
|
UY37758A
(es)
|
2017-06-12 |
2019-01-31 |
Novartis Ag |
Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
|
|
MA49457A
(fr)
|
2017-06-22 |
2020-04-29 |
Novartis Ag |
Molécules d'anticorps se liant à cd73 et leurs utilisations
|
|
MX2019015738A
(es)
|
2017-06-27 |
2020-02-20 |
Novartis Ag |
Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
|
|
US11084863B2
(en)
|
2017-06-30 |
2021-08-10 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
|
|
AR112603A1
(es)
|
2017-07-10 |
2019-11-20 |
Lilly Co Eli |
Anticuerpos biespecíficos inhibidores de punto de control
|
|
CN111278858B
(zh)
|
2017-07-11 |
2024-07-23 |
指南针制药有限责任公司 |
结合人cd137的激动剂抗体及其用途
|
|
KR20200031659A
(ko)
|
2017-07-20 |
2020-03-24 |
노파르티스 아게 |
항-lag-3 항체의 투여 요법 및 그의 용도
|
|
CN111492245A
(zh)
|
2017-07-21 |
2020-08-04 |
基因泰克公司 |
癌症的治疗和诊断方法
|
|
MX2020000957A
(es)
|
2017-07-26 |
2020-07-22 |
Forty Seven Inc |
Anticuerpos anti-sirp-alfa y metodos relacionados.
|
|
CN111406067B
(zh)
|
2017-08-04 |
2022-11-08 |
健玛保 |
与pd-l1和cd137结合的结合剂及其用途
|
|
SG11202001050PA
(en)
|
2017-08-09 |
2020-03-30 |
Merus Nv |
Antibodies that bind egfr and cmet
|
|
JP2020530297A
(ja)
|
2017-08-11 |
2020-10-22 |
ジェネンテック， インコーポレイテッド |
抗ｃｄ８抗体及びその使用
|
|
JP7374091B2
(ja)
|
2017-08-22 |
2023-11-06 |
サナバイオ， エルエルシー |
可溶性インターフェロン受容体およびその使用
|
|
AR113142A1
(es)
|
2017-09-29 |
2020-01-29 |
Chugai Pharmaceutical Co Ltd |
Moléculas de unión al antígeno multiespecíficas que tienen actividad de sustitución de la función de cofactor del factor viii de coagulación de sangre (fviii), y formulaciones farmacéuticas que contienen dicha molécula como ingrediente activo
|
|
AU2018347521A1
(en)
|
2017-10-12 |
2020-05-07 |
Immunowake Inc. |
VEGFR-antibody light chain fusion protein
|
|
TW201932142A
(zh)
|
2017-10-20 |
2019-08-16 |
瑞士商赫孚孟拉羅股份公司 |
自單特異性抗體產生多特異性抗體之方法
|
|
BR112020007736A2
(pt)
*
|
2017-10-30 |
2020-10-20 |
F. Hoffmann-La Roche Ag |
composição e método de tratamento
|
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
|
PL3704146T3
(pl)
|
2017-11-01 |
2022-03-07 |
F. Hoffmann-La Roche Ag |
Przeciwciało Contorsbody trifab
|
|
BR112020008393A2
(pt)
|
2017-11-01 |
2020-11-03 |
Chugai Seiyaku Kabushiki Kaisha |
variante e isoforma de anticorpos com atividade biológica reduzida
|
|
CA3076027A1
(en)
|
2017-11-01 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
Bispecific 2+1 contorsbodies
|
|
BR112020007630A2
(pt)
|
2017-11-01 |
2020-11-17 |
F. Hoffmann-La Roche Ag |
anticorpo biespecífico ox40, produto farmacêutico, composição farmacêutica e anticorpos biespecíficos anti-fap/ anti-ox40
|
|
JP2021500902A
(ja)
|
2017-11-01 |
2021-01-14 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
新規ｔｎｆファミリーリガンド三量体含有抗原結合分子
|
|
JP2021500930A
(ja)
|
2017-11-01 |
2021-01-14 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｃｏｍｐボディ−多価標的結合物質
|
|
WO2019090263A1
(en)
|
2017-11-06 |
2019-05-09 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
AU2018366199A1
(en)
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
|
JP7258021B2
(ja)
|
2017-11-09 |
2023-04-14 |
ケロス セラピューティクス インコーポレイテッド |
アクチビンＩＩａ型受容体変異体を含む医薬組成物
|
|
CN111556895B
(zh)
|
2017-11-14 |
2024-09-13 |
中外制药株式会社 |
抗-c1s抗体及使用方法
|
|
CA3081602A1
(en)
|
2017-11-16 |
2019-05-23 |
Novartis Ag |
Combination therapies
|
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
CA3079363A1
(en)
|
2017-11-21 |
2019-05-31 |
Innate Pharma |
Multispecific antigen binding proteins
|
|
CA3086199A1
(en)
|
2017-12-19 |
2019-06-27 |
Xencor, Inc. |
Engineered il-2 fc fusion proteins
|
|
EP3502140A1
(en)
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
|
|
EP3728317A2
(en)
|
2017-12-21 |
2020-10-28 |
F. Hoffmann-La Roche AG |
Antibodies binding to hla-a2/wt1
|
|
US20190211098A1
(en)
|
2017-12-22 |
2019-07-11 |
Genentech, Inc. |
Use of pilra binding agents for treatment of a disease
|
|
WO2019122054A1
(en)
|
2017-12-22 |
2019-06-27 |
F. Hoffmann-La Roche Ag |
Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography
|
|
SG11202005273XA
(en)
|
2017-12-28 |
2020-07-29 |
Nanjing Legend Biotech Co Ltd |
Antibodies and variants thereof against pd-l1
|
|
KR20200104333A
(ko)
|
2017-12-28 |
2020-09-03 |
난징 레전드 바이오테크 씨오., 엘티디. |
Tigit에 대한 단일-도메인 항체 및 이의 변이체
|
|
WO2019133512A1
(en)
|
2017-12-29 |
2019-07-04 |
Alector Llc |
Anti-tmem106b antibodies and methods of use thereof
|
|
JP7436365B2
(ja)
|
2017-12-29 |
2024-02-21 |
エフ． ホフマン－ラ ロシュ アーゲー |
抗ｖｅｇｆ抗体及び使用の方法
|
|
WO2019136309A1
(en)
|
2018-01-04 |
2019-07-11 |
Iconic Therapeutics, Inc. |
Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
|
|
WO2019139987A1
(en)
|
2018-01-09 |
2019-07-18 |
Elstar Therapeutics, Inc. |
Calreticulin binding constructs and engineered t cells for the treatment of diseases
|
|
IL275536B2
(en)
|
2018-01-12 |
2025-06-01 |
Genzyme Corp |
Methods for quantification of polypeptides
|
|
TWI802633B
(zh)
|
2018-01-15 |
2023-05-21 |
大陸商南京傳奇生物科技有限公司 |
針對pd-1之單域抗體及其變異體
|
|
WO2019143636A1
(en)
|
2018-01-16 |
2019-07-25 |
Lakepharma, Inc. |
Bispecific antibody that binds cd3 and another target
|
|
US20210107988A1
(en)
|
2018-01-24 |
2021-04-15 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
|
US20200354457A1
(en)
|
2018-01-31 |
2020-11-12 |
Hoffmann-La Roche Inc. |
Bispecific antibodies comprising an antigen-binding site binding to lag3
|
|
CN111630063A
(zh)
|
2018-01-31 |
2020-09-04 |
豪夫迈·罗氏有限公司 |
稳定化的免疫球蛋白结构域
|
|
CN111971301B
(zh)
|
2018-01-31 |
2025-01-07 |
艾莱克特有限责任公司 |
抗ms4a4a抗体及其使用方法
|
|
US20210038659A1
(en)
|
2018-01-31 |
2021-02-11 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
|
WO2019148410A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1 antibodies
|
|
JP7005772B2
(ja)
|
2018-02-06 |
2022-02-10 |
エフ．ホフマン－ラ ロシュ アーゲー |
眼科疾患の処置
|
|
FI3749346T3
(fi)
|
2018-02-08 |
2024-09-04 |
Dragonfly Therapeutics Inc |
Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät
|
|
PE20210375A1
(es)
|
2018-02-08 |
2021-03-02 |
Dragonfly Therapeutics Inc |
Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales
|
|
WO2019153200A1
(zh)
|
2018-02-08 |
2019-08-15 |
北京韩美药品有限公司 |
抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
|
|
AR115360A1
(es)
|
2018-02-08 |
2021-01-13 |
Genentech Inc |
Moléculas de unión al antígeno y métodos de uso
|
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
|
CA3226165A1
(en)
|
2018-02-09 |
2019-08-15 |
Genentech, Inc. |
Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
|
|
JP2021512624A
(ja)
|
2018-02-11 |
2021-05-20 |
ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッドＢｅｉｊｉｎｇ Ｈａｎｍｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． |
抗ｐｄ−１／抗ｖｅｇｆ天然抗体構造様ヘテロ二量体型二重特異性抗体及びその製造
|
|
US20200399373A1
(en)
|
2018-02-14 |
2020-12-24 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule and combination
|
|
MX2020008684A
(es)
|
2018-02-20 |
2020-12-07 |
Dragonfly Therapeutics Inc |
Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso.
|
|
KR20200130723A
(ko)
|
2018-03-12 |
2020-11-19 |
젠맵 에이/에스 |
항체
|
|
TWI841551B
(zh)
|
2018-03-13 |
2024-05-11 |
瑞士商赫孚孟拉羅股份公司 |
使用靶向4-1bb (cd137)之促效劑的組合療法
|
|
CN119074915A
(zh)
|
2018-03-13 |
2024-12-06 |
豪夫迈·罗氏有限公司 |
4-1bb激动剂与抗cd20抗体的治疗剂组合
|
|
US12152073B2
(en)
|
2018-03-14 |
2024-11-26 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
|
US20210009711A1
(en)
|
2018-03-14 |
2021-01-14 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
KR20200132938A
(ko)
|
2018-03-15 |
2020-11-25 |
추가이 세이야쿠 가부시키가이샤 |
지카 바이러스에 대해 교차-반응성을 갖는 항-뎅기 바이러스 항체 및 사용 방법
|
|
BR112020019726A2
(pt)
|
2018-03-29 |
2021-01-26 |
Genentech, Inc. |
células de mamífero, composição, métodos para reduzir ou eliminar a atividade lactogênica em uma célula, para produzir um produto de interesse e para cultivar uma população
|
|
JP7346790B2
(ja)
|
2018-03-30 |
2023-09-20 |
ナンジン レジェンド バイオテック カンパニー，リミテッド |
Ｌａｇ‐３に対する単一ドメイン抗体およびその使用
|
|
WO2019192432A1
(zh)
|
2018-04-02 |
2019-10-10 |
上海博威生物医药有限公司 |
结合淋巴细胞活化基因-3(lag-3)的抗体及其用途
|
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
|
AU2019247415A1
(en)
|
2018-04-04 |
2020-10-22 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
AU2019253462B2
(en)
|
2018-04-09 |
2025-04-24 |
Amgen Inc. |
Growth differentiation factor 15 fusion proteins
|
|
JP7724061B2
(ja)
|
2018-04-11 |
2025-08-15 |
インヒブルクス バイオサイエンシズ インコーポレイテッド |
制約されたｃｄ３結合を有する多重特異性ポリペプチド構築物ならびに関連する方法および使用
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
CN111741979B
(zh)
|
2018-04-13 |
2024-07-02 |
豪夫迈·罗氏有限公司 |
包含4-1BBL的Her2靶向性抗原结合分子
|
|
CN112867734A
(zh)
|
2018-04-18 |
2021-05-28 |
Xencor股份有限公司 |
包含IL-15/IL-15Ra Fc融合蛋白和PD-1抗原结合结构域的靶向PD-1的异源二聚体融合蛋白及其用途
|
|
JP2021520829A
(ja)
|
2018-04-18 |
2021-08-26 |
ゼンコア インコーポレイテッド |
ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＴＩＭ−３抗原結合ドメインを含む、ＴＩＭ−３標的化ヘテロ二量体融合タンパク質
|
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
|
IL278090B2
(en)
|
2018-04-18 |
2024-07-01 |
Xencor Inc |
Il-15/il-15rα heterodimeric fc fusion proteins and uses thereof
|
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
MX2020011552A
(es)
|
2018-05-03 |
2020-11-24 |
Genmab Bv |
Combinaciones de variantes de anticuerpos y usos de las mismas.
|
|
JP7206297B2
(ja)
|
2018-05-18 |
2023-01-17 |
エフ．ホフマン－ラ ロシュ アーゲー |
大核酸の細胞内標的指向送達
|
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
|
CN112384534A
(zh)
|
2018-05-21 |
2021-02-19 |
指南针制药有限责任公司 |
用于增强nk细胞对靶细胞的杀死的组合物和方法
|
|
TW202448946A
(zh)
|
2018-05-25 |
2024-12-16 |
美商阿列克特有限責任公司 |
抗-sirpa 抗體及其使用方法
|
|
WO2019227003A1
(en)
|
2018-05-25 |
2019-11-28 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
EP3802611A2
(en)
|
2018-06-01 |
2021-04-14 |
Novartis AG |
Binding molecules against bcma and uses thereof
|
|
TW202519270A
(zh)
|
2018-06-07 |
2025-05-16 |
美商思進公司 |
喜樹鹼結合物
|
|
TWI848953B
(zh)
|
2018-06-09 |
2024-07-21 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
|
CN112203725A
(zh)
|
2018-06-13 |
2021-01-08 |
诺华股份有限公司 |
Bcma嵌合抗原受体及其用途
|
|
US11993661B2
(en)
|
2018-06-18 |
2024-05-28 |
Eureka Therapeutics, Inc. |
Constructs targeting prostate-specific membrane antigen (PSMA) and uses thereof
|
|
US20210238268A1
(en)
|
2018-06-19 |
2021-08-05 |
Atarga, Llc |
Antibody molecules to complement component 5 and uses thereof
|
|
US12275797B2
(en)
|
2018-06-22 |
2025-04-15 |
Genmab Holding B.V. |
Anti-CD37 antibodies and anti-CD20 antibodies, compositions and methods of use thereof
|
|
KR20210025614A
(ko)
|
2018-06-29 |
2021-03-09 |
알렉터 엘엘씨 |
항-sirp-베타1 항체 및 그의 사용 방법
|
|
CN112955465A
(zh)
|
2018-07-03 |
2021-06-11 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
|
TW202035447A
(zh)
|
2018-07-04 |
2020-10-01 |
瑞士商赫孚孟拉羅股份公司 |
新穎雙特異性促效性4-1bb抗原結合分子
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
CA3060547A1
(en)
|
2018-07-13 |
2020-01-13 |
Alector Llc |
Anti-sortilin antibodies and methods of use thereof
|
|
MX2020013631A
(es)
|
2018-07-13 |
2021-03-25 |
Genmab As |
Variantes de anticuerpo grupo de diferenciacion (cd38) y usos de las mismas.
|
|
MA53123A
(fr)
|
2018-07-13 |
2021-05-19 |
Genmab As |
Thérapie à médiation par trogocytose utilisant des anticorps cd38
|
|
EP3823673A4
(en)
|
2018-07-20 |
2022-05-11 |
Surface Oncology, Inc. |
Anti-cd112r compositions and methods
|
|
TW202035451A
(zh)
|
2018-07-24 |
2020-10-01 |
美商英伊布里克斯公司 |
含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法
|
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
|
WO2020027330A1
(ja)
|
2018-08-03 |
2020-02-06 |
中外製薬株式会社 |
互いに連結された２つの抗原結合ドメインを含む抗原結合分子
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
JP7482363B2
(ja)
|
2018-08-08 |
2024-05-14 |
ドラゴンフライ セラピューティクス， インコーポレイテッド |
Ｎｋｇ２ｄ、ｃｄ１６及び腫瘍関連抗原に結合するタンパク質
|
|
US12384851B2
(en)
|
2018-08-08 |
2025-08-12 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
|
|
US12172106B2
(en)
|
2018-08-09 |
2024-12-24 |
Regeneron Pharmaceuticals, Inc. |
Methods for assessing binding affinity of an antibody variant to the neonatal Fc receptor
|
|
SG10202106830VA
(en)
|
2018-08-10 |
2021-08-30 |
Chugai Pharmaceutical Co Ltd |
Anti-cd137 antigen-binding molecule and utilization thereof
|
|
TW202021618A
(zh)
|
2018-08-17 |
2020-06-16 |
美商２３與我有限公司 |
抗ｉｌ１ｒａｐ抗體及其使用方法
|
|
JP7523349B2
(ja)
|
2018-08-29 |
2024-07-26 |
中外製薬株式会社 |
抗体半分子、および抗体半分子のホモ二量体形成を抑制する方法
|
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
|
CN112789293B
(zh)
|
2018-09-10 |
2024-05-10 |
南京传奇生物科技有限公司 |
针对cll1的单结构域抗体及其构建体
|
|
TWI850255B
(zh)
|
2018-09-10 |
2024-08-01 |
美商建南德克公司 |
用於親和毛細管電泳之系統及方法
|
|
US11573226B2
(en)
|
2018-09-10 |
2023-02-07 |
Genentech, Inc. |
Systems and methods for affinity capillary electrophoresis
|
|
MX2021003214A
(es)
|
2018-09-19 |
2021-05-12 |
Genentech Inc |
Metodos terapeuticos y de diagnostico para el cancer de vejiga.
|
|
AU2019349662A1
(en)
|
2018-09-24 |
2021-04-29 |
The Medical College Of Wisconsin, Inc. |
System and method for the development of cd30 bispecific antibodies for immunotherapy of cd30+ malignancies
|
|
JP2022511396A
(ja)
|
2018-10-01 |
2022-01-31 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｃｄ４０への三価結合を伴う二重特異性抗原結合分子
|
|
SG11202102477QA
(en)
|
2018-10-01 |
2021-04-29 |
Hoffmann La Roche |
Bispecific antigen binding molecules comprising anti-fap clone 212
|
|
KR102884523B1
(ko)
|
2018-10-03 |
2025-11-10 |
젠코어 인코포레이티드 |
IL-12 이종이량체 Fc-융합 단백질
|
|
MA53812A
(fr)
|
2018-10-04 |
2021-08-11 |
Genmab Holding B V |
Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques
|
|
CN120623346A
(zh)
|
2018-10-11 |
2025-09-12 |
因荷布瑞克斯生物科学公司 |
Pd-1单结构域抗体及其治疗组合物
|
|
CN113166263A
(zh)
|
2018-10-11 |
2021-07-23 |
印希比股份有限公司 |
Dll3单域抗体及其治疗性组合物
|
|
US20230124851A1
(en)
|
2018-10-11 |
2023-04-20 |
Inhibrx, lnc. |
B7h3 single domain antibodies and therapeutic compositions thereof
|
|
US20210340273A1
(en)
|
2018-10-11 |
2021-11-04 |
Inhlbrx, inc. |
5t4 single domain antibodies and therapeutic compositions thereof
|
|
CA3116188A1
(en)
|
2018-10-12 |
2020-04-16 |
Xencor, Inc. |
Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
|
|
CN113196061A
(zh)
|
2018-10-18 |
2021-07-30 |
豪夫迈·罗氏有限公司 |
肉瘤样肾癌的诊断和治疗方法
|
|
TWI891611B
(zh)
|
2018-10-23 |
2025-08-01 |
美商蜻蜓醫療公司 |
異二聚體fc融合蛋白
|
|
WO2020086858A1
(en)
|
2018-10-24 |
2020-04-30 |
Genentech, Inc. |
Conjugated chemical inducers of degradation and methods of use
|
|
MX2021004774A
(es)
|
2018-10-29 |
2021-08-24 |
Hoffmann La Roche |
Formulacion de anticuerpos.
|
|
US20220170097A1
(en)
|
2018-10-29 |
2022-06-02 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
|
KR20210124959A
(ko)
|
2018-11-06 |
2021-10-15 |
젠맵 에이/에스 |
항체 제제
|
|
US11046769B2
(en)
|
2018-11-13 |
2021-06-29 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
|
US20230183379A1
(en)
|
2018-11-20 |
2023-06-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Bispecific antibody targeting transferrin receptor 1 and soluble antigen
|
|
US20220041719A1
(en)
|
2018-12-05 |
2022-02-10 |
Morphosys Ag |
Multispecific antigen-binding molecules
|
|
KR20210100668A
(ko)
|
2018-12-06 |
2021-08-17 |
제넨테크, 인크. |
항-CD79b 면역접합체, 알킬화제 및 항-CD20 항체를 포함하는 미만성 큰 B-세포 림프종의 조합 요법
|
|
CN113227119A
(zh)
|
2018-12-10 |
2021-08-06 |
基因泰克公司 |
用于与含Fc的蛋白质进行位点特异性缀合的光交联肽
|
|
WO2020131697A2
(en)
|
2018-12-17 |
2020-06-25 |
Revitope Limited |
Twin immune cell engager
|
|
TWI874341B
(zh)
|
2018-12-18 |
2025-03-01 |
美商健生生物科技公司 |
產生異二聚體抗體之方法
|
|
EP3897853A1
(en)
|
2018-12-20 |
2021-10-27 |
Xencor, Inc. |
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
|
|
US20210386763A1
(en)
|
2018-12-20 |
2021-12-16 |
Novartis Ag |
Pharmaceutical combinations
|
|
CN113227131B
(zh)
|
2018-12-20 |
2025-03-04 |
豪夫迈·罗氏有限公司 |
经修饰的抗体Fc及其使用方法
|
|
AR117327A1
(es)
|
2018-12-20 |
2021-07-28 |
23Andme Inc |
Anticuerpos anti-cd96 y métodos de uso de estos
|
|
US20240245670A1
(en)
|
2018-12-20 |
2024-07-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
WO2020127628A1
(en)
|
2018-12-21 |
2020-06-25 |
F. Hoffmann-La Roche Ag |
Tumor-targeted superagonistic cd28 antigen binding molecules
|
|
AR123405A1
(es)
|
2018-12-21 |
2022-11-30 |
23Andme Inc |
Anticuerpos anti-il-36 y métodos de uso de estos
|
|
WO2020127619A1
(en)
|
2018-12-21 |
2020-06-25 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
PE20211696A1
(es)
|
2018-12-21 |
2021-09-01 |
Hoffmann La Roche |
Moleculas agonistas de union al antigeno cd28 que actuan sobre el tumor
|
|
JP7734075B2
(ja)
|
2018-12-24 |
2025-09-04 |
サノフイ |
疑似ｆａｂベースの多重特異性結合タンパク質
|
|
KR20210108421A
(ko)
|
2018-12-24 |
2021-09-02 |
사노피 |
돌연변이 Fab 도메인을 포함하는 다중특이성 결합 단백질
|
|
WO2020136060A1
(en)
|
2018-12-28 |
2020-07-02 |
F. Hoffmann-La Roche Ag |
A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response
|
|
CN113227789B
(zh)
|
2018-12-30 |
2024-12-24 |
豪夫迈·罗氏有限公司 |
基于pH梯度SPR的结合测定
|
|
WO2020142740A1
(en)
|
2019-01-04 |
2020-07-09 |
Resolve Therapeutics, Llc |
Treatment of sjogren's disease with nuclease fusion proteins
|
|
CA3125474A1
(en)
*
|
2019-01-07 |
2020-07-16 |
Shattuck Labs, Inc. |
Heterodimeric proteins for modulating gamma delta t cells
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
AU2020209257A1
(en)
|
2019-01-18 |
2021-08-05 |
Janssen Biotech, Inc. |
GPRC5D chimeric antigen receptors and cells expressing the same
|
|
WO2020153467A1
(ja)
|
2019-01-24 |
2020-07-30 |
中外製薬株式会社 |
新規がん抗原及びそれらの抗原に対する抗体
|
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
|
EP3924054B1
(en)
|
2019-02-15 |
2025-04-02 |
Novartis AG |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
EP3924055B1
(en)
|
2019-02-15 |
2024-04-03 |
Novartis AG |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
SG11202109056TA
(en)
|
2019-02-21 |
2021-09-29 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
GB2599227B
(en)
|
2019-02-21 |
2024-05-01 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to T cells and uses thereof to treat autoimmune disorders
|
|
JP2022521751A
(ja)
|
2019-02-21 |
2022-04-12 |
マレンゴ・セラピューティクス，インコーポレーテッド |
抗ｔｃｒ抗体分子およびその使用
|
|
WO2020172605A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
|
JP7710373B2
(ja)
|
2019-02-21 |
2025-07-18 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
|
|
WO2020172553A1
(en)
|
2019-02-22 |
2020-08-27 |
Novartis Ag |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
|
SG11202108311RA
(en)
|
2019-02-26 |
2021-09-29 |
Janssen Biotech Inc |
Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
|
|
SG11202109406TA
(en)
|
2019-03-01 |
2021-09-29 |
Xencor Inc |
Heterodimeric antibodies that bind enpp3 and cd3
|
|
WO2020180811A1
(en)
|
2019-03-04 |
2020-09-10 |
Qilu Puget Sound Biotherapeutics Corporation |
Anti-sirp-alpha antibodies
|
|
WO2020185535A1
(en)
|
2019-03-08 |
2020-09-17 |
Genentech, Inc. |
Methods for detecting and quantifying membrane-associated proteins on extracellular vesicles
|
|
JP7730761B2
(ja)
|
2019-03-14 |
2025-08-28 |
ジェネンテック， インコーポレイテッド |
抗ＨＥＲ２ ＭＡＢと組み合わせたＨＥＲ２ｘＣＤ３二重特異性抗体によるがんの処置
|
|
SG11202110732XA
(en)
|
2019-03-29 |
2021-10-28 |
Atarga Llc |
Anti fgf23 antibody
|
|
CN113677701B
(zh)
|
2019-03-29 |
2025-02-07 |
豪夫迈·罗氏有限公司 |
产生亲合结合多特异性抗体的方法
|
|
JP7249432B2
(ja)
|
2019-03-29 |
2023-03-30 |
エフ． ホフマン－ラ ロシュ アーゲー |
多価分子の機能分析のための、ｓｐｒをベースとする結合アッセイ
|
|
JP7301155B2
(ja)
|
2019-04-12 |
2023-06-30 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
リポカリンムテインを含む二重特異性抗原結合分子
|
|
CN114364703A
(zh)
|
2019-04-19 |
2022-04-15 |
豪夫迈·罗氏有限公司 |
抗mertk抗体及它们的使用方法
|
|
KR20220004052A
(ko)
|
2019-04-25 |
2022-01-11 |
에프. 호프만-라 로슈 아게 |
폴리펩티드 사슬 교환에 의해 활성화된 치료용 다중특이적 폴리펩티드
|
|
CA3132275A1
(en)
|
2019-04-25 |
2020-10-29 |
Ulrich Brinkmann |
Generation of antibody-derived polypeptides by polypeptide chain exchange
|
|
BR112021021210A2
(pt)
|
2019-04-25 |
2021-12-21 |
Hoffmann La Roche |
Conjunto de polipeptídeos, método para gerar um polipeptídeo heterodimérico, primeiro polipeptídeo precursor heterodimérico, segundo polipeptídeo precursor heterodimérico e composição farmacêutica
|
|
EP3962924A1
(en)
|
2019-05-03 |
2022-03-09 |
Genentech, Inc. |
Methods of reducing the enzymatic hydrolysis activity rate in a composition obtained from a purification platform
|
|
EP3966241A1
(en)
|
2019-05-09 |
2022-03-16 |
Genmab B.V. |
Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer
|
|
SG11202110525QA
(en)
|
2019-05-09 |
2021-10-28 |
Genentech Inc |
Methods of making antibodies
|
|
CN119470884A
(zh)
|
2019-05-13 |
2025-02-18 |
豪夫迈·罗氏有限公司 |
抑制干扰的药代动力学免疫测定
|
|
KR20220007136A
(ko)
|
2019-05-14 |
2022-01-18 |
제넨테크, 인크. |
소포 림프종을 치료하기 위한 항-CD79b 면역접합체의 사용 방법
|
|
CU20210096A7
(es)
|
2019-05-21 |
2022-06-06 |
Novartis Ag |
Moléculas de unión a cd19
|
|
US12037378B2
(en)
|
2019-05-21 |
2024-07-16 |
Novartis Ag |
Variant CD58 domains and uses thereof
|
|
AU2020279224B2
(en)
|
2019-05-21 |
2024-12-05 |
Novartis Ag |
Trispecific binding molecules against BCMA and uses thereof
|
|
CN119700933A
(zh)
|
2019-05-31 |
2025-03-28 |
Alx肿瘤生物技术公司 |
用SIRPαFc融合体组合免疫检查点抑制剂治疗癌症的方法
|
|
CN114126649A
(zh)
|
2019-06-10 |
2022-03-01 |
中外制药株式会社 |
用于和细胞因子抑制剂组合使用的抗t细胞抗原结合分子
|
|
CA3140023A1
(en)
|
2019-06-11 |
2020-12-17 |
Alector Llc |
Anti-sortilin antibodies for use in therapy
|
|
MX2021015537A
(es)
|
2019-06-19 |
2022-02-10 |
Hoffmann La Roche |
Metodo para la generacion de una celula que expresa anticuerpo biespecifico multivalente mediante la integracion diana de casetes de expresion multiples en una organizacion definida.
|
|
AU2020294878A1
(en)
|
2019-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Method for the generation of a multivalent, multispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
|
|
MX2021015540A
(es)
|
2019-06-19 |
2022-02-10 |
Hoffmann La Roche |
Metodo para la generacion de una celula que expresa un anticuerpo trivalente mediante la integracion dirigida de multiples casetes de expresion en una organizacion definida.
|
|
WO2020254357A1
(en)
|
2019-06-19 |
2020-12-24 |
F. Hoffmann-La Roche Ag |
Method for the generation of a protein expressing cell by targeted integration using cre mrna
|
|
CN114008081A
(zh)
|
2019-06-19 |
2022-02-01 |
豪夫迈·罗氏有限公司 |
通过以限定的组织形式靶向整合多个表达盒来产生二价双特异性抗体表达细胞的方法
|
|
JP7450647B2
(ja)
|
2019-06-26 |
2024-03-15 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｓｉｒｔ－１遺伝子ノックアウトを有する哺乳類細胞株
|
|
WO2020260329A1
(en)
|
2019-06-26 |
2020-12-30 |
F. Hoffmann-La Roche Ag |
Fusion of an antibody binding cea and 4-1bbl
|
|
JP7354306B2
(ja)
|
2019-06-27 |
2023-10-02 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
新規ｉｃｏｓ抗体及びそれらを含む腫瘍標的化抗原結合分子
|
|
WO2020264384A1
(en)
|
2019-06-28 |
2020-12-30 |
Amgen Inc. |
Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
|
|
JP2022538139A
(ja)
|
2019-07-02 |
2022-08-31 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
変異体インターロイキン－２及び抗ｃｄ８抗体を含む免疫複合体
|
|
AR119382A1
(es)
|
2019-07-12 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos de pre-direccionamiento y métodos de uso
|
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
|
WO2021011673A2
(en)
|
2019-07-16 |
2021-01-21 |
Ming Jin |
Neutralizing anti-amyloid beta antibodies for the treatment of alzheimer's disease
|
|
CN114174338A
(zh)
|
2019-07-31 |
2022-03-11 |
豪夫迈·罗氏有限公司 |
与gprc5d结合的抗体
|
|
PE20220394A1
(es)
|
2019-07-31 |
2022-03-18 |
Hoffmann La Roche |
Anticuerpos que se fijan a gprc5d
|
|
MY208743A
(en)
|
2019-07-31 |
2025-05-27 |
Alector Llc |
Anti-ms4a4a antibodies and methods of use thereof
|
|
WO2021024209A1
(en)
|
2019-08-06 |
2021-02-11 |
Aprinoia Therapeutics Inc. |
Antibodies that bind to pathological tau species and uses thereof
|
|
CN114585651A
(zh)
|
2019-08-08 |
2022-06-03 |
再生元制药公司 |
新型抗原结合分子形式
|
|
EP4013776A1
(en)
|
2019-08-13 |
2022-06-22 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
|
CA3152944A1
(en)
|
2019-09-03 |
2021-03-11 |
Amgen Inc. |
Il-22 oral, intra-rectal, or other gut-related compositions and methods of use thereof
|
|
JP2022547577A
(ja)
|
2019-09-12 |
2022-11-14 |
ジェネンテック， インコーポレイテッド |
ループス腎炎を治療する組成物及び方法
|
|
KR20220064980A
(ko)
|
2019-09-18 |
2022-05-19 |
제넨테크, 인크. |
항 klk7 항체, 항 klk5 항체, 다중특이적 항 klk5/klk7 항체, 및 사용 방법
|
|
CN114423454A
(zh)
|
2019-09-20 |
2022-04-29 |
豪夫迈·罗氏有限公司 |
抗类胰蛋白酶抗体的给药
|
|
WO2021057978A1
(zh)
|
2019-09-27 |
2021-04-01 |
南京金斯瑞生物科技有限公司 |
抗vhh域抗体及其用途
|
|
TWI878355B
(zh)
|
2019-10-02 |
2025-04-01 |
德商百靈佳殷格翰國際股份有限公司 |
用於癌症治療之多重專一性結合蛋白
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
KR20220086618A
(ko)
|
2019-10-18 |
2022-06-23 |
제넨테크, 인크. |
미만성 거대 B-세포 림프종을 치료하기 위한 항-CD79b 면역접합체의 사용 방법
|
|
JP2022553306A
(ja)
|
2019-10-21 |
2022-12-22 |
ノバルティス アーゲー |
Ｔｉｍ－３阻害剤およびその使用
|
|
MX2022004766A
(es)
|
2019-10-21 |
2022-05-16 |
Novartis Ag |
Terapias combinadas con venetoclax e inhibidores de tim-3.
|
|
JP7785669B2
(ja)
|
2019-11-05 |
2025-12-15 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｎ末端ｓｃＦｖ多重特異性結合分子
|
|
EP4055046A1
(en)
|
2019-11-06 |
2022-09-14 |
Genmab B.V. |
Antibody variant combinations and uses thereof
|
|
MX2022005566A
(es)
*
|
2019-11-08 |
2022-07-19 |
Amgen Inc |
Genomanipulación de mutaciones de par de carga para el emparejamiento de moléculas hetero-lgg.
|
|
WO2021096888A1
(en)
|
2019-11-12 |
2021-05-20 |
Foundation Medicine, Inc. |
Methods of detecting a fusion gene encoding a neoantigen
|
|
MX2022005317A
(es)
|
2019-11-15 |
2022-05-26 |
Hoffmann La Roche |
Prevencion de formacion de particulas visibles en soluciones acuosas de proteina.
|
|
JP2023502652A
(ja)
|
2019-11-18 |
2023-01-25 |
ヤンセン バイオテツク，インコーポレーテツド |
抗ｃｄ７９キメラ抗原受容体、ｃａｒ－ｔ細胞、及びそれらの使用
|
|
JP2023501717A
(ja)
|
2019-11-19 |
2023-01-18 |
アムジエン・インコーポレーテツド |
新規の多重特異性抗体フォーマット
|
|
PH12022551291A1
(en)
|
2019-11-26 |
2023-11-20 |
Novartis Ag |
Chimeric antigen receptors binding bcma and cd19 and uses thereof
|
|
CN113135996A
(zh)
|
2019-12-09 |
2021-07-20 |
启愈生物技术(上海)有限公司 |
一种双特异抗体及其应用
|
|
US11845799B2
(en)
|
2019-12-13 |
2023-12-19 |
Genentech, Inc. |
Anti-Ly6G6D antibodies and methods of use
|
|
US11702474B2
(en)
|
2019-12-17 |
2023-07-18 |
Pfizer Inc. |
Antibodies specific for CD47, PD-L1, and uses thereof
|
|
CN114867749A
(zh)
|
2019-12-17 |
2022-08-05 |
安进公司 |
用于疗法中的双重白介素-2/tnf受体激动剂
|
|
EP4076666A1
(en)
|
2019-12-18 |
2022-10-26 |
F. Hoffmann-La Roche AG |
Antibodies binding to hla-a2/mage-a4
|
|
CN114867532A
(zh)
|
2019-12-18 |
2022-08-05 |
豪夫迈·罗氏有限公司 |
双特异性抗ccl2抗体
|
|
TW202136317A
(zh)
|
2019-12-20 |
2021-10-01 |
美商再生元醫藥公司 |
新穎之ｉｌ２促效劑及其使用方法（二）
|
|
EP4077363A1
(en)
|
2019-12-20 |
2022-10-26 |
F. Hoffmann-La Roche AG |
Il-37 fusion proteins and uses thereof
|
|
KR20220116522A
(ko)
|
2019-12-20 |
2022-08-23 |
노파르티스 아게 |
증식성 질환의 치료를 위한 항-tgf-베타 항체 및 체크포인트 억제제의 용도
|
|
CR20220334A
(es)
|
2019-12-23 |
2022-08-26 |
Genentech Inc |
Anticuerpos específicos de apolipoproteína l1 y métodos de uso
|
|
CA3162444C
(en)
|
2019-12-27 |
2024-04-30 |
Hitoshi KATADA |
Anti-ctla-4 antibody and use thereof
|
|
JP7692916B2
(ja)
|
2020-01-02 |
2025-06-16 |
エフ． ホフマン－ラ ロシュ アーゲー |
脳内の治療用抗体の量を決定するための方法
|
|
CA3166629A1
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
WO2021138407A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
MX2022008214A
(es)
|
2020-01-09 |
2022-08-08 |
Hoffmann La Roche |
Nuevas moleculas de union al antigeno que contienen el trimero de 4-1bbl.
|
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
|
WO2021144422A1
(en)
|
2020-01-15 |
2021-07-22 |
F. Hoffmann-La Roche Ag |
Methods to decrease impurities from recombinant protein manufacturing processes
|
|
CN114980927A
(zh)
|
2020-01-16 |
2022-08-30 |
健玛保 |
Cd38抗体的配制剂及其用途
|
|
EP4090762A1
(en)
|
2020-01-17 |
2022-11-23 |
Becton, Dickinson and Company |
Methods and compositions for single cell secretomics
|
|
TW202140037A
(zh)
|
2020-01-17 |
2021-11-01 |
瑞士商諾華公司 |
組合療法
|
|
IL294879A
(en)
|
2020-01-29 |
2022-09-01 |
Inhibrx Inc |
Monodomain antibodies of cd28 and their multivalent and multispecific constructs
|
|
WO2021155916A1
(en)
|
2020-02-04 |
2021-08-12 |
BioNTech SE |
Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
|
|
US20230096452A1
(en)
|
2020-02-10 |
2023-03-30 |
Shanghai Escugen Biotechnology Co., Ltd. |
Claudin 18.2 antibody and use thereof
|
|
AU2021220887B2
(en)
|
2020-02-10 |
2024-11-21 |
Shanghai Escugen Biotechnology Co., Ltd. |
CLDN18.2 antibody and use thereof
|
|
TWI895351B
(zh)
|
2020-02-12 |
2025-09-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
|
WO2021173844A1
(en)
|
2020-02-26 |
2021-09-02 |
Biograph 55, Inc. |
C19 c38 bispecific antibodies
|
|
KR20220159989A
(ko)
|
2020-02-26 |
2022-12-05 |
바이오그래프 55, 인크. |
C19 c38 이중특이적 항체
|
|
CN115397460A
(zh)
|
2020-02-27 |
2022-11-25 |
诺华股份有限公司 |
制备表达嵌合抗原受体的细胞的方法
|
|
EP4118114A1
(en)
|
2020-03-13 |
2023-01-18 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
|
MY210125A
(en)
|
2020-03-18 |
2025-08-28 |
Genmab As |
Antibodies binding to b7h4
|
|
EP4121163A1
(en)
|
2020-03-19 |
2023-01-25 |
Genentech, Inc. |
Isoform-selective anti-tgf-beta antibodies and methods of use
|
|
EP4126949A1
(en)
|
2020-03-24 |
2023-02-08 |
Genentech, Inc. |
Tie2-binding agents and methods of use
|
|
US20230242671A1
(en)
|
2020-03-25 |
2023-08-03 |
Eli Lilly And Company |
Multispecific binding proteins and methods of developing the same
|
|
EP4127153A2
(en)
|
2020-03-26 |
2023-02-08 |
Genentech, Inc. |
Modified mammalian cells having reduced host cell proteins
|
|
US20230128499A1
(en)
|
2020-03-27 |
2023-04-27 |
Novartis Ag |
Bispecific combination therapy for treating proliferative diseases and autoimmune diseases
|
|
CN120058957A
(zh)
|
2020-03-30 |
2025-05-30 |
国立大学法人三重大学 |
双特异性抗体
|
|
AR121706A1
(es)
|
2020-04-01 |
2022-06-29 |
Hoffmann La Roche |
Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
|
|
EP4130732A4
(en)
|
2020-04-02 |
2024-06-19 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD FOR ANALYZING IMPURITIES MOLECULES IN A COMPOSITION CONTAINING MULTI-SPECIFIC ANTIGEN BINDING MOLECULES
|
|
CN115698717A
(zh)
|
2020-04-03 |
2023-02-03 |
基因泰克公司 |
癌症的治疗和诊断方法
|
|
CN115485028A
(zh)
|
2020-04-15 |
2022-12-16 |
豪夫迈·罗氏有限公司 |
免疫缀合物
|
|
CN116249712A
(zh)
|
2020-04-15 |
2023-06-09 |
沃雅戈治疗公司 |
Tau结合化合物
|
|
CN115916822A
(zh)
|
2020-04-24 |
2023-04-04 |
基因泰克公司 |
使用抗CD79b免疫缀合物的方法
|
|
CR20220531A
(es)
|
2020-04-24 |
2022-11-28 |
Hoffmann La Roche |
Modulacion de enzimas y vías con compuestos de sulfhidrilo y sus derivados
|
|
KR20230028242A
(ko)
|
2020-04-24 |
2023-02-28 |
마렝고 테라퓨틱스, 인크. |
T 세포 관련 암 세포에 결합하는 다중기능성 분자 및 그것의 용도
|
|
JP2023523450A
(ja)
|
2020-04-28 |
2023-06-05 |
ジェネンテック， インコーポレイテッド |
非小細胞肺がん免疫療法のための方法及び組成物
|
|
AU2021263408A1
(en)
|
2020-04-30 |
2022-10-27 |
Bristol-Myers Squibb Company |
Methods of treating cytokine-related adverse events
|
|
EP4143236A1
(en)
|
2020-05-01 |
2023-03-08 |
Novartis AG |
Engineered immunoglobulins
|
|
CN116963782A
(zh)
|
2020-05-03 |
2023-10-27 |
联宁（苏州）生物制药有限公司 |
包含抗trop-2抗体的抗体药物偶联物
|
|
TW202208428A
(zh)
|
2020-05-06 |
2022-03-01 |
美商蜻蜓醫療公司 |
結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質
|
|
JP2023524149A
(ja)
|
2020-05-08 |
2023-06-08 |
ジェンマブ エー／エス |
Ｃｄ３およびｃｄ２０に対する二重特異性抗体
|
|
KR20230010240A
(ko)
|
2020-05-11 |
2023-01-18 |
에프. 호프만-라 로슈 아게 |
변형된 pbmc 및 면역접합체를 이용한 병용 요법
|
|
AU2021270563A1
(en)
|
2020-05-12 |
2022-12-15 |
Regeneron Pharmaceuticals, Inc. |
Novel IL10 agonists and methods of use thereof
|
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
|
EP4149421A1
(en)
|
2020-05-15 |
2023-03-22 |
F. Hoffmann-La Roche AG |
Prevention of visible particle formation in parenteral protein solutions
|
|
KR20230012568A
(ko)
|
2020-05-18 |
2023-01-26 |
장쑤 심시어 파마슈티컬 컴퍼니 리미티드 |
인간 il-15 돌연변이체 및 그 용도
|
|
CN115605185A
(zh)
|
2020-05-19 |
2023-01-13 |
豪夫迈·罗氏有限公司（Ch） |
螯合剂用于防止胃肠外蛋白质溶液中形成可见颗粒的用途
|
|
EP4153316A1
(en)
|
2020-05-19 |
2023-03-29 |
Boehringer Ingelheim International GmbH |
Binding molecules for the treatment of cancer
|
|
CN116323665A
(zh)
|
2020-05-29 |
2023-06-23 |
23和我公司 |
抗cd200r1抗体及其使用方法
|
|
CN115697489A
(zh)
|
2020-06-08 |
2023-02-03 |
豪夫迈·罗氏有限公司 |
抗hbv抗体及其使用方法
|
|
EP4165415A1
(en)
|
2020-06-12 |
2023-04-19 |
Genentech, Inc. |
Methods and compositions for cancer immunotherapy
|
|
TW202519548A
(zh)
|
2020-06-19 |
2025-05-16 |
瑞士商赫孚孟拉羅股份公司 |
與 cd3 及 cd19 結合之抗體
|
|
IL296089A
(en)
|
2020-06-19 |
2022-11-01 |
Hoffmann La Roche |
Antibodies binding to cd3
|
|
BR112022024469A2
(pt)
|
2020-06-19 |
2023-01-17 |
Hoffmann La Roche |
Molécula biespecífica de ativação de células t ativáveis por protease, polipeptídeo específico de idiotipo, composição farmacêutica, polinucleotídeo isolado, vetor, célula hospedeira, método para produzir uma molécula biespecífica de ativação de células t ativáveis por protease, molécula biespecífica de ativação de células t ativáveis por protease, uso da molécula biespecífica de ativação de células t ativáveis por protease e método para tratar uma doença em um indivíduo
|
|
PE20230616A1
(es)
|
2020-06-19 |
2023-04-14 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y folr1
|
|
MX2022015764A
(es)
|
2020-06-19 |
2023-01-19 |
Chugai Pharmaceutical Co Ltd |
Molecula de union al antigeno anti-celulas t para usarse en combinacion con un inhibidor de angiogenesis.
|
|
PE20230470A1
(es)
|
2020-06-19 |
2023-03-14 |
Hoffmann La Roche |
Moleculas de union al dominio fc de activacion inmunitaria
|
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
|
JP2023531222A
(ja)
|
2020-06-22 |
2023-07-21 |
アルミラル・ソシエダッド・アノニマ |
抗ｉｌ－３６抗体およびその使用方法
|
|
CA3182346A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
CR20220627A
(es)
|
2020-06-23 |
2023-02-17 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se derigen a her2
|
|
IL299161A
(en)
|
2020-06-24 |
2023-02-01 |
Genentech Inc |
Cell lines resistant to apoptosis
|
|
JP2023531067A
(ja)
|
2020-06-25 |
2023-07-20 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗ｃｄ３／抗ｃｄ２８二重特異性抗原結合分子
|
|
US20230355722A1
(en)
|
2020-06-29 |
2023-11-09 |
Resolve Therapeutics, Llc |
Treatment of sjogren’s syndrome with nuclease fusion proteins
|
|
WO2022009052A2
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
EP4178529A1
(en)
|
2020-07-07 |
2023-05-17 |
F. Hoffmann-La Roche AG |
Alternative surfactants as stabilizers for therapeutic protein formulations
|
|
PE20230434A1
(es)
*
|
2020-07-10 |
2023-03-08 |
Hoffmann La Roche |
Anticuerpos que se unen a celulas cancerosas y dirigen radionucleotidos a dichas celulas
|
|
AU2021308712B2
(en)
|
2020-07-16 |
2025-10-09 |
Novartis Ag |
Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
|
|
CN116490518A
(zh)
|
2020-07-17 |
2023-07-25 |
西穆尔克斯股份有限公司 |
用于重定向免疫抑制信号传导的嵌合MyD88受体及相关组合物和方法
|
|
CN116406377A
(zh)
|
2020-07-17 |
2023-07-07 |
基因泰克公司 |
抗notch2抗体及其使用方法
|
|
IL299860A
(en)
|
2020-07-21 |
2023-03-01 |
Genentech Inc |
Antibody-conjugated chemical factors for the discharge of BRM and their methods
|
|
US20230293680A1
(en)
|
2020-07-23 |
2023-09-21 |
Genmab B.V. |
A composition of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
|
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
|
MX2023001120A
(es)
|
2020-07-31 |
2023-02-22 |
Chugai Pharmaceutical Co Ltd |
Composicion farmaceutica que comprende una celula que expresa un receptor quimerico.
|
|
CN116134027B
(zh)
|
2020-08-03 |
2025-01-24 |
诺华股份有限公司 |
杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
|
JP2023536340A
(ja)
|
2020-08-06 |
2023-08-24 |
ビオンテック・ソシエタス・エウロパエア |
コロナウイルスｓタンパク質のための結合剤
|
|
KR20230166150A
(ko)
|
2020-08-19 |
2023-12-06 |
젠코어 인코포레이티드 |
항-cd28 조성물
|
|
EP4204458A4
(en)
|
2020-08-26 |
2024-10-09 |
Marengo Therapeutics, Inc. |
METHODS FOR DETECTION OF TRBC1 OR TRBC2
|
|
AU2021331076A1
(en)
|
2020-08-26 |
2023-04-06 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to NKp30 and uses thereof
|
|
JP2023542080A
(ja)
|
2020-08-26 |
2023-10-05 |
マレンゴ・セラピューティクス，インコーポレーテッド |
カルレティキュリンに結合する多機能性分子およびその使用
|
|
US20230416371A1
(en)
|
2020-08-28 |
2023-12-28 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimer fc polypeptide
|
|
KR20230056766A
(ko)
|
2020-08-28 |
2023-04-27 |
제넨테크, 인크. |
숙주 세포 단백질의 CRISPR/Cas9 다중 녹아웃
|
|
EP4204020A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
WO2022043557A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
JP2023539525A
(ja)
|
2020-09-02 |
2023-09-14 |
ジェンマブ エー／エス |
抗体療法
|
|
CA3192256A1
(en)
|
2020-09-10 |
2022-03-17 |
Brian Elliott |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
|
US20230355753A1
(en)
|
2020-09-10 |
2023-11-09 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
|
BR112023004327A2
(pt)
|
2020-09-10 |
2023-04-04 |
Genmab As |
Método para tratar leucemia linfocítica crônica em um sujeito humano
|
|
MX2023002545A
(es)
|
2020-09-10 |
2023-03-14 |
Genmab As |
Anticuerpo biespecifico contra cumulo de diferenciacion 3 (cd3) y cumulo de diferenciacion 20 (cd20) en terapia de combinacion para el tratamiento de linfoma difuso de celulas b grandes.
|
|
CA3189883A1
(en)
|
2020-09-10 |
2022-03-17 |
Brian Elliott |
Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
|
|
BR112023004351A2
(pt)
|
2020-09-10 |
2023-04-04 |
Genmab As |
Método para tratar linfoma folicular em um sujeito humano
|
|
JP2023541627A
(ja)
|
2020-09-14 |
2023-10-03 |
イシュノス サイエンシズ ソシエテ アノニム |
Ｉｌ１ｒａｐに結合する抗体及びその使用
|
|
IL301258A
(en)
|
2020-09-21 |
2023-05-01 |
Genentech Inc |
Purification of multispecific antibodies
|
|
MX2023003328A
(es)
|
2020-09-24 |
2023-03-27 |
Hoffmann La Roche |
Lineas de celulas de mamifero con desactivacion genica.
|
|
AU2021351187A1
(en)
|
2020-10-02 |
2023-04-20 |
Genmab A/S |
Antibodies capable of binding to ROR2 and bispecific antibodies binding to ROR2 and CD3
|
|
CA3193952A1
(en)
|
2020-10-05 |
2022-04-14 |
Bernard Martin Fine |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
TW202231292A
(zh)
|
2020-10-13 |
2022-08-16 |
美商健生生物科技公司 |
用於調節分化簇ｉｖ及／或ｖｉｉｉ的經生物工程改造之ｔ細胞介導之免疫力、材料、及其他方法
|
|
KR20230091871A
(ko)
|
2020-10-20 |
2023-06-23 |
에프. 호프만-라 로슈 아게 |
Pd-1 축 결합 길항제 및 lrrk2 억제제의 병용 요법
|
|
AR123855A1
(es)
|
2020-10-20 |
2023-01-18 |
Genentech Inc |
Anticuerpos anti-mertk conjugados con peg y métodos de uso
|
|
CN117043186A
(zh)
|
2020-10-21 |
2023-11-10 |
勃林格殷格翰国际有限公司 |
用于治疗眼部疾病的激动性TrkB结合分子
|
|
CN116390950A
(zh)
|
2020-10-28 |
2023-07-04 |
詹森生物科技公司 |
用于调节δγ链介导的免疫的组合物和方法
|
|
US20230374147A1
(en)
|
2020-11-02 |
2023-11-23 |
Hummingbird Bioscience Pte. Ltd. |
Bcma/taci antigen-binding molecules
|
|
CN116390933A
(zh)
|
2020-11-06 |
2023-07-04 |
诺华股份有限公司 |
治疗b细胞恶性肿瘤的抗cd19剂和b细胞靶向剂组合疗法
|
|
MX2023005353A
(es)
|
2020-11-06 |
2023-05-22 |
Novartis Ag |
Moleculas de union a cd19 y usos de las mismas.
|
|
KR20230107305A
(ko)
|
2020-11-10 |
2023-07-14 |
상하이 치루 파마슈티컬 리서치 앤 디벨롭먼트 센터 리미티드 |
클라우딘 18a2 및 cd3에 대한 이중특이성 항체 및 이중특이성 항체의 용도
|
|
US20240033358A1
(en)
|
2020-11-13 |
2024-02-01 |
Novartis Ag |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
|
KR20230109674A
(ko)
|
2020-11-16 |
2023-07-20 |
에프. 호프만-라 로슈 아게 |
Fab 고 만노스 당형
|
|
WO2022101458A1
(en)
|
2020-11-16 |
2022-05-19 |
F. Hoffmann-La Roche Ag |
Combination therapy with fap-targeted cd40 agonists
|
|
JP2023553399A
(ja)
|
2020-12-02 |
2023-12-21 |
アレクトル エルエルシー |
抗ソルチリン抗体の使用法
|
|
CA3197740A1
(en)
|
2020-12-04 |
2022-06-09 |
F. Hoffman-La Roche Ag |
Ph-dependent mutant interleukin-2 polypeptides
|
|
EP4255925A1
(en)
|
2020-12-07 |
2023-10-11 |
UCB Biopharma SRL |
Antibodies against interleukin-22
|
|
IL303295A
(en)
|
2020-12-07 |
2023-07-01 |
UCB Biopharma SRL |
Multi-specific antibodies and antibody combinations
|
|
CA3204702A1
(en)
|
2020-12-17 |
2022-06-23 |
F. Hoffmann-La Roche Ag |
Anti-hla-g antibodies and use thereof
|
|
CN116601175A
(zh)
|
2020-12-18 |
2023-08-15 |
豪夫迈·罗氏有限公司 |
用于靶向疗法的前体蛋白和试剂盒
|
|
JP2024501662A
(ja)
|
2020-12-22 |
2024-01-15 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｘｂｐ１を標的とするオリゴヌクレオチド
|
|
IL304067A
(en)
|
2021-01-06 |
2023-08-01 |
Hoffmann La Roche |
Combined treatment using PD1-LAG3 bispecific antibody and CD20 T cell bispecific antibody
|
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
|
KR20230131204A
(ko)
|
2021-01-12 |
2023-09-12 |
에프. 호프만-라 로슈 아게 |
암 세포에 결합하여 방사성핵종을 상기 세포에 표적화하는분할 항체
|
|
WO2022152701A1
(en)
|
2021-01-13 |
2022-07-21 |
F. Hoffmann-La Roche Ag |
Combination therapy
|
|
WO2022162587A1
(en)
|
2021-01-27 |
2022-08-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
|
JP2024505049A
(ja)
|
2021-01-29 |
2024-02-02 |
ノバルティス アーゲー |
抗ｃｄ７３及び抗ｅｎｔｐｄ２抗体のための投与方式並びにその使用
|
|
JP2024509695A
(ja)
|
2021-02-03 |
2024-03-05 |
ジェネンテック， インコーポレイテッド |
多重特異性結合タンパク質分解プラットフォームおよび使用方法
|
|
MX2023009100A
(es)
|
2021-02-03 |
2023-09-25 |
Mozart Therapeutics Inc |
Agentes aglutinantes y métodos para usar los mismos.
|
|
CN117794566A
(zh)
|
2021-02-05 |
2024-03-29 |
Vib研究所 |
沙贝病毒结合剂
|
|
AU2022224508A1
(en)
|
2021-02-16 |
2023-10-05 |
Janssen Biotech, Inc. |
Materials and methods for enhanced linker targeting
|
|
EP4295154A1
(en)
|
2021-02-18 |
2023-12-27 |
F. Hoffmann-La Roche AG |
Method for resolving complex, multistep antibody interactions
|
|
US20240228613A9
(en)
|
2021-02-19 |
2024-07-11 |
Shaperon Inc. |
Single domain antibody against cd47 and use thereof
|
|
WO2022177393A1
(ko)
|
2021-02-19 |
2022-08-25 |
(주)샤페론 |
Pd-l1에 대한 단일 도메인 항체 및 이의 용도
|
|
EP4301774A4
(en)
|
2021-03-03 |
2025-08-13 |
Dragonfly Therapeutics Inc |
METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
|
|
US20240181073A1
(en)
|
2021-03-03 |
2024-06-06 |
Sorrento Therapeutics, Inc. |
Antibody-Drug Conjugates Comprising an Anti-BCMA Antibody
|
|
WO2022189380A1
(en)
|
2021-03-09 |
2022-09-15 |
F. Hoffmann-La Roche Ag |
Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies
|
|
KR20230156051A
(ko)
|
2021-03-09 |
2023-11-13 |
에프. 호프만-라 로슈 아게 |
Pd-1-표적화 il-2 변이체 면역접합체 및 fap/4-1bb 결합 분자의 병용 요법
|
|
WO2022192403A1
(en)
|
2021-03-09 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
JP2024509274A
(ja)
|
2021-03-10 |
2024-02-29 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
|
|
CN117062839A
(zh)
|
2021-03-12 |
2023-11-14 |
基因泰克公司 |
抗klk7抗体、抗klk5抗体、多特异性抗klk5/klk7抗体和使用方法
|
|
US20240150484A1
(en)
|
2021-03-12 |
2024-05-09 |
Genmab A/S |
Non-activating antibody variants
|
|
BR112023018621A2
(pt)
|
2021-03-15 |
2023-10-24 |
Hoffmann La Roche |
Métodos para tratar nefrite lúpica, esgotar células b periféricas, kits para tratar nefrite lúpica e anticorpos anti-cd20 tipo ii
|
|
US20240174746A1
(en)
|
2021-03-18 |
2024-05-30 |
Alector Llc |
Anti-tmem106b antibodies and methods of use thereof
|
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
|
US20240166738A1
(en)
|
2021-03-23 |
2024-05-23 |
Alector Llc |
Anti-tmem106b antibodies for treating and preventing coronavirus infections
|
|
AU2022244453A1
(en)
|
2021-03-24 |
2023-11-09 |
Janssen Biotech, Inc. |
Antibody targeting cd22 and cd79b
|
|
WO2022201122A1
(en)
|
2021-03-26 |
2022-09-29 |
Janssen Biotech, Inc. |
Humanized antibodies against paired helical filament tau and uses thereof
|
|
CN117321087A
(zh)
|
2021-03-26 |
2023-12-29 |
先天制药公司 |
包含与细胞因子融合用于nk细胞衔接的nkp46结合位点、癌抗原结合位点的多特异性蛋白质
|
|
PH12023500022A1
(en)
|
2021-03-29 |
2024-03-11 |
Daiichi Sankyo Co Ltd |
Stable multispecific molecule and use thereof
|
|
CN116897159A
(zh)
|
2021-03-31 |
2023-10-17 |
江苏恒瑞医药股份有限公司 |
截短的taci多肽及其融合蛋白和用途
|
|
TW202304994A
(zh)
|
2021-04-02 |
2023-02-01 |
美商泰尼歐生物公司 |
促效性抗ｉｌ－２ｒ抗體及使用方法
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
US20250099579A1
(en)
|
2021-04-08 |
2025-03-27 |
Marengo Therapeutics, Inc. |
Multispecific molecules binding to tcr and uses thereof
|
|
EP4320444A1
(en)
|
2021-04-09 |
2024-02-14 |
F. Hoffmann-La Roche AG |
Process for selecting cell clones expressing a heterologous polypeptide
|
|
CA3215049A1
(en)
|
2021-04-10 |
2022-10-13 |
Baiteng ZHAO |
Folr1 binding agents, conjugates thereof and methods of using the same
|
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
|
IL307501A
(en)
|
2021-04-19 |
2023-12-01 |
Hoffmann La Roche |
Modified mammalian cells
|
|
JP7742892B2
(ja)
|
2021-04-23 |
2025-09-22 |
ジェンマブ エー／エス |
抗ｃｄ７０抗体、そのコンジュゲートおよびこれを使用する方法
|
|
JP7707306B2
(ja)
|
2021-04-30 |
2025-07-14 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗ｃｄ２０／抗ｃｄ３二重特異性抗体による治療のための投薬
|
|
CA3213632A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
MX2023012984A
(es)
|
2021-05-03 |
2023-11-15 |
UCB Biopharma SRL |
Anticuerpos.
|
|
EP4334353A1
(en)
|
2021-05-04 |
2024-03-13 |
Regeneron Pharmaceuticals, Inc. |
Multispecific fgf21 receptor agonists and their uses
|
|
CN117597365A
(zh)
|
2021-05-04 |
2024-02-23 |
再生元制药公司 |
多特异性fgf21受体激动剂及其应用
|
|
US20240383982A1
(en)
|
2021-05-07 |
2024-11-21 |
Genmab A/S |
Pharmaceutical compositions comprising bispecific antibodies binding to b7h4 and cd3
|
|
WO2022238481A1
(en)
|
2021-05-11 |
2022-11-17 |
Modiquest B.V. |
Antibodies
|
|
CN117396232A
(zh)
|
2021-05-12 |
2024-01-12 |
基因泰克公司 |
使用抗cd79b免疫缀合物治疗弥漫性大b细胞淋巴瘤的方法
|
|
JP2024518081A
(ja)
|
2021-05-12 |
2024-04-24 |
江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 |
Ｒａｎｋｌとｎｇｆに特異的に結合する抗原結合分子およびその医薬用途
|
|
AU2022273727A1
(en)
|
2021-05-13 |
2023-11-09 |
ALX Oncology Inc. |
Combination therapies for treating cancer
|
|
JP2024517907A
(ja)
|
2021-05-14 |
2024-04-23 |
江蘇恒瑞医薬股▲ふん▼有限公司 |
抗原結合分子
|
|
EP4337317A1
(en)
|
2021-05-14 |
2024-03-20 |
Genentech, Inc. |
Agonists of trem2
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
WO2022243261A1
(en)
|
2021-05-19 |
2022-11-24 |
F. Hoffmann-La Roche Ag |
Agonistic cd40 antigen binding molecules targeting cea
|
|
CN117396599A
(zh)
|
2021-05-21 |
2024-01-12 |
基因泰克公司 |
用于生产目的重组产物的经修饰的细胞
|
|
CN113278071B
(zh)
|
2021-05-27 |
2021-12-21 |
江苏荃信生物医药股份有限公司 |
抗人干扰素α受体1单克隆抗体及其应用
|
|
AR126009A1
(es)
|
2021-06-02 |
2023-08-30 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
|
|
WO2022255440A1
(en)
|
2021-06-04 |
2022-12-08 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ddr2 antibodies and uses thereof
|
|
WO2022258678A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
|
|
CA3218793A1
(en)
|
2021-06-09 |
2022-12-15 |
Laurent Gauthier |
Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a
|
|
AU2022289684A1
(en)
|
2021-06-09 |
2023-10-05 |
F. Hoffmann-La Roche Ag |
Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
|
|
WO2022258691A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
|
|
IL308531A
(en)
|
2021-06-09 |
2024-01-01 |
Innate Pharma |
Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2
|
|
EP4355783A1
(en)
|
2021-06-16 |
2024-04-24 |
Alector LLC |
Monovalent anti-mertk antibodies and methods of use thereof
|
|
EP4355786A1
(en)
|
2021-06-16 |
2024-04-24 |
Alector LLC |
Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
|
|
WO2022263638A1
(en)
|
2021-06-17 |
2022-12-22 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
|
EP4355778A1
(en)
|
2021-06-17 |
2024-04-24 |
Boehringer Ingelheim International GmbH |
Novel tri-specific binding molecules
|
|
CN117500829A
(zh)
|
2021-06-18 |
2024-02-02 |
豪夫迈·罗氏有限公司 |
双特异性抗ccl2抗体
|
|
IL309319A
(en)
|
2021-06-21 |
2024-02-01 |
Genmab As |
Combined dosage regimen CD137 and PD-L1 binding agents
|
|
EP4359436A1
(en)
|
2021-06-22 |
2024-05-01 |
Novartis AG |
Bispecific antibodies for use in treatment of hidradenitis suppurativa
|
|
TW202306999A
(zh)
|
2021-06-24 |
2023-02-16 |
美商艾瑞斯卡公司 |
抗egfr抗體及其用途
|
|
WO2022270611A1
(ja)
|
2021-06-25 |
2022-12-29 |
中外製薬株式会社 |
抗ｃｔｌａ－４抗体
|
|
US12448451B2
(en)
|
2021-06-25 |
2025-10-21 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-CTLA-4 antibody and use thereof
|
|
CN119838007A
(zh)
|
2021-06-25 |
2025-04-18 |
中外制药株式会社 |
抗ctla-4抗体的用途
|
|
WO2023274183A1
(zh)
|
2021-06-29 |
2023-01-05 |
江苏先声药业有限公司 |
Cd16抗体及其应用
|
|
MX2023015416A
(es)
|
2021-07-02 |
2024-04-30 |
Genentech Inc |
Procedimientos y composiciones para tratar el cancer.
|
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
|
WO2023281120A1
(en)
|
2021-07-09 |
2023-01-12 |
Luxembourg Institute Of Health (Lih) |
Dimeric protein complexes and uses thereof
|
|
EP4371125A1
(en)
|
2021-07-13 |
2024-05-22 |
Genentech, Inc. |
Multi-variate model for predicting cytokine release syndrome
|
|
EP4372001A4
(en)
|
2021-07-14 |
2025-02-12 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
ANTIGEN-BINDING MOLECULE SPECIFICALLY BINDING TO HGFR AND EGFR, AND PHARMACEUTICAL USE THEREOF
|
|
PE20240638A1
(es)
|
2021-07-14 |
2024-03-27 |
Genentech Inc |
Anticuerpos anti-receptor de quimiocinas de motivo c-c 8 (ccr8) y metodos de uso
|
|
US20250066441A1
(en)
|
2021-07-19 |
2025-02-27 |
Regeneron Pharmaceuticals, Inc. |
Il12 receptor agonists and methods of use thereof
|
|
WO2023004386A1
(en)
|
2021-07-22 |
2023-01-26 |
Genentech, Inc. |
Brain targeting compositions and methods of use thereof
|
|
EP4373859A1
(en)
|
2021-07-22 |
2024-05-29 |
F. Hoffmann-La Roche AG |
Heterodimeric fc domain antibodies
|
|
EP4377347A1
(en)
|
2021-07-27 |
2024-06-05 |
MorphoSys AG |
Combinations of antigen binding molecules
|
|
JP2024527977A
(ja)
|
2021-07-27 |
2024-07-26 |
ノヴァブ， インコーポレイテッド |
免疫エフェクター機能を有する操作されたｖｌｒｂ抗体
|
|
AU2022317820A1
(en)
|
2021-07-28 |
2023-12-14 |
F. Hoffmann-La Roche Ag |
Methods and compositions for treating cancer
|
|
WO2023012147A1
(en)
|
2021-08-03 |
2023-02-09 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies and methods of use
|
|
JP2024534004A
(ja)
|
2021-08-13 |
2024-09-18 |
ジェネンテック， インコーポレイテッド |
抗トリプターゼ抗体のための投与量
|
|
AU2022331241A1
(en)
|
2021-08-16 |
2024-03-28 |
Regeneron Pharmaceuticals, Inc. |
Novel il27 receptor agonists and methods of use thereof
|
|
AU2022332285A1
(en)
|
2021-08-23 |
2024-02-15 |
Immunitas Therapeutics, Inc. |
Anti-cd161 antibodies and uses thereof
|
|
JP2024534151A
(ja)
|
2021-08-27 |
2024-09-18 |
ジェネンテック， インコーポレイテッド |
タウ病態の治療方法
|
|
EP4396223A1
(en)
|
2021-08-30 |
2024-07-10 |
Genentech, Inc. |
Anti-polyubiquitin multispecific antibodies
|
|
CN113603775B
(zh)
|
2021-09-03 |
2022-05-20 |
江苏荃信生物医药股份有限公司 |
抗人白介素-33单克隆抗体及其应用
|
|
CN113683694B
(zh)
|
2021-09-03 |
2022-05-13 |
江苏荃信生物医药股份有限公司 |
一种抗人tslp单克隆抗体及其应用
|
|
IL311141A
(en)
|
2021-09-06 |
2024-04-01 |
Genmab As |
Antibodies capable of binding to CD27, their variants and uses thereof
|
|
US20250223376A1
(en)
|
2021-09-20 |
2025-07-10 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
CA3232472A1
(en)
|
2021-09-23 |
2023-03-30 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Anti-klb antibodies and uses
|
|
WO2023051798A1
(zh)
|
2021-09-30 |
2023-04-06 |
江苏恒瑞医药股份有限公司 |
抗il23抗体融合蛋白及用途
|
|
CN118562019A
(zh)
*
|
2021-09-30 |
2024-08-30 |
宁波三生生物科技股份有限公司 |
重组促卵泡激素融合蛋白
|
|
EP4413998A1
(en)
|
2021-10-08 |
2024-08-14 |
Chugai Seiyaku Kabushiki Kaisha |
Method for preparing prefilled syringe formulation
|
|
AU2022361691A1
(en)
|
2021-10-08 |
2024-03-28 |
Genmab A/S |
Antibodies binding to cd30 and cd3
|
|
IL312043A
(en)
|
2021-10-14 |
2024-06-01 |
Teneobio Inc |
Mesothelin binding proteins and their uses
|
|
JP2024537096A
(ja)
|
2021-10-14 |
2024-10-10 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療のための代替的なＰＤ１－ＩＬ７ｖイムノコンジュゲート
|
|
AU2022362681A1
(en)
|
2021-10-14 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
New interleukin-7 immunoconjugates
|
|
JP2024542939A
(ja)
|
2021-10-15 |
2024-11-19 |
リジェネクスバイオ インコーポレイテッド |
抗体及びその使用方法
|
|
MX2024004763A
(es)
|
2021-10-20 |
2024-05-08 |
Synthekine Inc |
Citocinas heterodimericas fc y usos de las mismas.
|
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
|
WO2023073599A1
(en)
|
2021-10-28 |
2023-05-04 |
Novartis Ag |
Engineered fc variants
|
|
WO2023086807A1
(en)
|
2021-11-10 |
2023-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
|
AU2022383847A1
(en)
|
2021-11-11 |
2024-06-20 |
Regeneron Pharmaceuticals, Inc. |
Cd20-pd1 binding molecules and methods of use thereof
|
|
US20250034559A1
(en)
|
2021-11-17 |
2025-01-30 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
JP2024544607A
(ja)
|
2021-11-25 |
2024-12-03 |
エフ． ホフマン－ラ ロシュ アーゲー |
少量の抗体副産物の定量
|
|
JP2024543257A
(ja)
|
2021-11-26 |
2024-11-20 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗ｔｙｒｐ１／抗ｃｄ３二重特異性抗体およびｔｙｒｐ１特異性抗体の併用療法
|
|
KR20240113514A
(ko)
|
2021-11-30 |
2024-07-22 |
다이이찌 산쿄 가부시키가이샤 |
프로테아제 분해성 마스크 항체
|
|
US12460015B2
(en)
|
2021-12-01 |
2025-11-04 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical formulation comprising aqueous solution of antibody
|
|
WO2023098846A1
(zh)
|
2021-12-03 |
2023-06-08 |
江苏先声药业有限公司 |
抗bcma纳米抗体及其应用
|
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
|
JP2025501522A
(ja)
|
2021-12-17 |
2025-01-22 |
シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド |
抗ｏｘ４０抗体及び使用方法
|
|
WO2023109900A1
(en)
|
2021-12-17 |
2023-06-22 |
Shanghai Henlius Biotech, Inc. |
Anti-ox40 antibodies, multispecific antibodies and methods of use
|
|
CR20240246A
(es)
|
2021-12-20 |
2024-07-19 |
Hoffmann La Roche |
Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
|
|
EP4416301B1
(en)
|
2021-12-21 |
2025-06-11 |
F. Hoffmann-La Roche AG |
Method for the determination of hydrolytic activity
|
|
KR20240125958A
(ko)
|
2021-12-23 |
2024-08-20 |
지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 |
항-dll3 항체, 이의 항체-약물 접합체 및 이의 의약적 용도
|
|
CN118510805A
(zh)
|
2021-12-31 |
2024-08-16 |
山东先声生物制药有限公司 |
一种gprc5d抗体及其应用
|
|
CA3248241A1
(en)
|
2022-01-12 |
2023-07-20 |
Vib Vzw |
HUMAN NTCP BINDERS FOR THERAPEUTIC USE AND TARGETED LIVER ADMINISTRATION
|
|
TW202340251A
(zh)
|
2022-01-19 |
2023-10-16 |
美商建南德克公司 |
抗ｎｏｔｃｈ２抗體及結合物及其使用方法
|
|
AR128330A1
(es)
|
2022-01-26 |
2024-04-17 |
Genentech Inc |
Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
|
|
AR128331A1
(es)
|
2022-01-26 |
2024-04-17 |
Genentech Inc |
Inductores químicos de degradación conjugados con anticuerpos y métodos de estos
|
|
KR20240144239A
(ko)
|
2022-01-28 |
2024-10-02 |
젠맵 에이/에스 |
미만성 대 b-세포 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체
|
|
AU2023214116A1
(en)
|
2022-01-28 |
2024-07-18 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
|
TW202342548A
(zh)
|
2022-02-07 |
2023-11-01 |
美商威特拉公司 |
抗獨特型(anti-idiotype)抗體分子及其用途
|
|
US20250043022A1
(en)
|
2022-02-07 |
2025-02-06 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Antigen-binding molecule specifically binding to psma and cd3, and pharmaceutical use thereof
|
|
JPWO2023153442A1
(OSRAM)
|
2022-02-09 |
2023-08-17 |
|
|
|
WO2023151661A1
(zh)
|
2022-02-11 |
2023-08-17 |
江苏恒瑞医药股份有限公司 |
免疫缀合物及其用途
|
|
MX2024010773A
(es)
|
2022-03-03 |
2024-09-10 |
Pfizer |
Anticuerpos multiespecificos y usos de estos.
|
|
JP2025509286A
(ja)
|
2022-03-10 |
2025-04-11 |
ビバソル， インコーポレイテッド |
抗体－薬物コンジュゲートおよびその使用
|
|
CN119173530A
(zh)
|
2022-03-11 |
2024-12-20 |
詹森药业有限公司 |
多特异性抗体及其用途
|
|
EP4490184A1
(en)
|
2022-03-11 |
2025-01-15 |
JANSSEN Pharmaceutica NV |
Multispecific antibodies and uses thereof
|
|
EP4490183A1
(en)
|
2022-03-11 |
2025-01-15 |
JANSSEN Pharmaceutica NV |
Multispecific antibodies and uses thereof
|
|
CN118660910A
(zh)
|
2022-03-14 |
2024-09-17 |
江苏恒瑞医药股份有限公司 |
特异性结合gprc5d和cd3的抗原结合分子及其医药用途
|
|
WO2023174521A1
(en)
|
2022-03-15 |
2023-09-21 |
Genmab A/S |
Binding agents binding to epcam and cd137
|
|
TW202400232A
(zh)
|
2022-03-16 |
2024-01-01 |
日商第一三共股份有限公司 |
多特異性分子與免疫檢查點抑制劑之組合
|
|
CN119562970A
(zh)
|
2022-03-18 |
2025-03-04 |
进化免疫治疗公司 |
双特异性抗体融合分子及其使用方法
|
|
IL314211A
(en)
|
2022-03-23 |
2024-09-01 |
Genentech Inc |
Combined treatment of bispecific antibody and chemotherapy against CD20/ANTI-CD3
|
|
AU2023240941A1
(en)
|
2022-03-25 |
2024-09-19 |
Shanghai Henlius Biologics Co., Ltd. |
Anti-msln antibodies and methods of use
|
|
AR128876A1
(es)
|
2022-03-28 |
2024-06-19 |
Hoffmann La Roche |
Anticuerpos biespecíficos de linfocitos t activables con proteasa folr1 mejorados
|
|
EP4504780A1
(en)
|
2022-04-01 |
2025-02-12 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
JP2025512342A
(ja)
|
2022-04-13 |
2025-04-17 |
ジェネンテック， インコーポレイテッド |
治療用タンパク質の医薬組成物および使用方法
|
|
CA3255366A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions based on bispecific anti-CD20/anti-CD3 antibodies and methods of use
|
|
US20250304689A1
(en)
|
2022-04-13 |
2025-10-02 |
Genmab A/S |
Bispecific antibodies against cd3 and cd20
|
|
WO2023202967A1
(en)
|
2022-04-19 |
2023-10-26 |
F. Hoffmann-La Roche Ag |
Improved production cells
|
|
CR20240455A
(es)
|
2022-04-26 |
2024-12-20 |
Novartis Ag |
Anticuerpos multiespecíficos que se dirigen a il-13 e il-18
|
|
CN119486774A
(zh)
|
2022-04-26 |
2025-02-18 |
中外制药株式会社 |
含有药物制剂的内置过滤器的注射器
|
|
KR20250006932A
(ko)
|
2022-05-03 |
2025-01-13 |
제넨테크, 인크. |
항-Ly6E 항체, 면역접합체 및 이들의 용도
|
|
US20240059799A1
(en)
|
2022-05-11 |
2024-02-22 |
Pfizer Inc. |
Anti-tl1a antibodies and methods of use thereof
|
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
CA3252786A1
(en)
|
2022-05-11 |
2023-11-16 |
Regeneron Pharmaceuticals, Inc. |
PROPROTEINS OF MULTISPECIFIC BONDING MOLECULES AND THEIR USES
|
|
CA3252821A1
(en)
|
2022-05-12 |
2023-11-16 |
BioNTech SE |
LIAISON AGENTS CAPABLE OF BINDING TO CD27 IN POLYTHERAPY
|
|
JP2025516631A
(ja)
|
2022-05-12 |
2025-05-30 |
ジェンマブ エー／エス |
併用療法においてｃｄ２７に結合する能力を有する結合剤
|
|
US20250295809A1
(en)
|
2022-05-13 |
2025-09-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
KR20250030976A
(ko)
|
2022-05-27 |
2025-03-05 |
리제너론 파아마슈티컬스, 인크. |
인터루킨-2 프로프로테인 및 이의 용도
|
|
JP2025517572A
(ja)
|
2022-06-03 |
2025-06-05 |
エフ． ホフマン－ラ ロシュ アーゲー |
改良された産生細胞
|
|
US20230391844A1
(en)
|
2022-06-04 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Interleukin-2 proproteins and uses thereof
|
|
IL317463A
(en)
|
2022-06-06 |
2025-02-01 |
Shandong Simcere Biopharmaceutical Co Ltd |
Multispecific antibodies targeting BCMA, GPRC5D and T cells and their application
|
|
CN119256017A
(zh)
|
2022-06-23 |
2025-01-03 |
江苏恒瑞医药股份有限公司 |
特异性结合dll3和cd3的抗原结合分子及其医药用途
|
|
EP4554978A1
(en)
|
2022-07-13 |
2025-05-21 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2024013315A1
(en)
|
2022-07-15 |
2024-01-18 |
Boehringer Ingelheim International Gmbh |
Binding molecules for the treatment of cancer
|
|
JP2025523845A
(ja)
|
2022-07-19 |
2025-07-25 |
ジェネンテック， インコーポレイテッド |
抗ｆｃｒｈ５／抗ｃｄ３二重特異性抗体による処置のための投薬
|
|
CA3261121A1
(en)
|
2022-07-22 |
2024-01-25 |
Bristol-Myers Squibb Company |
ANTIBODIES THAT BIND TO HUMAN PAD4 AND THEIR USES
|
|
CN119654349A
(zh)
|
2022-07-22 |
2025-03-18 |
基因泰克公司 |
抗steap1抗原结合分子及其用途
|
|
JP2025524899A
(ja)
|
2022-07-27 |
2025-08-01 |
テネオバイオ， インコーポレイテッド |
メソテリン結合タンパク質及びその使用
|
|
EP4562044A2
(en)
|
2022-07-29 |
2025-06-04 |
Alector LLC |
Transferrin receptor antigen-binding domains and uses therefor
|
|
JP2025528751A
(ja)
|
2022-07-29 |
2025-09-02 |
アレクトル エルエルシー |
Ｃｄ９８ｈｃ抗原結合ドメイン及びその使用法
|
|
WO2024030956A2
(en)
|
2022-08-03 |
2024-02-08 |
Mozart Therapeutics, Inc. |
Cd39-specific binding agents and methods of using the same
|
|
PE20251076A1
(es)
|
2022-08-03 |
2025-04-10 |
Pfizer |
Anticuerpos anti-il27r y metodos de usos de estos
|
|
EP4565597A2
(en)
|
2022-08-03 |
2025-06-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
|
CN119546645A
(zh)
|
2022-08-05 |
2025-02-28 |
江苏恒瑞医药股份有限公司 |
特异性结合gucy2c和cd3的抗原结合分子及其医药用途
|
|
US20240067691A1
(en)
|
2022-08-18 |
2024-02-29 |
Regeneron Pharmaceuticals, Inc. |
Interferon receptor agonists and uses thereof
|
|
CN120051483A
(zh)
|
2022-08-18 |
2025-05-27 |
再生元制药公司 |
干扰素前蛋白及其用途
|
|
CN120153254A
(zh)
|
2022-09-01 |
2025-06-13 |
基因泰克公司 |
膀胱癌的治疗和诊断方法
|
|
EP4584297A1
(en)
|
2022-09-11 |
2025-07-16 |
Yeda Research and Development Co. Ltd |
Anti-klk4 antibodies and uses thereof
|
|
KR20250068626A
(ko)
|
2022-09-15 |
2025-05-16 |
아비디큐어 아이피 비.브이. |
Nk 세포 자극을 위한 다중특이적 항원 결합 단백질 및 이의 용도
|
|
AU2023342086A1
(en)
|
2022-09-15 |
2025-03-13 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
JP2025533570A
(ja)
|
2022-09-28 |
2025-10-07 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
改良されたプロテアーゼ活性化型ｔ細胞二重特異性抗体
|
|
WO2024068996A1
(en)
|
2022-09-30 |
2024-04-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
|
WO2024077044A1
(en)
|
2022-10-05 |
2024-04-11 |
Amgen Inc. |
Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
|
|
KR20250084938A
(ko)
|
2022-10-07 |
2025-06-11 |
제넨테크, 인크. |
항-c-c 모티프 케모킨 수용체 8(ccr8) 항체를 이용한 암 치료 방법
|
|
TW202423970A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
|
|
TW202423969A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法
|
|
TW202430211A
(zh)
|
2022-10-10 |
2024-08-01 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｉｍｉｄ之組合療法
|
|
JP2025535744A
(ja)
|
2022-10-12 |
2025-10-28 |
エフ． ホフマン－ラ ロシュ アーゲー |
細胞を分類するための方法
|
|
WO2024086796A1
(en)
|
2022-10-20 |
2024-04-25 |
Alector Llc |
Anti-ms4a4a antibodies with amyloid-beta therapies
|
|
CN115724975A
(zh)
|
2022-10-20 |
2023-03-03 |
江苏荃信生物医药股份有限公司 |
抗人白介素36受体单克隆抗体及其应用
|
|
AU2023367741A1
(en)
|
2022-10-25 |
2025-05-01 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|
|
WO2024094660A1
(en)
|
2022-10-31 |
2024-05-10 |
Genmab A/S |
Cd38 antibodies and uses thereof
|
|
EP4613767A1
(en)
|
2022-11-01 |
2025-09-10 |
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. |
Bispecific antibody for glypican-3 and use thereof
|
|
EP4612179A1
(en)
|
2022-11-02 |
2025-09-10 |
Genmab A/S |
Bispecific antibodies against cd3 and cd20 for treating richter's syndrome
|
|
CN120152989A
(zh)
|
2022-11-03 |
2025-06-13 |
豪夫迈·罗氏有限公司 |
抗cd19/抗cd28双特异性抗体的组合疗法
|
|
TW202434286A
(zh)
|
2022-11-08 |
2024-09-01 |
美商建南德克公司 |
治療兒童期發病的特發性腎病症候群之組成物及方法
|
|
WO2024102962A1
(en)
|
2022-11-10 |
2024-05-16 |
Immuvia Inc |
Cytotoxic bispecific antibodies binding to dr5 and muc16 and uses thereof
|
|
WO2024102948A1
(en)
|
2022-11-11 |
2024-05-16 |
Celgene Corporation |
Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
|
|
WO2024100170A1
(en)
|
2022-11-11 |
2024-05-16 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a*02/foxp3
|
|
EP4619428A1
(en)
|
2022-11-15 |
2025-09-24 |
F. Hoffmann-La Roche AG |
Antigen binding molecules
|
|
JP2025537782A
(ja)
|
2022-11-15 |
2025-11-20 |
エフ． ホフマン－ラ ロシュ アーゲー |
活性化可能なエフェクタードメインを有する組換え結合タンパク質
|
|
AU2023379743A1
(en)
|
2022-11-17 |
2025-07-03 |
Sanofi |
Ceacam5 antibody-drug conjugates and methods of use thereof
|
|
JP2025538565A
(ja)
|
2022-11-23 |
2025-11-28 |
エフ． ホフマン－ラ ロシュ アーゲー |
組換えタンパク質発現を増加させるための方法
|
|
TW202436348A
(zh)
|
2022-11-25 |
2024-09-16 |
日商中外製藥股份有限公司 |
蛋白質的製造方法
|
|
JP2025538642A
(ja)
|
2022-11-29 |
2025-11-28 |
江蘇恒瑞医薬股▲ふん▼有限公司 |
Ｃｌｄｎ１８．２／４－１ｂｂ結合タンパク質及びその医薬的使用
|
|
CN119546630A
(zh)
|
2022-12-08 |
2025-02-28 |
南京诺唯赞生物科技股份有限公司 |
特异性结合rsv的抗体
|
|
CN120693406A
(zh)
|
2022-12-12 |
2025-09-23 |
基因泰克公司 |
优化多肽唾液酸含量
|
|
EP4385999A1
(en)
|
2022-12-14 |
2024-06-19 |
ModiQuest B.V. |
Antibodies
|
|
EP4634172A1
(en)
|
2022-12-15 |
2025-10-22 |
F. Hoffmann-La Roche AG |
Combination therapy for cancer treatment
|
|
EP4634220A2
(en)
|
2022-12-16 |
2025-10-22 |
Regeneron Pharmaceuticals, Inc. |
Antigen-binding molecules that bind to aav particles and uses
|
|
US20240252601A1
(en)
|
2022-12-23 |
2024-08-01 |
Regeneron Pharmaceuticals, Inc. |
Ace2 fusion proteins and uses thereof
|
|
AU2024207469A1
(en)
|
2023-01-13 |
2025-08-28 |
Regeneron Pharmaceuticals, Inc. |
Fgfr3 binding molecules and methods of use thereof
|
|
WO2024151978A1
(en)
|
2023-01-13 |
2024-07-18 |
Regeneron Pharmaceuticals, Inc. |
Il12 receptor agonists and methods of use thereof
|
|
CR20250338A
(es)
|
2023-01-18 |
2025-09-02 |
Genentech Inc |
Anticuerpos multiespecíficos y usos de estos
|
|
CN120676957A
(zh)
|
2023-01-20 |
2025-09-19 |
豪夫迈·罗氏有限公司 |
重组Fc结构域-IL2变体多肽以及与膜锚定抗原结合多肽的组合疗法
|
|
CN120603846A
(zh)
|
2023-01-25 |
2025-09-05 |
豪夫迈·罗氏有限公司 |
承载有效载荷的多特异性抗体
|
|
EP4655322A1
(en)
|
2023-01-25 |
2025-12-03 |
F. Hoffmann-La Roche AG |
Antibodies binding to csf1r and cd3
|
|
TW202436339A
(zh)
|
2023-01-31 |
2024-09-16 |
瑞士商赫孚孟拉羅股份公司 |
治療選自非小細胞肺癌或三陰性乳癌的癌症之用途
|
|
WO2024163009A1
(en)
|
2023-01-31 |
2024-08-08 |
Genentech, Inc. |
Methods and compositions for treating urothelial bladder cancer
|
|
EP4662238A1
(en)
|
2023-02-06 |
2025-12-17 |
F. Hoffmann-La Roche AG |
Combination therapy and uses thereof
|
|
WO2024168061A2
(en)
|
2023-02-07 |
2024-08-15 |
Ayan Therapeutics Inc. |
Antibody molecules binding to sars-cov-2
|
|
EP4669669A1
(en)
|
2023-02-21 |
2025-12-31 |
Teneobio, Inc. |
C-KIT BINDING PROTEINS, CHIMERIC ANTIGENIC RECEPTORS AND THEIR USES
|
|
WO2024175031A1
(zh)
|
2023-02-21 |
2024-08-29 |
江苏恒瑞医药股份有限公司 |
Il-36r结合蛋白及其医药用途
|
|
KR20250153805A
(ko)
|
2023-02-27 |
2025-10-27 |
쑤저우 선카디아 바이오파마수티컬즈 컴퍼니 리미티드 |
항-dll3 항체, 이의 항체-약물 접합체 및 이의 의약적 용도
|
|
WO2024182540A2
(en)
|
2023-02-28 |
2024-09-06 |
Regeneron Pharmaceuticals, Inc. |
T cell activators and methods of use thereof
|
|
IL322940A
(en)
|
2023-02-28 |
2025-10-01 |
Regeneron Pharma |
Multivalent anti-spike protein binding molecules and their uses
|
|
CN120826234A
(zh)
|
2023-03-06 |
2025-10-21 |
豪夫迈·罗氏有限公司 |
抗EGFRvIII/抗CD3抗体与肿瘤靶向性4-1BB激动剂的组合疗法
|
|
WO2024191785A1
(en)
|
2023-03-10 |
2024-09-19 |
Genentech, Inc. |
Fusions with proteases and uses thereof
|
|
WO2024188965A1
(en)
|
2023-03-13 |
2024-09-19 |
F. Hoffmann-La Roche Ag |
Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
|
|
US12173081B2
(en)
|
2023-03-21 |
2024-12-24 |
Biograph 55, Inc. |
CD19/CD38 multispecific antibodies
|
|
US20240327522A1
(en)
|
2023-03-31 |
2024-10-03 |
Genentech, Inc. |
Anti-alpha v beta 8 integrin antibodies and methods of use
|
|
WO2024208776A1
(en)
|
2023-04-03 |
2024-10-10 |
F. Hoffmann-La Roche Ag |
Agonistic split antibodies
|
|
CN120882744A
(zh)
|
2023-04-03 |
2025-10-31 |
豪夫迈·罗氏有限公司 |
一体化激动性抗体
|
|
WO2024211235A1
(en)
|
2023-04-05 |
2024-10-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
WO2024211234A1
(en)
|
2023-04-05 |
2024-10-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
WO2024211236A2
(en)
|
2023-04-05 |
2024-10-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
AR132290A1
(es)
|
2023-04-05 |
2025-06-11 |
Genmab As |
Composiciones farmacéuticas que comprenden anticuerpos que se unen a cd30 y cd3
|
|
EP4442275A1
(en)
|
2023-04-06 |
2024-10-09 |
ModiQuest B.V. |
Anti-type ii collagen antibodies
|
|
WO2024213040A1
(zh)
|
2023-04-11 |
2024-10-17 |
浙江博锐生物制药有限公司 |
抗ror1抗体及其药物偶联物
|
|
TW202504915A
(zh)
|
2023-04-13 |
2025-02-01 |
丹麥商珍美寶股份有限公司 |
以抗ｃｄ３及ｃｄ２０之雙特異性抗體治療淋巴瘤之方法
|
|
CN121038814A
(zh)
|
2023-04-14 |
2025-11-28 |
中外制药株式会社 |
用于稳定含蛋白质药物制剂的方法
|
|
AU2024257248A1
(en)
|
2023-04-17 |
2025-11-06 |
Peak Bio, Inc. |
Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
|
|
AU2024270495A1
(en)
|
2023-05-05 |
2025-10-09 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2024231320A1
(en)
|
2023-05-08 |
2024-11-14 |
F. Hoffmann-La Roche Ag |
Targeted interferon alpha fusion proteins and methods of use
|
|
WO2024233926A1
(en)
|
2023-05-10 |
2024-11-14 |
Regeneron Pharmaceuticals, Inc. |
Cd20-pd1 binding molecules and methods of use thereof
|
|
WO2024233646A1
(en)
|
2023-05-10 |
2024-11-14 |
Genentech, Inc. |
Methods and compositions for treating cancer
|
|
WO2024238415A1
(en)
|
2023-05-12 |
2024-11-21 |
Regeneron Pharmaceuticals, Inc. |
Interferon receptor antagonists and uses thereof
|
|
TW202509071A
(zh)
|
2023-05-12 |
2025-03-01 |
丹麥商珍美寶股份有限公司 |
能夠與ｏｘ４０結合之抗體、其變異體及其用途
|
|
AR132687A1
(es)
|
2023-05-16 |
2025-07-23 |
Hoffmann La Roche |
Inmunoconjugados de il-2 regulados por pd-1 y sus usos
|
|
WO2024243423A1
(en)
|
2023-05-24 |
2024-11-28 |
Mozart Therapeutics, Inc. |
Cd8-specific binding proteins and methods of using the same
|
|
CN121219321A
(zh)
|
2023-06-01 |
2025-12-26 |
豪夫迈·罗氏有限公司 |
与bcma特异性结合的免疫刺激性抗原结合分子
|
|
WO2024246083A1
(en)
|
2023-06-01 |
2024-12-05 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies targeting bcma and cd28
|
|
WO2024251884A1
(en)
|
2023-06-09 |
2024-12-12 |
Innate Pharma |
Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl
|
|
US20250011449A1
(en)
|
2023-06-11 |
2025-01-09 |
Regeneron Pharmaceuticals, Inc. |
Circularized antibody molecules
|
|
UY40783A
(es)
|
2023-06-12 |
2024-12-31 |
Amgen Inc |
Proteínas de unión a agonistas del receptor beta de linfotoxina
|
|
WO2024256623A1
(en)
|
2023-06-16 |
2024-12-19 |
Heidelberg Immunotherapeutics Gmbh |
Novel anti-hsv antibody
|
|
WO2024261013A1
(en)
|
2023-06-21 |
2024-12-26 |
F. Hoffmann-La Roche Ag |
Combination therapy with fap-targeted lymphotoxin beta receptor agonists
|
|
TW202504929A
(zh)
|
2023-06-22 |
2025-02-01 |
美商建南德克公司 |
用於癌症治療之方法及組成物
|
|
US20250011450A1
(en)
|
2023-06-22 |
2025-01-09 |
Genentech, Inc. |
Antibodies and uses thereof
|
|
WO2024263904A1
(en)
|
2023-06-23 |
2024-12-26 |
Genentech, Inc. |
Methods for treatment of liver cancer
|
|
WO2024263195A1
(en)
|
2023-06-23 |
2024-12-26 |
Genentech, Inc. |
Methods for treatment of liver cancer
|
|
AU2024307352A1
(en)
|
2023-06-27 |
2025-12-11 |
Amgen Inc. |
Charge pair mutations to enable correct heavy-light chain pairing
|
|
WO2025007037A1
(en)
|
2023-06-28 |
2025-01-02 |
Dragonfly Therapeutics, Inc. |
Variant il-2 proteins
|
|
WO2025003280A1
(en)
|
2023-06-30 |
2025-01-02 |
Genmab A/S |
Antibodies binding to fibroblast activation protein alpha and death receptor 4
|
|
US12319747B2
(en)
|
2023-07-03 |
2025-06-03 |
Medicovestor, Inc. |
Methods of using anti-SP17 immunotherapeutics
|
|
WO2025010272A1
(en)
*
|
2023-07-03 |
2025-01-09 |
Neoimmunetech, Inc. |
Heterodimeric fc molecules and uses thereof
|
|
WO2025024265A1
(en)
|
2023-07-21 |
2025-01-30 |
Bristol-Myers Squibb Company |
Methods of assessing citrullination and activity of pad4 modulators
|
|
WO2025021838A1
(en)
|
2023-07-26 |
2025-01-30 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
WO2025027511A1
(en)
|
2023-07-30 |
2025-02-06 |
Janssen Biotech, Inc. |
Molecules that bind to mutant calreticulin and uses thereof
|
|
WO2025034806A1
(en)
|
2023-08-08 |
2025-02-13 |
Wisconsin Alumni Research Foundation |
Single-domain antibodies and variants thereof against fibroblast activation protein
|
|
WO2025032069A1
(en)
|
2023-08-09 |
2025-02-13 |
F. Hoffmann-La Roche Ag |
Mono and multispecific anti-trem2 antibodies, methods and uses thereof
|
|
WO2025032071A1
(en)
|
2023-08-09 |
2025-02-13 |
F. Hoffmann-La Roche Ag |
Mono and multispecific anti-trem2 antibodies, methods and uses thereof
|
|
US20250051434A1
(en)
|
2023-08-11 |
2025-02-13 |
Merck Sharp & Dohme Llc |
Monovalent interleukin 12 (il-12) heterodimeric fc proteins
|
|
WO2025038668A1
(en)
|
2023-08-14 |
2025-02-20 |
Voro Therapeutics, Inc. |
Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof
|
|
WO2025036892A1
(en)
|
2023-08-14 |
2025-02-20 |
Morphosys Ag |
Cycat halfbody molecules comprising sterically occluding moieties
|
|
WO2025042742A1
(en)
|
2023-08-18 |
2025-02-27 |
Bristol-Myers Squibb Company |
Compositions comprising antibodies that bind bcma and cd3 and methods of treatment
|
|
WO2025040567A1
(en)
|
2023-08-18 |
2025-02-27 |
F. Hoffmann-La Roche Ag |
Protease activatable fc domain binding molecules
|
|
EP4630457A1
(en)
|
2023-08-18 |
2025-10-15 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen-binding molecules and uses thereof
|
|
WO2025041077A1
(en)
|
2023-08-23 |
2025-02-27 |
Sanofi |
Ctla-4-based lysosomal degraders and uses thereof
|
|
WO2025054500A2
(en)
|
2023-09-08 |
2025-03-13 |
Mlab Biosciences, Inc. |
Bifunctional proteins and uses thereof
|
|
WO2025059162A1
(en)
|
2023-09-11 |
2025-03-20 |
Dana-Farber Cancer Institute, Inc. |
Car-engager containing il-2 variants to enhance the functionality of car t cells
|
|
WO2025059037A1
(en)
|
2023-09-11 |
2025-03-20 |
Evolveimmune Therapeutics, Inc. |
Bispecific antibody fusion molecules targeting b7-h4 and cd3 and methods of use thereof
|
|
WO2025056180A1
(en)
|
2023-09-15 |
2025-03-20 |
BioNTech SE |
Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
|
|
WO2025064890A1
(en)
|
2023-09-20 |
2025-03-27 |
Evolveimmune Therapeutics, Inc. |
Bispecific antibody fusion molecules targeting cd180 and cd3 and methods of use thereof
|
|
WO2025064885A1
(en)
|
2023-09-20 |
2025-03-27 |
Evolveimmune Therapeutics, Inc. |
Multispecific antibodies that bind cd3 and cd2 and methods of use thereof
|
|
AR133909A1
(es)
|
2023-09-25 |
2025-11-12 |
Hoffmann La Roche |
ANTICUERPO QUE SE UNE A C3bBb
|
|
TW202535954A
(zh)
|
2023-09-26 |
2025-09-16 |
丹麥商珍美寶股份有限公司 |
Ｐｔｋ７結合劑、其共軛物及使用彼等之方法
|
|
WO2025068957A1
(en)
|
2023-09-29 |
2025-04-03 |
Novartis Ag |
Bispecific antibodies for use in lowering the risk of cardiovascular disease events in subjects known to be a carrier of clonal expansion of hematopoietic cell lines with somatic mutations
|
|
WO2025082777A1
(en)
|
2023-10-17 |
2025-04-24 |
Morphosys Ag |
Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules
|
|
WO2025085489A1
(en)
|
2023-10-17 |
2025-04-24 |
Bristol-Myers Squibb Company |
Gspt1-degrading compounds, anti-cd33 antibodies and antibody-drug conjugates and uses thereof
|
|
US12364777B2
(en)
|
2023-10-20 |
2025-07-22 |
Medicovestor, Inc. |
Homodimeric antibodies for use in treating cancers and methods of use
|
|
WO2025099632A1
(en)
|
2023-11-08 |
2025-05-15 |
Sanofi |
Cd25 based lysosomal degrader and uses thereof
|
|
WO2025101982A1
(en)
|
2023-11-10 |
2025-05-15 |
Pfizer Inc. |
Anti-migis-alpha antibodies and methods of use thereof
|
|
WO2025106474A1
(en)
|
2023-11-14 |
2025-05-22 |
Genentech, Inc. |
Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2025106469A1
(en)
|
2023-11-14 |
2025-05-22 |
Regeneron Pharmaceuticals, Inc. |
Engineered heavy chain variable domains and uses thereof
|
|
WO2025106634A1
(en)
|
2023-11-17 |
2025-05-22 |
Genentech, Inc. |
Mcl-1 inhibitor compounds and use in antibody drug conjugates
|
|
WO2025114541A1
(en)
|
2023-11-30 |
2025-06-05 |
Genmab A/S |
Antibodies capable of binding to ox40 in combination therapy
|
|
WO2025113643A1
(en)
|
2023-12-01 |
2025-06-05 |
Gilead Sciences Inc. |
Anti-fap-light fusion protein and use thereof
|
|
WO2025122614A1
(en)
|
2023-12-05 |
2025-06-12 |
Regeneron Pharmaceuticals, Inc. |
Il18 receptor agonists and methods of use thereof
|
|
WO2025122634A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
WO2025125118A1
(en)
|
2023-12-11 |
2025-06-19 |
F. Hoffmann-La Roche Ag |
Protease activatable fc domain binding molecules
|
|
WO2025125386A1
(en)
|
2023-12-14 |
2025-06-19 |
F. Hoffmann-La Roche Ag |
Antibodies that bind to folr1 and methods of use
|
|
WO2025129010A1
(en)
|
2023-12-14 |
2025-06-19 |
Genentech, Inc. |
Methods of structure determination using antibodies
|
|
WO2025137086A1
(en)
|
2023-12-20 |
2025-06-26 |
Genentech, Inc. |
Reducing alpha-gal
|
|
WO2025132503A1
(en)
|
2023-12-20 |
2025-06-26 |
F. Hoffmann-La Roche Ag |
Antibodies binding to ceacam5
|
|
WO2025137454A1
(en)
|
2023-12-21 |
2025-06-26 |
Amgen Inc. |
Stabilizing homodimer mutations for two cell heterodimer production
|
|
WO2025133042A2
(en)
|
2023-12-22 |
2025-06-26 |
F. Hoffmann-La Roche Ag |
Activatable fusion proteins and methods of use
|
|
US12121587B1
(en)
|
2023-12-26 |
2024-10-22 |
Medicovestor, Inc. |
Dimeric antibodies
|
|
US12116410B1
(en)
|
2023-12-26 |
2024-10-15 |
Medicovestor, Inc. |
Methods of manufacturing dimeric antibodies
|
|
WO2025147696A1
(en)
|
2024-01-05 |
2025-07-10 |
Resolve Therapeutics, Llc |
Treatment of symptoms associated with sars-cov viral infection or a prior sars-cov viral infection with nuclease agents
|
|
US20250296992A1
(en)
|
2024-01-10 |
2025-09-25 |
Genmab A/S |
Slitrk6 binding agents, conjugates thereof and methods of using the same
|
|
WO2025149633A1
(en)
|
2024-01-12 |
2025-07-17 |
Laigo Bio B.V. |
Bispecific antigen binding proteins
|
|
WO2025166045A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF
|
|
WO2025166040A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof
|
|
WO2025166042A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
Cd98hc antigen-binding domains and uses therefor
|
|
WO2025166077A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
Compositions comprising progranulin and uses thereof
|
|
US12240900B1
(en)
|
2024-02-02 |
2025-03-04 |
Medicovestor, Inc. |
Nucleic acids, vectors, and cells that encode antibodies and other proteins that bind folate receptor alpha
|
|
US12258396B1
(en)
|
2024-02-02 |
2025-03-25 |
Medicovestor, Inc. |
Methods of using immunotherapeutics that bind folate receptor alpha
|
|
US12378314B1
(en)
|
2024-02-02 |
2025-08-05 |
Medicovestor, Inc. |
Proteins that bind folate receptor alpha including fully-human antibodies
|
|
WO2025174974A1
(en)
|
2024-02-14 |
2025-08-21 |
Bristol-Myers Squibb Company |
Anti-cd33 antibodies and uses thereof
|
|
WO2025172924A1
(en)
|
2024-02-15 |
2025-08-21 |
Janssen Biotech, Inc. |
Anti-transferrin receptor compositions and methods thereof
|
|
WO2025181219A1
(en)
|
2024-02-29 |
2025-09-04 |
Genmab A/S |
Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
|
|
WO2025181189A1
(en)
|
2024-03-01 |
2025-09-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
WO2025191136A1
(en)
|
2024-03-15 |
2025-09-18 |
Avidicure Ip B.V. |
Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
|
|
WO2025191139A1
(en)
|
2024-03-15 |
2025-09-18 |
Avidicure Ip B.V. |
Conjugates of her2-specific antigen binding proteins and cytokines
|
|
WO2025191133A1
(en)
|
2024-03-15 |
2025-09-18 |
Avidicure Ip B.V. |
Il-21 muteins, fusion proteins comprising the same and uses thereof
|
|
WO2025199243A1
(en)
|
2024-03-20 |
2025-09-25 |
Regeneron Pharmaceuticals, Inc. |
Trivalent multispecific binding molecules and methods of use thereof
|
|
US20250295801A1
(en)
|
2024-03-21 |
2025-09-25 |
Seagen Inc. |
Cd25 antibodies, antibody drug conjugates, and uses thereof
|
|
WO2025202147A1
(en)
|
2024-03-27 |
2025-10-02 |
F. Hoffmann-La Roche Ag |
Interleukin-7 immunoconjugates
|
|
WO2025217101A2
(en)
|
2024-04-09 |
2025-10-16 |
Amgen Inc. |
Agonistic anti-il-2rbg heavy‑chain antibodies
|
|
WO2025215060A1
(en)
|
2024-04-11 |
2025-10-16 |
F. Hoffmann-La Roche Ag |
Antibodies that specifically bind modified oligonucleotides
|
|
WO2025219504A1
(en)
|
2024-04-19 |
2025-10-23 |
F. Hoffmann-La Roche Ag |
Treatment of ophthalmologic diseases
|
|
WO2025222129A2
(en)
|
2024-04-19 |
2025-10-23 |
Mozart Therapeutics, Inc. |
Engineered cytokines and targeted cytokine delivery
|
|
WO2025226808A1
(en)
|
2024-04-24 |
2025-10-30 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
|
WO2025233825A1
(en)
|
2024-05-06 |
2025-11-13 |
Janssen Pharmaceutica Nv |
Enrichment of cells expressing a bird linker
|
|
WO2025233431A1
(en)
|
2024-05-07 |
2025-11-13 |
Immatics Biotechnologies Gmbh |
Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof
|
|
WO2025233304A1
(en)
|
2024-05-08 |
2025-11-13 |
F. Hoffmann-La Roche Ag |
Recombinant fc domain – il7 variant polypeptides and combination therapy with membrane-anchored antigen binding polypeptides
|
|
WO2025240335A1
(en)
|
2024-05-13 |
2025-11-20 |
Regeneron Pharmaceuticals, Inc. |
Fgfr3 binding molecules and methods of use thereof
|
|
WO2025237931A1
(en)
|
2024-05-15 |
2025-11-20 |
F. Hoffmann-La Roche Ag |
Recombinant binding proteins with conditionally activatable t cell and nk cell recruiting effector domains
|
|
WO2025240781A2
(en)
|
2024-05-15 |
2025-11-20 |
Werewolf Therapeutics, Inc. |
Modified antibodies and immunoglobulin formats
|
|
WO2025240670A2
(en)
|
2024-05-15 |
2025-11-20 |
Abalytics Oncology, Inc. |
Anti-pd-1 antibodies and related binding molecules and methods and uses thereof
|
|
WO2025238135A2
(en)
|
2024-05-17 |
2025-11-20 |
UCB Biopharma SRL |
Antibody with binding specificity for il-11
|
|
WO2025238133A1
(en)
|
2024-05-17 |
2025-11-20 |
UCB Biopharma SRL |
Multispecific antibody with binding specificity for il-11 and il-17
|
|
WO2025250969A1
(en)
|
2024-05-31 |
2025-12-04 |
Vertex Pharmaceuticals Incorporated |
Anti-cd74 antibodies, conjugates and uses thereof
|
|
US20250376511A1
(en)
|
2024-06-05 |
2025-12-11 |
Genzyme Corporation |
BINDING PROTEINS THAT TARGET aC1s, TfR, OR BOTH, AND COMPOSITIONS THEREOF
|
|
WO2025253337A2
(en)
|
2024-06-05 |
2025-12-11 |
Sanofi |
Monospecific and bispecific tau binding proteins and compositions thereof
|
|
US20250376536A1
(en)
|
2024-06-06 |
2025-12-11 |
Bristol-Myers Squibb Company |
Multispecific anti-cd40 / anti-fap antibodies and uses thereof
|
|
WO2025255452A2
(en)
|
2024-06-07 |
2025-12-11 |
Regeneron Pharmaceuticals, Inc. |
Antigen-binding molecules that bind to aav particles and uses thereof
|
|
US20250376524A1
(en)
|
2024-06-07 |
2025-12-11 |
Regeneron Pharmaceuticals, Inc. |
Tetravalent multispecific binding molecules and methods of use thereof
|
|
WO2025259718A2
(en)
|
2024-06-11 |
2025-12-18 |
Regeneron Pharmaceuticals, Inc. |
Vegf antagonists and methods of use thereof
|
|
WO2025257181A1
(en)
|
2024-06-11 |
2025-12-18 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies targeting trans-active response dna-binding protein-43 (tdp-43)
|
|
CN121135878A
(zh)
|
2024-06-14 |
2025-12-16 |
康诺亚生物医药科技（成都）有限公司 |
针对ox40l和il-13的双特异性抗体及其用途
|
|
WO2025259871A1
(en)
|
2024-06-14 |
2025-12-18 |
Gilead Sciences, Inc. |
Anti-ccr8 antibodies and uses thereof
|